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ABSTRACT

STRUCTURAL CHARACTERIZATION AND SELECTIVE DRUG
TARGETING OF HIGHER-ORDER DNA G-QUADRUPLEX
SYSTEMS

Robert Chandos Monsen
November 20, 2020

There is now substantial evidence that guanine-rich regions of DNA form non-B DNA
structures known as G-quadruplexes in cells. G-quadruplexes (G4s) are tetraplex DNA structures
that form amid four runs of guanines which are stabilized via Hoogsteen hydrogen bonding to form
stacked tetrads. DNA G4s have roles in key genomic functions such as regulating gene expression,
replication, and telomere homeostasis. Because of their apparent role in disease, G4s are now
viewed as important molecular targets for anticancer therapeutics. To date, the structures of many
important G4 systems have been solved by NMR or X-ray crystallographic techniques. Small
molecules developed to target these structures have shown promising results in treating cancer in
vitro and in vivo, however, these compounds commonly lack the selectivity required for clinical
success. There is now evidence that long single-stranded G-rich regions can stack or otherwise
interact intramolecularly to form G4-multimers, opening a new avenue for rational drug design. For
a variety of reasons, G4 multimers are not amenable to NMR or X-ray crystallography. In the current
dissertation, I apply a variety of biophysical techniques in an integrative structural biology (ISB)
approach to determine the primary conformation of two disputed higher-order G4 systems: (1) the
extended human telomere G-quadruplex and (2) the G4-multimer formed within the human
telomerase reverse transcriptase (hTERT) gene core promoter. Using the higher-order human
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telomere structure in virtual drug discovery approaches I demonstrate that novel small molecule
scaffolds can be identified which bind to this sequence in vitro. I subsequently summarize the
current state of G-quadruplex focused virtual drug discovery in a review that highlights successes
and pitfalls of in silico drug screens. I then present the results of a massive virtual drug discovery
campaign targeting the hTERT core promoter G4 multimer and show that discovering selective
small molecules that target its loops and grooves is feasible. Lastly, I demonstrate that one of these
small molecules is effective in down-regulating hTERT transcription in breast cancer cells. Taken
together, I present here a rigorous ISB platform that allows for the characterization of higher-order
DNA G-quadruplex structures as unique targets for anticancer therapeutic discovery.
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CHAPTER I

INTRODUCTION

In 1953, James Watson and Francis Crick provided a model of the B-form of DNA (1). This
seminal work suggested, for the first time, the structural basis of genetic inheritance inferred from
purine-pyrimidine base pairing in the double helix. The structure itself is arguably just as important.
It is now known that the structure of DNA is critical for coherent interactions with proteins, without
which would result in chaos within the cell. Since its discovery, a variety of non-B DNA structures
have been revealed, each of which with their own sequence requirements for formation (2). In
particular, DNA G-quadruplexes (G4s) have garnered serious attention over the past few decades
as their role in disease has become increasingly evident.
Just as the DNA duplex is made up of constitutive base pairs (or “dyads”), the G-quadruplex
is made up of guanine tetrads (G-tetrads) (Figure 1A-B) (3,4). G-tetrads are stabilized by hydrogen
bonding across the O6 oxygen and N7 nitrogen of the first guanine with the N1 and N2 nitrogen of
the adjacent guanine. This Hoogsteen bonding pattern repeats to form a square planar
arrangement, allowing tetrads to stack atop one another as shown in Figure 1C. The “canonical”
unimolecular G-quadruplex has between 2 and 4 contiguous stacks of G-tetrads. A variety of
topologies exist for a single-stranded intra-molecular G-quadruplex, and these various forms are
dictated primarily by phosphodiester backbone directionality and nucleoside conformations (syn or
anti) with respect to the glycosidic bond. This implies that a unimolecular two-tetrad G-quadruplex
has 26 possible loop configurations and 24 possible combinations of G-tetrad glycosidic bond
orientations (5). The same number of loop combinations exist for a three-tetrad system, however,
the number of possible G-tetrad glycosidic bond combinations increases, making the maximum
total configurations 32 (5). Further, loop sizes, orientations, and interactions can vary considerably.
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Thus, the conformational diversity of these structures has led to significant interest recently for their
potential to be selectively targeted with small molecules.

2

Figure 1. Chemical structures of the duplex “dyads”, G-quadruplex tetrad, and a simplified
schematic of a G-quadruplex. (A) Traditional base pairs, A:T and G:C, of the DNA duplex. (B) Gquadruplex tetrad, showing the coordination of a potassium ion in the central cavity. Broken bond
symbols represent the disconnect from the deoxyribose (i.e. the glycosidic bond). (C) schematic
representation of a basic three tetrad G-quadruplex. Gray squares represent the G-tetrads, black
lines represent the phosphate backbone, and pink circles represent potassium ions.
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Since the discovery that G-quadruplex structures form spontaneously in biologically
relevant ionic conditions, the field has exploded with reports of their wide array of biological roles.
Early investigations of eukaryotic telomere sequences determined that G-quadruplex formation
critically regulates the activity of human telomerase reverse transcriptase (hTERT), the enzyme
that extends the telomere (6-8). This has obvious implications in cancer, as more than 85% of all
cancers have reactivated hTERT, and its activity at the telomeres is essential in cellular immortality
(9,10). Moreover, bioinformatic studies reveal that ~300,000 putative G-quadruplex forming
sequences (PQSs) are scattered throughout the human genome non-randomly (11,12). PQSs are
highly concentrated in regions such as immunoglobulin switch regions, mRNA 5’ and 3’
untranslated regions (UTRs), and regulatory regions in gene promoters (13,14), all of which are
unique points for therapeutic intervention. Some promoter G-quadruplexes with relevance in
disease have since been successfully targeted by small molecules (14,15). A notable example is
the nuclease hypersensitivity element III1 (NHE III1) G-quadruplex of the c-MYC promoter.
Stabilizing this G-quadruplex with the G4 ligand TMPyP4 resulted in marked repression of c-MYC
expression—cementing the case for G-quadruplex-mediated transcriptional regulation (16).
Currently there are about a thousand or more G-quadruplex interacting ligands which have been
reported that bind to the telomeres, various promoters, and mRNA G-quadruplexes (17). However,
just as selectivity is an issue with many protein targeting small molecules, the same issue now
pertains to G-quadruplexes (18). G-quadruplex “monomers” (i.e. a single intra-molecular Gquadruplex unit consisting 2-4 G-tetrad stacks) are often amenable to high-resolution structural
biology techniques, such as NMR and X-ray crystallography (although typically requiring stabilizing
mutations), allowing for their unambiguous structural characterization. This has positioned them as
prime targets in the pursuit of G-quadruplex selective drugs. Unfortunately, efforts are hampered
by the common feature among all monomeric G-quadruplexes: their 3’ and 5’ G-tetrad faces.
Binding, or “end-pasting”, to these sites is the primary reason for ligand promiscuity (18).
Long single-stranded regions of G-rich DNA containing multiple G-quadruplex motifs have
the potential to form G-quadruplex “multimers”, that is, monomeric G-quadruplexes which can stack
atop or otherwise interact with one another to form a tertiary arrangement (19,20). It is apparent
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that such structures offer a more specific target for rational drug discovery whereby loop, groove,
and G-quadruplex stacking junctions form specific pockets useful for rational drug discovery
techniques (18,20). Unfortunately, these multimeric forms are difficult to characterize, which stems
from their size, inherent heterogeneity in solution, guanine imino spectral overlap in NMR, and
propensity to favor (often not relevant) conformations in X-ray diffraction. Therefore, a critical
limitation in understanding the role these structures play in the cell, as well as in developing new
selective anticancer therapeutics, resides in their structural characterization.
This dissertation provides an integrative structural biology (ISB) platform that allows for
detailed characterization of multimeric G-quadruplexes in their wild type (WT) state and under
physiologically relevant conditions. Using a suite of robust biophysical tools, such as size-exclusion
chromatography (SEC), small-angle X-ray scattering (SAXS), analytical ultracentrifugation (AUC),
circular dichroism (CD), nuclear magnetic resonance (NMR), and molecular dynamics (MD), I show
that it is possible to determine the tertiary structure of higher-order G-quadruplexes at 20-40 Å
resolution. I begin with an example of this approach, whereby a rigorous investigation of the higherorder human telomere reveals that it is composed of alternating hybrid-2 and hybrid-1 G4
topologies, and that it maximizes its usage of G-tracts in solution. The derived telomere G4 multimer
structures are subsequently targeted at their inter-quadruplex junctional regions; whereby novel
ligand scaffolds are identified. I next apply this characterization approach to the hTERT core
promoter G-quadruplex and show that it preferentially adopts an all-parallel stacked G-quadruplex
arrangement with multiple unique loop sites useful in drug discovery efforts. Following this, I
describe and summarize the current state of G-quadruplex virtual screening in a review, pointing
out where improvements could be made to increase selectivity and novelty of virtually screened
small molecules. Last, using the derived model of the hTERT core promoter G-quadruplex, I show
that unique, drug-like small molecules can be discovered which preferably bind to it over duplex,
triplex, and monomeric G-quadruplex topologies. Additionally, I provide biological evidence that
one of these small molecules can repress hTERT transcription in breast cancer cells, and so is a
suitable lead for development as an anticancer therapeutic.
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A Brief History of G-quadruplex DNA

When one thinks about deoxyribonucleic acid (DNA) in the cell, we traditionally think of the
classical double helix (1), discovered more than 60 years ago by Watson, Crick, Franklin, and
Wilkins. The double helix structure provided a platform by which we could relate structure to
function, where base-pairing provided a mechanistic basis for the transfer of genetic information,
and codons provided the blueprints for making proteins. Of course, we know now that DNA is more
than just a medium for information transfer, it is dynamic and structurally diverse. For instance, the
majority of DNA in the cell is negatively supercoiled, which favors the formation of non-B DNA
structures (21). Less than 10 years after the duplex was elucidated, four-stranded guanylic acid
structures were observed by fiber diffraction which indicated that guanines could form stable, planar
tetrads via hydrogen bonding of their Hoogsteen faces (Figure 1B) (3,4). At the time, guanine
tetrads were viewed as mere test tube oddities [and even “nuisances” (22)]. It wasn’t until the late
80’s when it was discovered that under physiological cation conditions, in vitro, guanine-rich
telomere sequences spontaneously formed discrete four-stranded structures, now known as Gquadruplexes (G4s) (6,23,24). Although speculation of their in vivo relevance was widespread at
the time, the discovery of these spontaneously formed G4s prompted Nobel Laurette Aaron Klug
to remark “If G-quadruplexes form so readily in vitro, Nature will have found a way of using them in
vivo” (25).
The 2000’s hailed a new era for G-quadruplex biology. It was the advent of G4-targeting
antibodies that visualized, for the first time, the formation of G4 DNA structures in cells (26-30).
Their visualization across the genome was simultaneously verified by advances in G-quadruplex
sequencing techniques (31) and bioinformatic inquiries (11,12). These technological advances
paved the way for studies demonstrating that G-quadruplexes can be targeted and stabilized by
small molecules in cells (27,30). A variety of quadruplex-interacting proteins have since been
verified to interact with biological G-quadruplexes, such as telomerase (32), helicases (27,30,33),
transcription factors (34), and chromatin remodeling complexes (35). For an excellent review of the
newfound diversity of G-quadruplex functions in biology see that of Spiegel, Santosh, and
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Balasabrumanian (36). Clearly, G-quadruplexes are important structures in vivo, and their roles in
biology and disease are of great interest to the biomedical community.

Monomeric G-quadruplex Structure

The discovery that guanylic acids could form higher order structure dates back to 1910
when Ivar Bang reported that, upon heating and cooling, guanylic acid formed an extremely
viscous, clear gel (37). It wasn’t until 1962 when this phenomenon was further investigated. Ralph
and colleagues showed that guanylic acid, but not other nucleotide derivatives, formed aggregates
or other higher-order species in the presence of physiological buffers using analytical
ultracentrifugation experiments (38). This same year, Gellert et al. reported the unique optical
properties and arrangement of the G-quartet using X-ray diffraction, showing unambiguously the
formation of a guanine helix (G-quadruplex) (3). A decade later the geometry of the G-quadruplex
tetrad stack was elucidated using X-ray diffraction (4,39).
The basic structural motif of the G-quadruplex is the G-tetrad (or G-quartet), which consists
of four cyclically Hoogsteen hydrogen-bonded guanines situated in a planar square shape (Figure
1). Bonding is through the protons of the nitrogen N7 and oxygen O6 atoms with that of the adjacent
base nitrogen N1 and N2. The O6 atoms project towards the interior of the central G-tetrad helical
axis and, when stacked onto an adjacent tetrad, the cavity formed among the eight central O6
atoms is large enough to house a variety of monovalent cations. Stabilization of the stacked Gtetrads is primarily through overlap of π-orbitals of stacked guanines and cation coordination (40).
Monovalent cation coordination within the central cavity imparts a major stabilizing effect by
neutralization of the partial negative charges from the inward projecting O6 oxygens (40).
Commonly, the coordination ions are either K+ or Na + but other ions of appropriate size can also
fulfil this stabilizing role (41).
Two or more contiguous G-tetrad stacks constitute a G-quadruplex. The features of Gquadruplexes, which are used in describing their overall topology, are glycosidic conformations of
guanines, strand orientations, groove widths, and loop arrangements (42,43). It is the arrangement
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of nucleobases within a G-quadruplex that give rise to their diagnostic circular dichroism signatures
(44). The glycosidic bond angle (GBA) is the orientation of the guanosine about the N-glycosidic
bond of the deoxyribose, and this can be syn or anti (with anti being most prevalent in B-DNA). The
specific GBAs of guanines within G-tetrads define the G-quadruplex’s groove (43). The three types
of grooves are narrow (n), medium (m), and wide (w) (Figure 2), and only G-tetrads with the same
groove combinations may stack to form a G-quadruplex (43). The three loop types (diagonal,
propeller, and lateral) are entwined with GBA. The lateral loop (a.k.a. edgewise loop) links guanines
within the same tetrad that share hydrogen bonds. Conversely, diagonal loops link guanines within
the same tetrad but do not share hydrogen bonds. In both cases the loops link guanines of different
GBA. G-quadruplexes with these types of loops are said to be “hybrid” or “antiparallel” (Figure 3).
The third loop type, now commonly known as propeller (but earlier called “double chain reversal”),
links guanines which are not in the same tetrad, but within the same groove, and this groove is
always medium since the bases of propeller loops always have the same glycosidic bond angle
(43). G-quadruplexes which have all propeller type loops (and thus all bases with the same anti
GBA) are said to be “parallel”, as all the runs of guanines in the G-tetrads point in the same 5’ to 3’
direction (Figure 3A). There are primarily three types of loop “directionalities” observed in Gquadruplexes. These are known as parallel (↑↑↑↑), hybrid 3+1 (↑↑↓↑ or ↑↓↑↑), and anti-parallel or
basket (↑↓↑↓) (depending on looping), where the arrows are from 5’ (left) to 3’ (right) and indicate
the phosphodiester backbone direction (Figure 3) (42).
The G-quadruplex topological descriptors above (parallel, hybrid, and antiparallel) are the
informal classes of G4s, and these descriptions are not sufficient to fully describe G4 conformation.
For instance, the human telomere G4-forming sequence(s), depending on flanking nucleotides and
solution conditions (45,46) can adopt six variations of these topologies (e.g. parallel, basket, two
different hybrid forms, and two different antiparallel forms) (45-48). To this end, the Webba da Silva
lab has created a formalism for describing quadruplex folding based on the loop orientation and
GBA relative to the starting nucleotide closest to the 5’ end of the G4 strand (49). The authors
propose that, starting with the 5’-most guanine (which is typically anti in conformation), the looping
type and direction can be described as ‘-‘ or ‘+’ for anti-clockwise and clockwise progression,
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respectively. The anti-clockwise ‘-‘ looping is most commonly observed in G4s and is akin to the
right-handed B-DNA double helical turn [although clockwise ‘+’ progressions have recently been
observed, which are akin to Z-DNA and are deemed “Z-G4” (50,51)]. Further, the type of loop,
parallel ‘p’, lateral ‘l’, and diagonal ‘d’, can be assigned as such. Thus, these formal assignments
are more adequate at describing looping type and directionality (although diagonal loops do not
have ‘-‘ or ‘+’ because they do not connect in an anti-clockwise or clockwise fashion). For instance,
a parallel G-quadruplex with loops that run anti-clockwise is -p-p-p for three anti-clockwise propeller
loops, and +p+p+p for three clockwise propeller loops (Figure 3). An antiparallel G4 with a diagonal
loop (such as the human telomere in sodium, PDB ID: 143D) would be +ld-l (Figure 3D). For lateral
loops, an additional descriptor can be added for even more specificity. The designation of a
subscript ‘m’, ‘n’, or ‘w’ for medium, narrow, or wide grooves can be appended after ‘l’ (52). For the
antiparallel (143D) example above, its descriptor would become +lwd-ln. Clearly, this naming
convention is powerful compared with the traditional parlance.
Altogether, the structural diversity of two- and three-tetrad G-quadruplexes is immense,
whereby each can theoretically adopt 26 different looping configurations and 32 different
combinations of anti and syn guanines (43). This diversity is further compounded when considering
that many biologically relevant sequences contain more than four runs of G-tracts which are often
longer than two consecutive guanines, and can be variable in number (53). While this greatly
complicates G-quadruplex structure determination, it is also the reason why these structures are
so enticing from a drug discovery perspective.
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Figure 2. Guanine glycosidic bonds and G-tetrad groove definitions. The two possible
conformations, syn and anti, of guanines about their glycosidic bonds (A), and the G-tetrad with
groove designations based on guanine glycosidic bonds and spatial arrangements (B). Pink ovals
indicate guanines with a syn-conformation and cyan ovals indicate guanines with anticonformations. The grooves are marked as medium, wide, or narrow, as determined by the
arrangement of guanines and their respective glycosidic bond orientations.
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Figure 3. G-quadruplex conformations. In each diagram grey squares represent G-tetrads, black
lines indicate the phosphate backbone, blue and red arrows highlight backbone directionality,
yellow text and arrows indicate the three main loop types, and green represents any non-tetrad
participating nucleotide. (A) Parallel fold with three propeller loops -p-p-p. (B & C) two different
hybrid 3 + 1 folds, each with two lateral (or edgewise) loops, and a single propeller loop (-l-l-p and
-p-l-l, respectively). (D) Antiparallel fold with two lateral loops and one diagonal loop -ld+l. (E) A
two-tetrad antiparallel fold with the same loop types as in D but showing how additional nucleotides
can potentially stack on the 5’ and 3’ G-tetrad faces -ld+l. (F) A “chair” formation, with three
consecutive lateral loops +l+l+l.
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Multimeric G-quadruplex Structure

The diversity of G-quadruplex structures extends well past that of single “monomeric” intrastranded structures. Multimeric G-quadruplexes also exist, and these can be inter-stranded Gquadruplexes such as “dimers”, “trimers”, and “tetramers”, as well as oligomer and polymer type
“G-wires”. In this dissertation the emphasis will remain primarily on intra-strand (unimolecular) Gquadruplexes and, for clarity, the term “monomer” will hence forth refer only to a single intra-strand
G-quadruplex. In the context of long single-stranded DNA (ssDNA), such as would be found in a
cell during replication or transcription, it could be envisioned that multiple monomer G-quadruplexes
could form on the same strand. These G4s could either act independently (known as “beads-on-astring”) (Figure 4A) or interact with each other by direct contact. In the latter case, the G-quadruplex
(i.e. the entire G-rich strand of DNA) will be referred to as a G-quadruplex “multimer” (Figure 4B)
(20).
Just as duplex dyads and G-quadruplex tetrads are stabilized through nucleotide stacking,
monomeric G-quadruplexes can stack atop on another under physiologically relevant DNA
concentrations (as low as a few micromolar strand concentration) (20). G-quadruplex multimers
form in primarily two ways: direct G-tetrad stacking of terminal (5’ or 3’) tetrad faces, or via
“sandwiching” of non-tetrad-participating loop residues between tandem monomeric G-quadruplex
units (54), although other inter-domain interactions have been proposed (55). Direct G-tetrad face
interactions of monomer quadruplexes of 3’ to 5’ and 5’ to 5’ occur most readily, as the 3’ to 3’
stacking interface is thought to be energetically unfavorable without facilitation by small molecule
ligands or sandwiched adenine residues (54). A variety of monomeric G-quadruplex stacking
interfaces have been reported using both NMR and X-ray crystallographic techniques (hundreds of
structures of unimolecular and stacked dimer DNA G-quadruplexes in the Protein Data Bank:
https://www.rcsb.org/). There are only a few multimers with high-resolution structures available: a
dimer of the c-MYB promoter (56), a synthetic aptamer two-stacked two-tetrad G4 (57), and two,
two-stacked two-tetrad multimers containing left-handed “Z-G4s” (50,51).
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Figure 4. Schematic showing the “beads-on-a-string” and “multimer” higher-order G-quadruplex
structures. Schematics are represented as in Figure 3, with labeling of the 5’ and 3’ tetrad faces.
(A) G-quadruplex monomers can spontaneously fold adjacent to one another on the same DNA
strand but not necessarily interact, forming the beads-on-a-string structure. These quadruplexes
could also contain 2-, 4-, or more tetrads. (B) Two monomers on the same strand of DNA interacting
to form a G-quadruplex multimer.
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G-quadruplex Functions

Telomere G-quadruplexes
At the end of eukaryotic chromosomes is a specialized, non-coding sequence of
nucleotides known as the telomere which consists of tandem repeats of the sequence 5’-TTAGGG3’ (58). The telomeres have long been associated with human disease, such as cancer (59),
telomeropathies (60), the aging process (61), and genome (in)stability (62). The common etiology
among these conditions is dysregulated telomere length control. In normal human somatic cells
telomeres are approximately 5-25 kb in length and have an extended single-stranded 3’ overhang
of ~35-600 bases (63). The entire region is coated in telomere associated proteins known as the
shelterin complex, which protect the exposed ends from nucleolytic cleavage, end-to-end fusion
events, and unintentional activation of the DNA damage response pathway (64,65).
In most normal somatic (non-germ) cells, progressive shortening of the telomeres occurs
with each round of cell division due to the end replication problem (66). This replicative “clock” has
long been thought to be a protective mechanism against tumorigenesis (65). Once a critical number
of replications have occurred the telomeres become sufficiently small and trigger a DNA damage
response by “uncapping” of the telomere shelterin proteins, leading to cellular senescence (65,66).
Cancer cells have found mechanisms which circumvent natural telomere attrition. The two main
mechanisms used in cancer to restore telomere length are DNA recombination (known as the
alternative lengthening of telomeres [ALT] pathway), and re-activation of human telomerase
reverse transcriptase (hTERT). hTERT is the catalytic protein component of the telomerase
ribonucleoprotein which extends the telomere using its reverse transcriptase activity (67). The ALT
pathway is only observed in a small fraction of cancers (~10-15%), with the majority (85-90%) of
cancer cells exhibiting aberrant telomerase activity (10,68,69). Thus, by extending the telomere,
cancer cells can divide indefinitely, and so telomeres and their associated proteins are promising
targets for anticancer therapeutics (59).
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In 1987, while studying the telomere sequences in Tetrahymena, Henderson and
Blackburn discovered that the G-rich single-stranded telomeres spontaneously form non-WatsonCrick type intramolecular structures (6). Two years later the telomere G-quadruplex was confirmed
by DNA foot-printing experiments, which showed protection of the G-tetrad guanine N7 groups
exclusively when folded in the presence of Na+ and K+ salts (24,70). These discoveries suggested
an in vivo role for G-quadruplexes, and along with advances in oligonucleotide synthesis schemes
(71), renewed interest in their study. In 1992 the first atomic resolution crystal structure of a
telomere DNA G-quadruplex was reported using sequences from Oxytricha (72), followed soon
after by the NMR solution structure of the same sequence (73). One year later, the first atomic
structure of the human telomere G-quadruplex was reported by Wang and Patel, which showed
that it adopted an antiparallel “basket” type fold (like Figure 3D) in a sodium buffer (74). A variety
of monomer telomeric G-quadruplexes have since been solved by X-ray crystallography or NMR
techniques: parallel (75), hybrid 3+1 (76,77), antiparallel (74), and a two-tetrad antiparallel (47).
Not all telomere topologies are biologically relevant, as some appear to be the result of either nonphysiological cation conditions or unnatural physical forces, such as those in crystal packing (78).
Extensive investigations have led to the conclusion that the two prominent forms of the human
telomere G-quadruplex, under physiologically relevant ion concentrations in vitro, are the hybrid
3+1 topologies, called “hybrid-1” (↓↓↑↓) (76) and “hybrid-2” (↓↑↓↓) (77). In 2019, Bao et al. found
that the hybrid-1 and -2 type conformations exist within HeLa cells by monitoring the folding of an
injected 22-nt long telomere sequence, AGGG(TTAGGG)3, using a state-of-the-art in-cell 19F-NMR
technique (79).
Initial investigations of telomeric G-quadruplexes demonstrated that they act as a steric
inhibitor of telomerase (7,32), and therefore are a transient protection mechanism in cells with
exposed 3’ single-stranded ends. Indeed, when shelterin proteins are absent (or “uncapped”), the
exposed ssDNA folds into a G-quadruplex and elicits a specific DNA damage response (80). There
may also be a role for G-quadruplexes in mediating the so-called “T-loop” protective structure. The
T-loop is formed when the telomere end forms a protective circle which requires a strand-invasion
by the free 3’ overhang (65). Thus, the T-loop requires a free 3’ overhang for interaction with the
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shelterin proteins TRF1 and TRF2 (TTAGGG Repeat binding Factors 1 and 2) (81,82). Indeed,
when telomere G-quadruplexes are stabilized by small molecules a DNA damage response is
observed in cells (83), which is a result of sequestering the free 3’ (TTAGGG)n overhang from both
telomerase and TRF1/2 (82). Another shelterin protein, human protection of telomeres 1 (hPOT1),
binds directly to the free 3’ terminus and acts as a critical regulator of its length by both unfolding
telomere G4s for hTERT to gain access and preventing aberrant extension by blocking access to
the free 3’ end (84,85). Direct inhibition of hPOT1 results in reduced cellular proliferation of cells
requiring telomerase activity (86). Thus, targeting the telomeric G-quadruplex is a promising route
for anti-cancer therapeutic development (87).

Non-telomere G-quadruplexes
The first glimpse of non-telomeric G-quadruplex functionality came from a report in 1988
in which evidence of an inter-stranded tetramer G-quadruplex was described in immunoglobulin
switch regions based on mobility shift assays (23). This discovery was essential in explaining the
peculiar rearrangements observed within the human insulin gene promoter reported six years prior
(88). It was subsequently discovered that the Bloom’s syndrome helicase is able to unwind DNA
G-quadruplexes in vitro (89), prompting sequencing studies of G4 helicase knock out cells which
ultimately confirmed that G-quadruplexes play a direct role in recombination events (90). In 1994,
Woodford and colleagues observed the first biologically relevant intra-strand G-quadruplex in the
promoter of the chicken β-globin gene (91). Using a standard linear polymerase reaction, and clever
mutational analyses, the authors showed that this tetraplex formation stalled DNA polymerase in a
potassium-dependent manner and, further, demonstrated that the effect was not observed when
Hoogsteen hydrogen bonding was disrupted through mutation with 7-deaza-dGTP. These
discoveries were paramount for understanding, in part, the “obscure” mechanism by which c-MYC
transcription is regulated.
The c-MYC gene is a part of the MYC family of oncogenes which are best known for their
central role in cell growth and proliferation (92). MYC is overexpressed in as much as half of all
human cancers, and its ability to initiate and maintain tumorigenesis has long made it an attractive
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anticancer target (93). However, it has thus far been “undruggable” using traditional protein-centric
techniques due to the nature of its protein structure, and so alternative strategies for its inhibition
have been in the works for decades (94). One of the major regulatory control elements of c-MYC
transcription, located from -115 to -142 bp upstream of the promoter, known as the nucleasehypersensitive element III1 (NHE-III1), accounts for as much as 85% of total transcription (95,96).
The NHE-III1 is interesting because of its strand asymmetry, meaning that one strand is nearly
exclusively homopurine. Further, in vitro this sequence is able to adopt a non-helical, atypical DNA
structure (97). In their 1998 seminal work, Simonsson et al. showed that the c-MYC NHE-III1
sequence forms a unique intra-strand antiparallel G-quadruplex, indicating for the first time the
possibility of a G-quadruplex-mediated transcriptional control mechanism (98). Four years later,
transcriptional repression of c-MYC via G-quadruplex stabilizing small molecules was confirmed,
sparking a much wider interest in the G-quadruplex as a potential new class of receptor (99).
To date, In vitro studies conducted with G4-specific antibodies and fluorescent probes (2630), G-quadruplex sequencing (31), and targeted bioinformatic inquiries (11,12) have unearthed
hundreds of thousands of places in the human genome where G-quadruplexes putatively form
(putative quadruplex forming sequences, PQSs). PQSs are non-randomly distributed, conserved
between species, and primarily reside in functionally important regions (100). Further, these motifs
are significantly associated with oncogene promoters and somatic copy number alterations related
to cancer development (31). To date, a variety of monomeric oncogenic promoter G-quadruplexes
have been validated both in vitro and in functional cell-based assays: c-MYC (16), KRAS (101),
HRAS (102), HIF-1α (103), VEGF (104), and hTERT (105,106).
Genome-wide mapping studies have now identified what appears to be a universal
epigenetic mechanism of genomic G-quadruplexes. PQSs are highly susceptible to the formation
of 8-oxoguanine (8-oxoG) as the result of oxidative insult (107). These lesions are recognized by
8-oxoG DNA glycosylase (OGG1) an initiator of the base excision-repair (BER) pathway (108).
Excision by OGG1 of the oxidized base results in an apurinic (AP) site, which in turn, leads to the
recruitment of AP endonuclease 1 (APE1) (108,109). Using an innovative “AP-seq” technique,
along with traditional ChIP- and G4-sequencing, Roychoudhury and colleagues have now shown
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that APE1, in response to 8-oxoG induced AP site generation, is essential in facilitating the
formation of G-quadruplexes throughout the genome (109). Further, they show that the recruitment
of APE1 to 8-oxoG G4 sites directly increases transcription factor loading onto the promoter,
providing essential insight into the role of G-quadruplexes in transcriptional control.
Aside from telomere protection, recombination events, and transcriptional regulation, Gquadruplexes serve a variety of other biological roles. For instance, in mammals, the telomere is
transcribed into a long non-coding G-rich stretch of RNA (UUAGGGn) known as “TERRA”
(Telomeric Repeat-containing RNA) (110). TERRA forms parallel stacked RNA multimeric Gquadruplexes (111), and is currently under investigation as an essential component in telomere
maintenance, genome stability, and heterochromatin formation (110). Other “structural” RNA Gquadruplexes have been identified in ribosomal RNA (112), recruitment sites for histone modifiers
(113), and transiently in other RNA transcripts across the cell (114). RNA G-quadruplexes play
important roles in mRNA translation, processing, and targeting (25). One early example is the
identification of a G-quadruplex motif within the insulin-like growth factor II mRNA that flanks the
major cleavage site within its 3’ untranslated region (3’ UTR) and appears essential in its processing
(115). In fact, many such examples exist of mRNA with G-quadruplex formation within their 5’ and
3’ UTRs, and this mode of regulation appears to be a common mechanism [see ref (116) for a
recent review]. For instance, the NRAS proto-oncogene mRNA transcript contains a G-quadruplex
motif in its 5’ UTR 222 nucleotides upstream of the translation start site that acts as a repressor of
its translation (117). Altogether, G-quadruplexes are diverse and important nucleic acid secondary
structures involved in a wide array of essential biological processes, making them exciting new
targets in drug discovery (Figure 5).

G-quadruplexes in nanotechnology and therapeutics
G-quadruplex based systems have applications outside of their biological functionality,
such as in nanotechnology (118) and as therapeutics (119). When Ivar Bang made the discovery
that concentrated guanosine monophosphate solutions would spontaneously form “gels”, he
suggested that the gel was the result of polymerization of the nucleotides (37). This polymerization
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results in long stacking interactions of hundreds of G-tetrad units, now known as G4-wires (120).
Due to their extensive π overlap, structural rigidity, and guanine having the lowest ionization
potential of all nucleotides, G4-wires are now being assessed for their use in nanoelectronics
applications (121,122). Further, the formation of G-quadruplexes can be rapid and reversible,
making them well suited as components or “building blocks” of nanodevices (118). For instance,
G4s are now being used as biosensor logic gates, where the formation of a G4 in response to a
given analyte results in the complexation of hemin with the G4, which in turn, leads to an amplified
redox reaction that can be monitored spectroscopically (123).
G-quadruplexes have also made their way into the clinic as macromolecular drugs called
aptamers (119). DNA aptamers are short oligonucleotides that bind specifically to biological targets
to exert their functions. Currently, DNA G-quadruplex aptamers are being developed for the
purposes of anticoagulation, anti-cancer, antiviral, antibacterial, antifungal, and as treatments for a
variety of human maladies such as inflammatory diseases, prion diseases, and thyroid disorders
(119,124). A notable example is the G-quadruplex aptamer AS1411 discovered by Bates et al.
(125,126). Originally, AS1411 was shown to exert its anti-cancer activity by selectively binding to
nucleolin expressed on the cell surfaces of cancer cells (as nucleolin is absent from normal cell
surfaces) (126). At the time it was believed that nucleolin acted as a cancer-specific receptor for
AS1411. Once internalized, the aptamer could interfere with nucleolin’s pro-survival functions,
resulting in cancer cell death (126). However, recent work has called this mechanism into question
(127). AS1411 entered clinical trials but did not progress past phase 2 (127). Overall, it was well
tolerated by patients and exhibited an excellent safety profile. The response rate in patients was
low, although 3 patients with renal cell carcinoma and 4 with acute myeloid leukemia had favorable
and lasting responses (127). Since its clinical assessment AS1411 has spurred great interest in
anti-cancer G-quadruplex aptamer development.
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Figure 5. Locations and functions of G-quadruplexes in cells. G4s are non-randomly distributed in
the genome, and specifically occupy telomeres (A), gene promoters or replication forks (B), and 5’
UTRs of mRNAs (C). Red T-bars indicate their putative functions (e.g. prevention of telomere
extension by telomerase [A] or blockage of transcription [B], replication [B], or translation [C]).
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Targeting G-quadruplexes

Due to the wealth of conformational diversity, the various monomeric G-quadruplex
conformations have been targeted extensively for over two decades with hopes of finding selective
small molecules with in vivo efficacy. The first report of a telomere-interacting small molecule was
in 1997 when Sun et al. demonstrated that a di-substituted anthraquinone derivative was able to
stabilize the telomere G-quadruplex and effectively inhibit telomerase’s ability to extend in vitro
(101). Soon after, the cationic porphyrin molecule TMPyP4 was identified which had a 2-fold
preference for binding G-quadruplex over duplex DNA (128). Since then, a variety of other G4
selective molecules have been developed with drug-like affinities in the low nanomolar range,
notably: BRACO-19 (129), Telomestatin (130), Pyridostatin (131), Phen-DC3 (132), CX-5461
(133), and CX-3543 (a.k.a. “Quarfloxin”) (134) (Figure 6). TMPyP4, BRACO-19, Telomestatin, and
Pyridostatin all interact with the telomeres, and induce a variety of biological responses, such as:
telomerase inhibition, induction of DNA damage responses, telomere shortening, selective
induction of apoptosis in cancer cells, uncapping of shelterin proteins, induction of double-stranded
breaks, and inhibition of oncogene transcription (via promoter G-quadruplex stabilization) (135).
CX-5461 was initially shown to block the initiation of ribosomal RNA (rRNA) synthesis, and this was
believed to be its anticancer mechanism (136). However, it was recently revealed that CX-5461
interacts strongly with G-quadruplexes, and in doing so induces double-stranded DNA breaks
which effectively kill DNA repair-deficient cancer cells (133). Currently, CX-5461 is in phase I
clinical trials as a general cancer treatment (Trial NCT02719977, opened May 2016), although the
trial is not currently recruiting patients. Conversely, Quarfloxin has completed Phase II clinical trials
and was shown effective against neuroendocrine tumors, carcinoid tumors, and lymphoma (134).
Interestingly, the mechanism of Quarfloxin appears to be the disruption of nucleolin binding to
ribosomal DNA, causing nucleolin to reroute to the c-MYC promoter G-quadruplex to repress it.
However, Phase III clinical trials have stopped due to its high serum albumin binding (18). A variety
of other G4 ligands can be found in the G-quadruplex ligands database, or “G4LDB” (17), which
was created in 2012 and contains nearly 1,000 confirmed G4 ligands.
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Figure 6. Structures of some common high affinity G4 ligands. (A) 2,6-diamidoanthraquinone, (B)
TMPyP4, (C) Phen-DC3, (D) BRACO-19, (E) Telomestatin, (F) CX-3543, and (G) CX-5461
(Quarfloxin).
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G-quadruplex stabilizing ligands are clearly viable anti-tumor agents. Why then have the
majority of identified G4 ligands not succeeded clinically? The answer, in part, is two-fold: (1)
monomeric G4s share too similar a structural landscape [selective targeting of the G-tetrad face is
akin to the protein kinase promiscuity problem (15)] and, (2) attempts at improving the selectivity
of small molecules towards these monomeric G4s, which is typically achieved by adding loop
interacting chemical moieties, tend to render them less “drug-like” or impact their bioavailability
(18,137). For instance, BRACO-19, which inhibits telomerase with an IC50 (half maximal inhibitory
concentration) of 115 nM, was developed from a core disubstituted acridine scaffold (129). In vitro,
BRACO-19 binds tightly to the telomere and leads to uncapping of the shelterin protein complex,
ultimately eliciting a severe telomere DNA damage response (83). A crystal structure of BRACO19 in complex with the human telomere sequence d(TAGGGTTAGGGT)2 was reported, showing
that BRACO-19 preferentially end-pastes onto the terminal G-tetrad face (Figure 7) (138). BRACO19 has demonstrable anti-tumor activity in cells derived from epidermoid carcinoma, colorectal
cancer, uterus carcinoma, and prostate cancer (although also cardiotoxic) (135). The acridine
scaffold is well known to end-paste on the terminal tetrads of the telomere G-quadruplexes (139).
The addition of the pyrrolidine rings to the core acridine scaffold in BRACO-19 increases its
selectivity via interaction with the G4 loops. However, the increase in both molecular weight (MW)
and charge from the protonated tertiary amines reduces its ability to cross membranes (140),
rendering it less bioavailable and drug-like. While this is not the rule (See Quarfloxin above), it
emphasizes the problem of selectivity faced by the G4 drug discovery community (18).
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Figure 7. Top and side views of BRACO-19 bound to the human telomere sequence
d(TAGGGTTAGGGT)2 via an end-pasting mechanism. BRACO-19 is shown in green and the
telomere G-quadruplex is shown as a ribbon model with semi-transparent space-fill.
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Most rational drug discovery studies targeting G4s to date have focused on targeting the
monomeric forms of G-quadruplexes—owing to the wealth of atomic structures available (>250 in
the Protein Data Bank). It has been evident since the 1980’s [but observed well before then (37)]
that guanine-rich DNAs can multimerize under physiologically relevant buffer conditions and
oligonucleotide concentrations (19,20). There is now evidence for the occurrence of G4 multimers
in the telomeres (141,142) and in oncogene promoters [hTERT (143-145), c-MYB (146), kRAS
(147), c-MYC (148), and c-KIT (149)]. The few multimers with high-resolution structures available
are the putative T:H:H:T dimer of the c-MYB promoter (56), a synthetic aptamer two-stacked twotetrad G4 (57), and two, two-stacked two-tetrad multimers containing left-handed “Z-G4s” (50,51).
Importantly, G4 multimers offer unique binding sites among their loop and groove interface that
may allow circumvention of the non-specificity problem encountered with monomers (141). Indeed,
this potential for selective-targeting of a multimer over monomer G4 has already been
demonstrated using a non-drug-like chiral metallo-supramolecular complex targeting the higherorder telomere sequence (150). Altogether, these findings highlight the dire need for a better
understanding of multimeric G-quadruplexes as specific targets for rational drug discovery
campaigns.

Summary of Dissertation Works

The ISB approach to solve the structure and spatial organization of higher order protein,
RNA, protein-RNA, and protein-DNA systems has been a paradigm for over 20 years (151), yet no
such approach has been applied to higher-order G-quadruplex DNA structures. Here I have
outlined a clear need for tools which will enable a detailed description of these multimeric systems
which putatively reside in both telomeres and oncogene promoters. To this end, the major goal of
this work is to apply the ISB approach to G-quadruplex multimers for their use in rational drug
discovery.
In Chapter II I have characterized the major structure of the higher-order telomere Gquadruplex. I first applied size-exclusion chromatography coupled with small-angle X-ray scattering
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(SEC-SAXS) to the telomere sequences Tel48 (d[TTAGGG]8), Tel72 (d[TTAGGG]12), and Tel96
(d[TTAGGG]16) which allowed for their qualitative and quantitative structural descriptions. I
subsequently showed that the higher-order telomere sequences preferentially maximize their G4
formation. I then rigorously dissected the major structural components of the intramolecular “dimer”,
Tel48, and a variety of mutant sequences by circular dichroism (CD) spectroscopy. This mutational
study revealed that the higher-order human telomere favors the hybrid-1 and hybrid-2 topologies,
adopting a ~25:75 ratio of hybrid-1 and hybrid-2. Next, by combining monomeric atomic coordinate
files from previous NMR studies with MD simulations, I constructed and refined the first ever allatom molecular models of the extend human telomere at the highest resolution to date. From these
models, multiple unique sites among junctions and grooves were revealed that could be used as
receptors in future rational drug discovery campaigns. This work has been submitted to Nucleic
Acids Research and is in review as of the drafting of this dissertation.
Chapter III uses the telomere G-quadruplex multimer models described above as targets
in a massive virtual drug discovery campaign. In this chapter I applied the program Surflex-Dock
v2.11 to screen millions of compounds virtually against G4-junctional sites formed between the
hybrid-1 and hybrid-2 moieties. From this screen I purchased 37 compounds and, using CD melting
and analytical ultracentrifugation (AUC) binding studies, found that one compound, C37, binds in a
1:1 stoichiometry with the G4-juntions (e.g. 1:1 with the telomere dimer, tel48, 2:1 with the telomere
trimer, tel72. This binding is specific for the higher-order telomere G4s over monomer telomere Gquadruplexes. C37 is currently being investigated for its binding mode and potential anticancer
effects in cells.
In Chapter IV I applied a similar ISB approach to the hTERT core promoter G-quadruplex.
In this study I used circular dichroism to characterize the full-length and truncated hTERT core
promoter sequences. 1H-NMR spectroscopy was employed to investigate the extent of G-tetrad
formation as well as investigate the possibility of hairpin formation. I then utilized a novel circular
dichroism-monitored DNase I reaction to confirm that no hairpin forms within the hTERT WT
sequence, but does in the artificial hairpin control. Hydrodynamic investigations were then
conducted in combination with hydrodynamic bead model calculations from MD-derived atomistic
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models to investigate the size and organization of G4 domains. I then used SEC-SAXS to probe
the overall higher-order assemblies which confirmed that the WT promoter is an all-parallel stacked
G4 system. This work is published in Nucleic Acids Research and is reproduced in Chapter IV.
G4 DNA virtual drug discovery is still in its infancy, and so in light of this Chapter V is a
review of the contemporary G-quadruplex virtual screening (VS) techniques. In this chapter I have
presented the various methods used in pharmacophore and docking-based screens, library size
and preparation, scoring functions, and the future of computational VS approaches. I also discuss
past successes and failures in the field and point out pitfalls that can be avoided in future
campaigns. Lastly, I provide recommendations on how to properly report on virtual screening
campaigns by describing guidelines for future investigators. This work is published in the journal
Biochimie and is reproduced in Chapter V.
In my final experimental section, I applied our recommendations outlined in Chapter V to
targeting the hTERT core promoter G-quadruplex multimer characterized in Chapter IV. I began
with a massive virtual screening campaign using the docking program Surflex-Dock v2.11, whereby
I targeted 12 different loop and groove pockets of the hTERT G4 in silico. I then clustered the
resulting top hits using a hierarchical clustering algorithm and identified 69 unique molecular
scaffolds which were available for purchase. Multiple rounds of a high-throughput thermal
denaturation screens and orthogonal biophysical assays were then used to assess drug selectivity
for the hTERT multimer over duplex, triplex, and monomer G-quadruplex DNA topologies. I
subsequently utilized an in-house automated docking to MD simulation pipeline to investigate the
potential binding modes of the top hits, revealing multiple preferential loop and groove binding
modes. Lastly, I employed quantitative real-time polymerase chain reaction (qRT-PCR) and
proliferation assays to assess compound efficacy in human breast cancer cells, confirming that one
compound, 3B1, reduces hTERT transcription. Compound 3B1 is currently being investigated
extensively in breast cancer cells as a lead molecule.
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CHAPTER II

THE SOLUTION STRUCTURES OF HIGHER-ORDER HUMAN
TELOMERE G-QUADRUPLEX MULTIMERS

Human telomeres contain the repeat DNA sequence 5’(TTAGGG), with duplex regions that
are several kilobases long terminating in a 3’ single-stranded overhang. The structure of the singlestranded overhang is not known with certainty, with disparate modes proposed in the literature. We
report here the results of an integrated structural biology approach that combines small-angle Xray scattering, circular dichroism (CD), analytical ultracentrifugation, size-exclusion column
chromatography and molecular dynamics simulations that provide the most detailed
characterization to date of the structure of the telomeric overhang. We find that the single-stranded
sequences 5’(TTAGGG)n, with n=8, 12, and 16, fold into multimeric structures containing the
maximal number (2, 3, and 4, respectively) of contiguous G4 units with no long gaps between units.
The G4 units are a mixture of hybrid-1 and hybrid-2 conformers. In the multimeric structures, G4
units interact, at least transiently, at the interfaces between units to produce distinctive CD
signatures. Global fitting of our hydrodynamic and scattering data to a worm-like chain (WLC)
model indicates that these multimeric G4 structures are semi-flexible, with a persistence length of
about 34 Å. Investigations of its flexibility using MD simulations reveal stacking, unstacking, and
coiling movements, which yield unique sites for drug targeting.

35

Introduction

Telomeres are structures found at the end of eukaryotic chromosomes which protect
genomic DNA from degradation, end-to-end fusion, and homologous recombination (64,65). The
human telomere consists of the repeat d(TTAGGG) n, and ranges from 5-25 kb in length with an
extended single-stranded 3’ overhang of a few hundred bases in non-germ cells (63). This locus
has long been associated with human diseases, such as cancer (59) and telomeropathies (60), as
well as aging (61) and general genome homeostasis (62). In normal somatic cells, each round of
cellular division results in a shortening of the telomere due to the so-called end replication
problem—a mechanism believed to be protective against uncontrolled replication (66). Once the
telomere has become critically short in normal (non-stem) cells, a DNA damage response is
triggered, resulting in uncapping of the telomere-bound shelterin proteins and, eventually,
apoptosis (65,66). Cancer cells avoid this fate by utilizing mechanisms that restore telomere length.
In more than 85% of cancers, this is accomplished by reactivating human telomerase reverse
transcriptase (hTERT), a ribonucleoprotein that extends the telomere 3’ overhang (10,68,69). Gquadruplex (G4) formation in the telomere overhang can inhibit hTERT binding and extension
function (7). Treating cells with telomere G4-specific small molecules leads to uncapping of the
shelterin proteins and a sequestering of the free single-stranded telomere overhang, ultimately
resulting in a telomere-specific DNA damage response (82,83,87). These findings have made
telomere G4 an attractive cancer target (87).
G-quadruplexes form in guanine-rich sequences, in which guanine tracts interact to form
square planar tetrads (G-tetrads) that stack atop one another and are stabilized by coordinating
cations, pi-stacking interactions, and a Hoogsteen hydrogen bonding network (40). Many telomere
G4 topologies have been characterized at the atomic level by X-ray crystallography and NMR
studies. These studies have demonstrated that the monomeric form of the human telomere can
exist as parallel (75), hybrid 3+1 (76,77), antiparallel (74), and two-tetrad antiparallel (47) structures
under various ionic and crowding conditions. The Yang lab (76,77,152), Patel lab (153,154), and
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we (78) have since shown that the wild-type telomere adopts primarily the hybrid-1 and hybrid-2
topologies in physiologically relevant solution conditions. The Yang lab has shown by NMR that in
vitro the wild-type monomeric telomere sequence of the form (TTAGGG)4T exists in a dynamic
equilibrium of hybrid-2 (~75%) and hybrid-1 (~25%) (46).
Telomere G-quadruplexes have also been observed directly in cells. In vivo, G4-specific
antibodies and fluorescent ligands have confirmed the formation of telomere G4s (26-28). Using
the sequence AGGG(TTAGGG)3, Hong-Liang and colleagues used

19F-NMR

cell studies to show

that the hybrid-1, -2, and a two-tetrad anti-parallel type (hybrid-3), but not the parallel or antiparallel
“basket” topologies, spontaneously form when injected into live HeLa cells (79). Altogether, these
studies demonstrate that the most physiologically and thermodynamically relevant monomeric
telomere conformations are of the hybrid type.
Although the monomeric telomere G-quadruplex has been extensively studied, there is
little structural information on longer telomere sequences forming higher-order telomere structures.
Conservative estimates of the length of the single-stranded overhang of the human telomere in
fibroblasts indicate that the sequence exceeds the ~30 nucleotides necessary for formation of a
single telomere G-quadruplex. Estimates of “normal” single-stranded overhangs range from ~50 to
>600 nucleotides (58,63), supporting the possibility of multiple G4s forming in tandem. There have
been few attempts to characterize these systems at the atomic level because of the difficulties
involving guanine imino overlap and structural polymorphism which hamper NMR studies (46), and
the difficulty of obtaining quality crystals for X-ray diffraction (78). Elucidating this higher-order
structure is important, as its role in mediating interactions with shelterin proteins, single-stranded
binding proteins, and telomerase is critical in maintaining genomic integrity (64,155,156).
To date, only a few low-resolution molecular models and characterizations were reported
for the long telomere sequences. In 2006, using a combination of gel electrophoresis, CD, and UVmelting, Yu et al. proposed that the telomere multimer of the form (TTAGGG) n, where n is 4, 8, or
12, maximizes its usage of G-tracts by forming a “beads-on-a-string” assembly of a variety of
telomere topologies (parallel, antiparallel, and hybrid) (55). In 2009 Renčiuk and colleagues, using
CD and PAGE experiments, came to the same general conclusion that the higher-order telomere
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is capable of folding into multiple conformations in K + buffers (parallel, antiparallel, or hybrid) but
also that they have the potential to stack, depending on the amount of macromolecular crowding
(157). The same year Xu et al. demonstrated the formation of higher-order G-quadruplex formation
in 96 nucleotide (nt) long telomere sequences by atomic force microscopy (AFM) (158). While the
authors arrived at a similar conclusion about the overall higher order assembly (e.g. maximized G4
formation and potential for G4-G4 interactions), they did not report on the topologies of the G4
subunits. A later AFM investigation of a 96 nt long telomere sequence, (TTAGGG)16, by Wang and
colleagues reported the presence of gaps between G4 units, and suggested that the extended
sequences “rarely” maximize G-tract usage (159). A similar conclusion was drawn from lowresolution studies using electron microscopy (EM), single-molecule magnetic tweezers, and singlemolecule force ramp assays (160,161). Although, these studies may suffer from insufficient sample
annealing protocols or equilibration times. Our prior biophysical studies investigating the secondary
and tertiary structure of the higher-order telomere sequences (TTAGGG)n and (TTAGGG)nTT,
where n = 4, 8, 12, 16 and 32, gave evidence that these sequences preferentially maximize G-tract
usage, and preferentially form a mixture of the hybrid-1 and hybrid-2 conformations (141,162,163).
Subsequent investigations by molecular dynamics (MD) simulations, analytical ultracentrifugation
(AUC) (163), and differential scanning calorimetry (DSC) (162) studies indicated that, overall, the
extended telomere G4s adopt compact, somewhat rod-like structures via stacking interactions
between G4 subunits and intervening TTA linkers (162). The best-fit models from these analyses
were alternating (5’) hybrid-1 (3’) hybrid-2, referred to as hybrid-12 and hybrid-121, for n = 8 and n
= 12 runs, respectively. Interestingly, thermodynamic studies of these two higher-order systems
revealed that “each quadruplex in the higher-order structures is not independent and identical but
is thermodynamically unique and is influenced by its neighbors” (162). Clearly, there is no
consensus on the higher-order telomere’s behavior in solution. Low-resolution imaging and singlemolecule studies would suggest a very flexible beads-on-a-string arrangement with large gaps
occurring between G-quadruplexes, whereas the latter investigations suggest a more rigid
structure, with maximal G-quadruplex formation.
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Using an integrative structural biology approach (164,165), which combines CD,
hydrodynamics, molecular dynamics, and small-angle X-ray scattering (SAXS), we show that the
telomeric sequences form the maximal number of G4 units without any long gaps. Modeling the
hydrodynamic and scattering-derived properties of sequences from 24 nt to 96 nt to a worm-like
chain (WLC) model reveals a persistence length of ~34 Å, which is in between that of singlestranded DNA (ssDNA) (~22 Å) (166) and double-stranded DNA (dsDNA) (~550 Å) (167), indicating
that the extended telomere G4 is semi-flexible. This flexibility is consistent with MD simulations,
which show transient stacking interfaces that create potentially unique binding grooves useful in
drug targeting. We follow this with an extensive sequence analysis of the sequence d(TTAGGG) 8
to determine the major constituent G4 topologies. Using CD and mutational analyses we show that
the higher-order human telomere is composed of a ratio of hybrid-1 (~25%) and hybrid-2 (~75%)
topologies. Our results are in excellent agreement with prior hydrodynamic and NMR analyses of
the human telomere sequences (77,154,163). The resulting structural ensembles provide the first
“medium-resolution” look at the conformational heterogeneity and dynamics of the higher-order
telomere G-quadruplex.

Materials and Methods

Oligonucleotides
Oligonucleotide sequences were purchased from IDT (Integrated DNA Technologies,
Coralville, IA) with standard desalting. Upon receipt, stock oligos were dissolved in MilliQ ultrapure
water (18.2 MΩ x cm at 25°C) at 1 mM and stored at -20.0°C until use. All experiments were carried
out in a potassium phosphate buffer (6 mM Na2HPO4, 2 mM NaH2PO4, 185 mM KCl, 1 mM
Na2EDTA, pH 7.2). Folding was achieved by diluting stock oligos into buffer and boiling in a water
bath for 20 minutes, followed by slow cooling overnight. Purification was achieved using size
exclusion chromatography (SEC) as detailed previously (168). Briefly, oligos were annealed at
concentrations of 40-60 μM, filtered through 0.2 μm filters, and injected onto an equilibrated
Superdex 75 16/600 SEC column (GE Healthcare 28-9893-33) using a Waters 600 HPLC system.
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The flow rate was maintained at 0.5 mL/min and sample fractions were collected every 2 minutes
from 100 to 180 minutes run time. The molecular weights of fractionated species were estimated
based on a regression analysis of elution time vs. log(MW) of protein standards (Sigma #69385),
the major folded species were visually evident as symmetric peaks when monitored at 260 nm (or
280 nm for protein standards). Fractionated samples were pooled and stored at 4°C prior to
concentration. Where applicable, pooled fractions were concentrated using Pierce protein
concentration devices with 3k MWCO (Thermo #88512, #88515, and #88525) which were rinsed
free of glycerol. For AUC and SEC-SAXS experiments, samples were dialyzed after concentration
using Spectra/Por Float-A-Lyzers G2 3.5 kDa (Sigma #Z726060) in order to buffer match.
Concentrations were determined using molar extinction coefficient given in Table 1.
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Table 1. Names, properties, and sequences of oligonucleotides used in this study.

41

Name

Length MW (kDa)

Sequence

E260 (M-1cm-1)

(nt)
2JSL

TAGGGTTAGGGTTAGGGTTAGGGTT

25

7.9

253100

Tel48

(TTAGGGTTAGGGTTAGGGTTAGGG)2

48

15.2

489100

Tel72

(TTAGGGTTAGGGTTAGGGTTAGGG)3

72

22.8

733400

Tel96

(TTAGGGTTAGGGTTAGGGTTAGGG)4

96

30.5

977800

Tel49

TTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGT

49

15.5

497500

Tel50

TTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTT

50

15.8

505600

M1

TAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGG

47

14.9

480900

M2

TAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTT

49

15.5

497500

hybrid-12* TT_GGGTTAGGGTTAGGGTTAGGGATAGGGTTAGGGTTAGGGTTAGGGT

48

15.2

488000

hybrid-11* TT_GGGTTAGGGTTAGGGTTAGGGAT_GGGTTAGGGTTAGGGTTAGGGA

47

14.9

479200

hybrid-21* TTAGGGTTAGGGTTAGGGTTAGGGTT_GGGTTAGGGTTAGGGTTAGGGA

48

15.2

488700

48

15.2

489500

hybrid-32* AGGGTTAGGGTTAIGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTT

48

15.2

489850

M4

GGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTT

47

14.9

476000

M5

AGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGT

47

14.9

481100

47

14.9

482100

M3

AGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTT

hybrid-33* AGGGTTAGGGTTAIGGTTAGGGTTAGGGTTAGGGTTAIGGTTAGGGT

_ = removed base, I = Inosine sub, * = sequence has internal stabilizing modification
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Size exclusion chromatography (SEC) determination of Stokes radii
Elution times from re-injections of SEC purified fractions were used in the method of Irvine
(169) to determine Stokes radii, which were converted to translational diffusion (Dt) coefficients for
use in Multi-HYDFIT hydrodynamic modeling (see below). Stokes radii were determined from a
regression analysis of elution time vs. log(MW) of protein standards (Sigma #69385).

Analytical ultracentrifugation (AUC)
Sedimentation velocity (SV) experiments were performed in a Beckman Coulter
ProteomeLab XL-A analytical ultracentrifuge (Beckman Coulter Inc., Brea, CA) at 20.0°C and
40,000 rpm in standard 2-sector cells using either an An60Ti or An50Ti rotor. Samples were
equilibrated in the rotor at 20.0°C for at least 1 hour prior to the collection of 100 scans over an 8hour period. Initial analyses were performed in SEDFIT (170) using the continuous C(s) model with
resolution 100 and S range from 0 to 10. A partial specific volume of 0.55 mL/g for DNA Gquadruplexes was used as previously determined (163). The Tel72 and Tel96 sequence
sedimentation coefficients were additionally corrected for any concentration-dependence using
three separate concentrations.

Circular dichroism
CD spectra were collected on a Jasco-710 spectropolarimeter (Jasco Inc. Eason, MD)
equipped with a Peltier thermostat regulated cell holder equilibrated to 20.0°C. Spectra were
collected using the following instrument parameters: 1 cm path length quartz cuvettes, 1.0 nm step
size, 200 nm/min scan rate, 1.0 nm bandwidth, 2 second integration time, and 4 scan accumulation.
Spectra were corrected by subtracting a buffer blank and normalized to molar circular dichroism
(Δε, M-1cm-1) based on DNA strand concentration using the following equation:
∆𝜀 = 𝜃/(32982𝑐𝑙)
where θ is ellipticity in millidegrees, c is molar DNA concentration in mol/L, and l is the path length
of the cell in cm. Comparison or fitting of CD spectra with their monomer theoretical spectra was
done manually in Microsoft Excel using spectra from a previously reported database (171).
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Residual sum of squares (RSS) analysis of the CD ΔΔε “residuals” was carried out and plotted in
Origin 2020.

Size exclusion chromatography resolved small angle X-ray scattering (SEC-SAXS)
SAXS was performed at BioCAT (beamline 18ID at the Advanced Photon Source, Chicago)
with in-line size exclusion chromatography. Samples in BPEK buffer (6 mM Na2HPO4, 2 mM
NaH2PO4, 185 mM KCl, 1 mM Na2EDTA, pH 7.2) were loaded onto an equilibrated Superdex 75
10/300 GL column, which was maintained at a constant flow rate of 0.7 mL/min using an AKTA
Pure FPLC (GE Healthcare Life Sciences) and the eluate after it passed through the UV monitor
was directed through the SAXS flow cell, which consists of a 1 mm ID quartz capillary with 50 μm
walls. A co-flowing buffer sheath was used to separate the sample from the capillary walls, helping
to prevent radiation damage (172). Scattering intensity was recorded using a Pilatus3 1M (Dectris)
detector which was placed 3.5 m from the sample giving access to a q-range of 0.004 Å-1 to 0.4 Å1.

A series of 0.5 second exposures was acquired every 2 seconds during elution and data was

reduced using BioXTAS RAW 1.6.3 (173). Buffer blanks were created by averaging regions flanking
the elution peak and subtracted from exposures selected from the elution peak to create the I(q)
vs. q curves used for subsequent analyses. More information on SAXS data collection, reduction
and interpretation can be found in Table 2. SAXS sample preparation, analysis, data reduction,
and data presentation has been done in close accordance with recent guidelines (174).
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Table 2. Tabulated collection parameters, data reduction methods, and data analyses for smallangle X-ray scattering data.
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(a) Sample Details.
2JSL

Tel48

Tel72

Tel96

Organism

synthetic

synthetic

synthetic

synthetic

Source

IDT

IDT

IDT

IDT

253100

489000

733400

974870

0.55

0.55

0.55

0.55

7879

15212

22849

30486

Loading concentration (mg/mL)

7.0

13.0

10.0

6.0

Injection volume (μL)

300

300

250

440

Flow rate (mL/min)

0.7

0.7

0.7

0.7

6 mM Na2HPO4,

6 mM Na2HPO4,

6 mM Na2HPO4,

6 mM Na2HPO4,

Extinction

coefficient

(nearest

neighbor approximation) (M-1 cm-1)
3

vbar (cm /g) (estimate)
M from chemical composition (Da)
SEC-SAXS

column,

10

x

300

Superdex 75

2 mM NaH2PO4,

2 mM NaH2PO4,

2 mM NaH2PO4,

2 mM NaH2PO4,

Solvent (solvent blanks taken from

185 mM KCl, 1

185 mM KCl, 1

185 mM KCl, 1

185 mM KCl, 1

SEC flow through prior to elution of

mM

mM

mM

mM

protein)

pH 7.2

Na2EDTA,

Na2EDTA,

pH 7.2

Na2EDTA,

pH 7.2

Na2EDTA,

pH 7.2

(b) SAXS data-collection parameters.
BioCAT facility at the Advanced Photon Source beamline 18ID with Pilatus3 1M
Instrument/data processing

(Dectris) detector

Wavelength (Å)

1.033

Beam size (μm)

150 (h) x 25 (ν)

Camera length (m)

3.5
-1

q measurement range (Å )

0.004-0.4

Absolute scaling method

N/A
To incident intensity, by ion chamber

Normalization

counter
Automated

Monitoring for radiation damage

frame-by-frame

comparison of relevant regions
0.5 s exposure time with a 2s total exposure period (0.5 s

Exposure time, number of exposures

on, 1.5 s off) of entire SEC elution
SEC-SAXS. Size separation by an AKTA Pure with a Superdex 75 Increase

Sample configuration

10/300 GL column. SAXS data measured in a 1.5 mm ID quartz capillary

Sample temperature (°C)

20

(c) Software employed for SAXS data
reduction, analysis, and interpretation.
Radial averaging; frame comparison, averaging, and subtraction done using
SAXS data reduction

BioXTAS RAW 1.6.3 (Hopkins et al. 2017 (172))

Extinction coefficient estimate

Nearest neighbor approximation
Guinier fit, Kratky analysis, and molecular weight using BioXTAS RAW 1.6.3,

Basic analyses: Guinier, P(r), Vp

P(r) function using PRIMUSqt (ATSAS v2.8.4 (173))
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DAMMIF (Franke & Svergun, 2009) via ATSAS online (https://www.emblShape/bead modelling

hamburg.de/biosaxs/atsas-online/)

CRYSOL from PRIMUSqt in ATSAS v2.8.4(Svergun et al.,
Atomic structure modelling
Three-dimensional

1995 (175))

graphic

model

representations

UCSF

Chimera

v1.11

(d) Structural parameters.
Guinier analysis

2JSL
0.00957

-1

Tel48
±

0.0318

Tel72
±

0.003742

Tel96
±

0.0202

I(0) (cm )

0.00002

0.00002

0.000005

0.0000406

Rg (Å)

12.41 ± 0.05

19.23 ± 0.03

25.37 ± 0.06

31.68 ± 0.13

qmin (Å-1)

0.014

0.009

0.007

0.007

1.27

1.33

1.32

1.17

0.972

0.998

0.996

0.996

6600 (0.84)

16100 (1.06)

23500 (1.03)

30900 (1.01)

qRg max
Coefficient of correlation, R

2

±

M from volume of correlation, Vc
(ratio to predicted)
P(r) analysis (GNOM)
0.00954

±

0.00376

±

0.0203

±

I(0) (cm-1)

0.00002

0.032 ± 0.00002

0.000005

0.00004

Rg (Å)

12.33 ± 0.03

19.69 ± 0.03

26.01 ± 0.06

32.65 ± 0.10

Dmax (Å)

38

65

87

109

0.95

1.76

0.84

1.1

9040 ( 1.15)

16100 (1.06)

26300 (1.15)

32700 (1.07)

2JSL

Tel48

Tel72

Tel96

19, 1.279

634, 2.802

712, 2.852

644, 2.809

potentially

highly

highly

highly

unique

ambiguous

ambiguous

ambiguous

q range for fitting (Å-1)

-

-

0.0088-0.3146

0.0054-0.2539

Symmetry, anisotropy assumptions

-

-

P1, prolate

P1, prolate

-

-

1.204 (0.082), 4

1.126 (0.095), 11

-

-

1.166

1.167

31 ± 3

38 ± 3

-

-

ꭕ

2

Porod

volume

(Å-3)

(ratio

Vp/calculated M)

(e) Shape model-fitting results

Ambimeter (default parameters)
Number

of

compatible

shape

categories, ambiguity score

3D reconstruction
DAMMIF (default parameters, 20
calculations)

NSD (standard deviation), No. of
clusters
ꭕ

2

Resolution (from SASRES) (Å)
DAMMIN (default, slow)
q range for fitting (Å-1)

0.014-0.3488

0.0115-0.3488
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Symmetry, anisotropy assumptions

P1, none

P1, prolate

-

-

ꭕ2, CORMAP P-values

1.508, 0.1322

1.713, 0.249

-

-

Constant adjustment to intensities

8.46E-05

0.00E+00

-

-

(f) Atomistic modelling.
Crystal structures/atomic coordinate
files

PDB ID: 2JSL

Modeled

Modeled

Modeled

q range for modelling

0.01-0.3

0.006-0.3

0.007-0.3

0.0054-0.2500

ꭕ2

-

1.81

1.09

1.154

79.26 (88.83) /

79.96 (85.17) /

79.80 (86.06) /

Rflex (random) / Rsigma

-

0.62

0.97

1.39

Constant subtraction

-

0

0

0

No. of representative structures

-

6

4

4

Final ensemble Rg (Å), Dmax (Å)

-

19.58, 65.62

25.78, 82.65

32.11, 103.18

1.20

1.82

1.81

2.08

12.3

19.82

25.74

32.63

0.060, 1.760

0.065, 1.800

0.045, 1.400

0.075,1.400

SASDKF3

SASDKG3

SASDKH3

SASDKJ3

EOM GAJOE 2.1 (min ensembles = 1,
max = 20, default parameters)

CRYSOL

(single

model,

default

parameters)
ꭕ2
Predicted Rg (Å)
Dro

(optimal

hydration

shell

contrast), Ra (optimal atomic group
radius (Å)

(g) SASBDB IDs for data and models.
ID
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Molecular dynamics simulations and hydrodynamic calculations
Molecular dynamics simulations were carried out on Tel48, Tel72, and Tel96 constructs
created previously (141), or modeled based on their solution NMR structures from the Protein Data
Bank using the following IDs: 2GKU (hybrid-1), 2JSL (hybrid-2). Base modifications and
optimization of starting configurations were performed in UCSF Chimera v1.12 (176) or Maestro
v11.8 (177). The partial negative charges of carbonyls at the center of tetrads were neutralized with
coordinated potassium counter-ions added manually in Maestro with subsequent minimization prior
to simulation. The PDB structures created were then imported into the xleap module of AMBER
2018 (178), neutralized with K+ ions, and solvated in a rectangular box of TIP3P water molecules
with a 12 Å buffer distance. All simulations were equilibrated using sander at 300 K and 1 atm using
the following steps: (1) minimization of water and ions with weak restraints of 10.0 kcal/mol/Å on
all nucleic acid residues (2000 cycles of minimization, 500 steepest decent before switching to
conjugate gradient) and 10.0 Å cutoff, (2) heating from 0 K to 100 K over 20 ps with 50 kcal/mol/Å
restraints on all nucleic acid residues, (3) minimization of the entire system without restraints (2500
cycles, 1000 steepest decent before switching to conjugate gradient) with 10 Å cutoff, (4) heating
from 100 K to 300 K over 20 ps with weak restraints of 10.0 kcal/mol/Å on all nucleic acid residues,
and (5) equilibration at 1 atm for 100 ps with weak restraints of 10.0 kcal/mol/Å on nucleic acids.
The resulting coordinate files from equilibration were then used as input for 100 ns of unrestrained,
solvated MD simulations using pmemd with GPU acceleration in the isothermal isobaric ensemble
(P = 1 atm, T = 300 K) with DNA OL15 and TIP3P water force fields. Periodic boundary conditions
and PME were used. 2.0 fs time steps were used with bonds involving hydrogen frozen using
SHAKE (ntc = 2). For the Tel48 constructs, an additional 100 ns of accelerated MD (aMD)
simulation were carried out using the average torsional and potential energies from the end of the
standard 100 ns simulations as input for calculating the “boosting” of both whole potential and
torsional terms (iamd=3). Trajectories were analyzed using the CPPTRAJ module in the
AmberTools18 package. Hydrodynamic properties were calculated as average and standard
deviation of equally spaced trajectory snapshots (i.e. every 100 ps) using the program
HYDROPRO10 (179) with the recommended parameters for G-quadruplexes (180). Clustering of
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the trajectories was performed using the DBSCAN method in the CPPTRAJ module of Amber
(minpoints = 5, epsilon = 1.7, sieve 10, rms residues 1-48 over atoms P, O3’, and O5’). Electrostatic
calculations for visualization were performed using PDB2PQR software on the APBS web server
(http://server.poissonboltzmann.org/) (181,182) with AMBER force field and pH set to 7.2. All
molecular visualizations were performed in UCSF Chimera v1.12 (176).

Ensemble optimization method (EOM)
Telomere ensembles were derived using the Ensemble Optimization Method 2.1 (183)
program from the ATSAS suite of tools. For the Tel48 constructs, which included the four
combinations of hybrid-1 and hybrid-2 topologies (i.e. hybrid-11, hybrid-12, hybrid-21, and hybrid22), a total of 2,000 PDB snapshots were derived from the 100 ns of MD and aMD trajectories
stripped of water and K+ and pooled, totaling 8,000 coordinate files. GAJOE was used in pool “-p”
mode, with maximum curves per ensemble set to 30, minimum curves per ensemble set to 1,
constant subtraction allowed, curve repetition allowed, and the genetic algorithm (GA) repeated
200 times. Where noted, the minimum curves were increased to higher numbers, and the curve
repetition was disallowed. The same process was repeated for the Tel72 (hybrid-122, -121, -212,
and -221) and Tel96 (hybrid-1222, -2122, -2212, -2221) constructs with a total of 4,000 pooled
structures. In brief, EOM takes a large pool of macromolecules covering as much conformational
space as possible (and reasonable) and selects from this pool a sub-ensemble of conformers that
best recapitulate the experimental scattering. The best fitting ensemble is the subset of weighted
theoretical
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𝐾
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where Iexp(sj) is the experimental scattering, I(sj) is the calculated scattering, K is the number of
experimental points, σ(sj) are standard deviations, and μ is a scaling factor (184).
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Ab initio model generation and single model validation
P(r) distributions obtained from GNOM (185) using scattering data from 2JSL, Tel48, Tel72,
and

Tel96

were

submitted

using

the

ATSAS

online

servers

(https://www.embl-

hamburg.de/biosaxs/atsas-online/) for either DAMMIN or DAMMIF bead model generation.
Relevant parameters, anisotropy assumptions, normalized spatial discrepancy values (NSDs), χ2
values, and resolutions are given in Table 2. Single best fit models for each telomere construct
were determined using the initial pool of conformers derived from MD simulations (or NMR
structures for 2JSL) and calculated using CRYSOL (186). The best fit structure was determined by
minimization of a χ2 function:
𝜒 2 (𝑟𝑜 , 𝛿𝜌 ) =

𝑁𝑝 𝐼
1
𝑒𝑥𝑝 (𝑞𝑖 ) − 𝑐𝐼(𝑞𝑖 , 𝑟𝑜 , 𝛿𝜌 )
∑ (
)
𝑁𝑝
𝜎(𝑞𝑖 )
𝑖=1

2

where 𝐼𝑒𝑥𝑝 (𝑞𝑖 ) and 𝐼(𝑞𝑖 ) are the experimental and computed profiles, respectively, σ(qi) is the
experimental error of the measured profile, 𝑁𝑝 is the number of points in the profile, and c is the
scaling factor. Two other parameters, 𝑟𝑜 and 𝛿𝜌 , are fitted and represent the effective atomic radius
and the hydration layer density, respectively.

Flexibility analyses by swollen Gaussian chain and WLC models
Fitting of the radii of gyration, as measured by SEC-SAXS for 2JSL, Tel48, Tel72, and
Tel96 was performed as outlined recently by Capp at al. (187) using the following relationship
describing the stiffness and conformational space of a swollen Gaussian coil:

𝑅𝑔 = 𝑙𝑝 √

𝑁 2𝑣
(2𝑣 + 1)(2𝑣 + 2)

Where 𝑙𝑝 is the persistence length and 𝑣 is the Flory coefficient. The Rg values with their respective
errors were plotted against their G4 number and fit using a non-linear least squares fitting
procedure in Origin 2020 (OriginLab Corporation, Northampton, MA, USA).
For the worm-like chain (WLC) modeling, a global analysis of three properties was used in
the program Multi-HYDFIT (188,189). Measurements of two other properties, diffusion coefficient,
Dt (calculated from measured Stokes radii, Rs, via the Stokes-Einstein equation), and corrected
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sedimentation coefficient, S20,w, were obtained for each sequence using SEC (average ± S.D. of 4
measurements each) or AUC (concentration series extrapolated to infinite dilution ± standard error
from regression analysis), respectively. Each value, with respective weighting, and molecular
weight (MW) was used as the input for the Multi-HYDFIT program. Multi-HYDFIT uses comparisons
of the so-called equivalent radii and ratios of radii to calculate theoretical values of Rg, Dt, and S20,w,
which are then compared to that of the measured values. The ratios of radii are directly related to
the ratios of length to diameter (L/d) and length to persistence length (L/𝑙𝑝 ). With starting estimates
of 𝑙𝑝 , d, and mass per unit length (ML), the Multi-HYDFIT procedure seeks to minimize a target
function (189):
𝑁𝑠

1
Δ (𝑙𝑝 , 𝑀𝐿 , 𝑑) =
∑ [(∑ 𝑤𝑌 )
𝑁𝑠

−1

2
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2

𝑎𝑌(𝑐𝑎𝑙) − 𝑎𝑌(𝑒𝑥𝑝)
∑ 𝑤𝑌 (
) ]
𝑎𝑌(𝑒𝑥𝑝)
𝑌

where 𝑁𝑠 is the number of samples of different MW, 𝑤𝑌 is the weighting, and 𝑎𝑌 is the ratio of radii
for each property. In this equation, the outermost sum runs over the 𝑁𝑠 samples and the inner most
sum runs over the available properties of each sample. The Δ2 is a mean-square relative deviation
for the data, and 100Δ is the percent difference between experimental and theoretical values over
the entire set. Additional information is required for the calculation, such as temperature (here
20.0°C was used), solvent viscosity (0.00995 poise), starting guesses for diameter, d (10 to 100
angstrom), mass per unit length, ML (10 to 300 Da/angstrom), and persistence length, 𝑙𝑝 (20 to 100
angstrom). Intrinsic viscosities calculated from best-fit models using HYDROPRO10 were also
included with modest weighting, as they were not empirically determined but rather derived from
SAXS best-fit models. The goal of the procedure is to determine the best-fit values of the latter
properties, which are given in Table 3.
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Table 3. Table of properties derived from Multi-HYDFIT fitting of the higher-order telomere
experimental properties to a worm-like chain model.
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HYDFIT Worm-like Chain results
Diameter (Å)

40 (±5)

Persistence length (Å)

33 (±3)

Mass per unit length (Da/Å)

163 (±15)

Deviation from exp. equiv. radii (%)

3.7
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Force of bending curves were calculated using the literature persistence length values for
single- and double-stranded DNA at cationic conditions similar to used here, based on the
relationship (190):
𝐹𝑏𝑒𝑛𝑑 =

1
𝑘 𝑇𝐿 𝑅−2
2 𝐵 𝑝

where Fbend is the bending force in piconewtons, 𝑘𝐵 is the Boltzmann constant, T is temperature in
Kelvin, Lp is the persistence length in meters, and R is the radius of the arc of a curve. The data
was plotted such that the values on the X-axis correspond to the end-to-end length of the polymer
curved 180° around the arc of a semi-circle.

Molecular visualizations
All molecular visualizations of MD trajectories and models and RMSD calculations were performed
in UCSF Chimera v1.11 (176).
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Results

Small-angle X-ray scattering reveals G4 maximization and indicates that the higher-order
telomere G4s are semi-flexible

To verify that the extended telomere sequences are in fact maximizing their G-tract usage
we employed size-resolved small-angle X-ray scattering (SEC-SAXS) to assess each sequence
for size, shape, and compactness (191,192). The results of the SEC-SAXS analysis for sequences
2JSL (hybrid-2), Tel48, Tel72, and Tel96 (Table 1) are shown in Figures 8, 9, and Table 2. Figure
8A shows the scattering intensity as a function of momentum transfer (q) on a log-log scale for
each sequence. Each scattering profile proceeds horizontally to the Y-axis at low values of q,
indicating the absence of inter-particle interactions or repulsions (191). Scattering from 2JSL shows
a distinct smooth curvature at higher q values which is indicative of a globular particle, whereas the
extended telomere sequences deviate from this curvature between about 0.05 and 0.2 q,
suggesting a non-globular structure (192).
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Figure 8. SEC-SAXS analysis of 2JSL (gray), Tel48 (red), Tel72 (blue), and Tel96 (green). (A) Loglog plot of the scattering intensity vs. scattering vector, q. (B) Dimensionless Kratky plots of data in
A. (C) Pair distribution function plots of data in A normalized to I(0). (D) Scatter plot of the radii of
gyration from each sequence as a function of G-quadruplex motif fit to a swollen Gaussian chain
polymer model (see methods) with (inset) derived persistence length (L p) and Flory coefficient (v).
(E) DAMMIN and DAMMIF ab initio space-filling models from the data in C.
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Figure 9. Guinier analyses of 2JSL, Tel48, Tel72, and Tel96 (left) with fit overlaid in yellow for each
sequence and (right) residuals of fits. Guinier fit results are tabulated in Table 2.
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Two useful transformations of the scattering data are the Kratky plot and distance
distribution, P(r), plots (Figures 8B and 8C), which allow for qualitative appraisal of compactness
and overall structure, respectively (192). In Figure 8B the dimensionless Kratky plot shows that
2JSL (gray) exhibits a nearly perfect Gaussian distribution that returns to baseline at high qR g,
confirming that it is globular and folded (192). The Tel48 and Tel72 sequences also approach
baseline at high qRg, indicating that they are folded and do not contain significant amounts of
flexibility (192). The higher-order sequences also exhibit distinct plateau regions above 2 qR g,
indicating that they have non-globular shapes and are likely multi-domain, consistent with tandem
G4 domains. However, Tel96 (green) exhibits a slight rise in its plateau towards higher qRg,
indicating that it is flexible relative to 2JSL, Tel48, and Tel72. Figure 8C shows the corresponding
P(r) distributions (normalized to scattering intensity, I[0]), which are probability distributions of the
inner-atomic distances within each macromolecule (191). 2JSL (gray) again exhibits a symmetric
distribution, indicative of a globular molecule (192). Conversely, the extended sequences are all
multi-modal. Tel48 exhibits a biphasic distribution (red) indicating a characteristic dumbbell-like
tertiary arrangement (192), consistent with two G4 domains separated by a small linker region.
Tel72 and Tel96 have tri- and tetra-phasic curves, respectively, which we take as indicating three
and four contiguous globular domains in tandem, respectively.

P(r) distributions also allow for quantitative characterization of macromolecules. The point
on the X-axis at which each sequence converges to zero is the maximum diameter, Dmax, which is
the diameter of the particle’s longest axis (192). The Dmax of each sequence increases
approximately linearly with a ~24 Å increase with each additional G4 motif. Any substantial amount
of telomere species with gaps, or non-maximization of G4s, would likely result in a non-linearity (as
well as large upticks in the Kratky curves at high qRg). The radius of gyration, Rg, is the root mean
square distance of the macromolecule’s parts from its center of mass and reflects the particle’s size
(191). The Rg can be calculated by either the Guinier approximation (from plots shown in Figure 9)
or directly from its P(r) distribution, the latter of which is thought to be more representative in cases
where flexibility is assumed (although both values should be in general agreement)(192). Dmax and
Rg values for each sequence are reported in Table 2. Shown in Figure 8D is a plot of each
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sequence’s radii of gyration plotted against G4 number. Each additional G4 motif leads to an
approximate Rg increase of 6.7 Å.

The extended tails of the P(r) distributions and upward trend in plateau regions of the Kratky
plots (Figure 8B) signify flexibility. Although plotting the radii of gyration versus the putative number
of G4 subunits appears entirely linear (R2 = 0.9985), a better fit is obtained when fitting to a swollen
Gaussian polymer model (R2 = 0.9999, Figure 8D). The non-linear least-squares fit to this model
allows for the estimation of two parameters: persistence length, Lp, and the Flory exponent, v. The
persistence length represents the distance along the telomere G4 polymer which behaves as a
rigid rod. At lengths much greater than this, the polymer behaves as a flexible Gaussian chain. The
Flory coefficient (also known as the excluded volume parameter) varies between 0.5 and 1.0 and
describes the degree of flexibility of the system. A Flory coefficient for a theoretical freely jointed
flexible chain is 0.5 (maximum flexibility), whereas that of a rigid rod is 1.0. For reference, the
empirical value of chemically denatured proteins is v = ~0.588 (193). Fitting to this model we find
that the telomere G4 has a persistence length of 34.8 ± 0.2 Å and Flory coefficient of 0.69 ± 0.01.
The persistence length is approximately the size of a single telomere G4 (~32 Å, calculated from
PDB 2JSL less the flanking nucleotides), which indicates that the TTA linkers may provide a point
of flexibility. This persistence length is about 50% greater than ssDNA (Lp = ~22 Å under similar
ionic conditions (194)). As an independent method of estimating the persistence length, we used
the hydrodynamic modeling program Multi-HYDFIT (188). This program integrates multiple
independently measured properties, such as sedimentation coefficients (S20,w) from AUC (Figure
10) (163), translational diffusion coefficients (Dt) from SEC, and radii of gyration (Rg) from SECSAXS, for a series of macromolecules of given molecular weight (MW), and uses these values to
find the optimum values of the model parameters for a worm-like chain (WLC) model (189). In total,
we fit 12 independent properties from three independent techniques with their respective weights
(estimated from standard deviations of multiple measurements), yielding a persistence length of 33
± 3 Å (Table 3), in excellent agreement with the Lp estimated from the swollen Gaussian chain
model. Altogether, these results, along with the qualitative information from Kratky and P(r)
distributions, suggest that the extended telomere maximizes G4 formation, is closely packed, and
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is moderately flexible. The flexibility is consistent with rigid G4 units linked by flexible, hinged,
interfaces.
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Figure 10. Sedimentation velocity analysis of higher-order telomere sequences. (Top) Analysis of
Tel72 and Tel96 concentration dependence on sedimentation. Extrapolation to the Y-axis gives the
infinite dilution S20,w values. (Bottom) representative C(s) vs. S20,w distributions for 2JSL, Tel48,
Tel72, and Tel96.
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Ab initio and atomistic modeling reveals an ensemble of conformations ranging from
entirely stacked and condensed to a coiled “beads-on-a-string” configuration

The above analyses suggest a flexible system which would render the higher-order SAXS
data unsuitable for use in ab initio bead reconstruction methods. However, upon seeing the
resulting space-filling models we were compelled to include them. Figure 8E shows the resulting
DAMMIN and DAMMIF space-filling models of 2JSL, Tel48, Tel72, and Tel96 created based on the
P(r) data in Figure 8C (with corresponding fit results tabulated in Table 2). Consistent with
predictions from the Kratky and P(r) distribution plots Tel48 looks like a dumbbell with two domains
roughly the size of the 2JSL reconstruction with a small linker region in the middle. Similarly, Tel72
and Tel96 have what appear to be three and four G-quadruplex domains (indicated by their distinct
“bends”), although their resolution is not quite as high as the Tel48 reconstruction (Table 2). The
similar overall shape and curvature coupled with the flexibility assessment above indicates a nonrod-like structure for telomere sequences with more than two G4 motif repeats. These shapes are
generally in accord with previous hydrodynamic investigations based on rigid structures (163), but
offer a more detailed and nuanced characterization because the flexibility of the structures can be
taken into account.

We next employed an ensemble modeling approach that combined explicit solvent MDderived models with the ensemble optimization tool GAJOE (of the EOM 2.0 suite) (184). A CD
analysis that will follow indicated that the telomere sequences are best represented by a
combination of hybrid-1 and hybrid-2 topologies. However, the order in which they occur is not
evident, and it may be that the extended sequences are dynamic and interconvert on timescales
much longer than is accessible by standard MD simulations (>1 ms). Therefore, we modeled every
combination of the simplest multimer system, Tel48. Using the PDB atomic structures for hybrid-1
(PDB ID: 2GKU) and hybrid-2 (PDB ID: 2JSL) we generated each of the four possible combinations:
hybrid-11, hybrid-12, hybrid-21, and hybrid-22. Each structure was subjected to 100 ns of both
standard MD and accelerated MD (aMD) simulations to produce a pool of 8,000 conformations for
use in minimal ensemble and single structure modeling efforts. In the GAJOE ensemble
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optimization method, a pool of PDB atomic coordinate files are generated that cover as much
conformational space as possible and utilized in calculating theoretical scattering profiles. Next, a
genetic algorithm acts on these scattering profiles to minimize a fitness function by weighting each
scattering profile and comparing combined profiles to the experimental (see methods). The output
is an ensemble of conformers which best recapitulate the experimental scattering profile based the
minimized χ2 value. An ensemble is considered a better fit than a single conformer when its χ2
value is reduced relative to the single best-fit conformation.

Figures 11 and 12 shows the results of modeling efforts with the Tel48 constructs. Figures
11A and 11B are scatter plots which show the calculated radii of gyration (Y-axis) and corrected
sedimentation coefficients (X-axis) (Figure 10), for each of 2,000 frames across both MD (light
gray) and aMD (dark gray) trajectories for the hybrid-12, -21, -11, and -22 constructs. These plots
indicate that both hybrid-12 and -21 sample conformations which agree with either the experimental
Rg, S20,w, or intersect both values. The hybrid-11 and hybrid-22 constructs rarely sampled
conformations that corresponded with the experimental values (see Figure 12). Interestingly,
although hybrid-12 extensively samples conformations which agree with both hydrodynamic and
scattering-derived measurements, the best fit model by CRYSOL analysis was found to be a highly
extended hybrid-21 conformation (cyan dot and curve in Figures 11B & 11C). Because this
conformation appeared unnatural (e.g. maximally extended) and did not agree very well with the
P(r)-derived Rg and Dmax values, we speculated that this configuration may be biased simply by our
initial start configurations. The hybrid-21 clearly tended towards an overall more compact structure
as indicated by the histograms. Therefore, we next asked what the maximum number of curves
could be which could reconstruct the experimental scattering without worsening the ꭕ2 value. We
found that an ensemble of six conformations gave approximately the same ꭕ2 value (magenta dots
in Figures 11A and 11B, magenta curve Figure 11C) and agreed much better with the
experimental Rg and Dmax values from the P(r) analysis (Rg,cal = 19.58 Å vs. Rg,exp = 19.69 Å and
Dmax,calc = 66 Å vs. Dmax,exp = 65 Å, Table 2). The resulting topologies were a 50/50 mix of hybrid-12
and -21 (Figure 11D), which sampled conformations ranging from extended to fully stacked. The
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flexibility of the ensemble was only marginally lower than the pool, as judged by EOM’s Rflex
flexibility analysis, supporting semi-flexibility. Interestingly, we found that one of the hybrid-12
conformers (bottom right of Figure 11D) was nearly identical in conformation to our previously
reported hybrid-12 model (141), with an RMSD of just 1.6 Å over all residue pairs (Figure 13).
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Figure 11. Results of Tel48 SAXS atomistic modeling efforts. (A-B) scatter plots of calculated radii
of gyration and sedimentation coefficients for hybrid-12 (A) and hybrid-21 (B) with MD-derived
values shown in light gray and aMD-derived values in dark gray. The inset dashed red and blue
lines represent the experimentally measured values for sedimentation coefficient and radius of
gyration, respectively. The outer histograms represent the distributions of values from both MD and
aMD snapshots combined. The cyan dot represents the single best-fit model (hybrid-21) as
determined by CRYSOL (top left model in D). Magenta dots represent the six conformers in the
best fit ensemble (all six models in D). (C) Experimental SAXS scattering data with fits from single
(cyan) or ensemble (magenta) calculated scattering overlaid with χ 2 values inset. (D) Single best
fit model (hybrid-21, top left model) and best fit ensemble of six conformers (top row hybrid-21,
bottom row hybrid-12). Models are oriented with their 5’ ends at the top.
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Figure 12. Additional results of Tel48 SAXS atomistic modeling efforts shown in Figure 11. (A-B)
scatter plots of calculated radii of gyration and sedimentation coefficients for hybrid-11 (A) and
hybrid-22 (B) with MD-derived values shown in light gray and aMD-derived values in dark gray.
The inset dashed red and blue lines represent the experimentally measured values for
sedimentation coefficient and radius of gyration, respectively. The outer histograms represent the
distributions of values from both MD and aMD snapshots combined. The histograms indicate that
the major sampled conformations in both cases are much more compact than would be expected
from either SAXS or AUC analyses.
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Figure 13. Comparison of the Tel48 (cyan) and Tel50 (tan) hybrid-12 conformers. The tan hybrid12 conformer was taken from an earlier report by Petraccone et al.(141) and the cyan hybrid-12 is
the model derived here from EOM (bottom right-most conformer in Figure 11). The pair-wise
residue RSMD is 1.6 Å as determined by the matchmaker module of UCSF Chimera v1.12.
Potassium is shown as purple spheres and is derived from the Petraccone model (EOM hybrid-12
potassium is hidden).
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Next, we investigated the Tel72 and Tel96 constructs in the same manner as above but
only using standard MD. Models were created to reflect the ratio of hybrid-1/-2 (25/72) as
determined by our later CD analyses of telomere mutants (e.g. hybrid-121, -122, -212, and -221 for
Tel72 and hybrid-1222, -2122, -2212, and -2221 for Tel96). The hybrid-121 was included because
it was proposed previously (141). Each model was then subjected to explicit solvent MD and
simulated for a total of 100 ns. From these trajectories, 1,000 equally spaced frames were used as
the pool for EOM’s GAJOE program. For the Tel72 the best fit was obtained with an ensemble of
four conformers (ꭕ2ensemble = 1.09 vs. ꭕ2single-model = 1.81) which was composed of the hybrid-212
(89.7%) and hybrid-221 (10.3%) (Figure 14). Surprisingly, this configuration agrees well with Tel48
having a 5’ preference for hybrid-2 followed by hybrid-1. The Rg and Dmax values of the Tel72
ensemble (Figure 14C) agree with the experimental values (Rg,calc = 25.8 Å vs. Rg,exp = 26.0 Å and
Dmax,calc = 83 Å vs. Dmax,exp = 87 Å), indicating that the ensemble is an excellent solution. Similarly,
Tel96 scattering was best recapitulated by an ensemble of four conformers ( ꭕ2ensemble = 1.15 vs.

ꭕ2single-model = 2.08) but was composed entirely of different conformations of the hybrid-2122 (Figure
15). Again, there is an agreement with a 5’ hybrid-2 followed by hybrid-1. The Rg and Dmax values
of this conformer ensemble are also in agreement with the experimental values (Rg,calc = 32.1 Å vs.
Rg,exp = 32.7 Å and Dmax,calc = 103 Å vs. Dmax,exp = 109 Å), indicating that this ensemble is reasonable.
In both cases, the EOM Rflex quantification of flexibility indicates that the ensembles are only
marginally less flexible than the pool (Table 2), consistent with the system semi-flexibility. This
flexibility is also illustrated by the conformer ensembles themselves (Figures 14C and 15). Further,
docking of each ensemble into their respective ab initio space-filling models from Figure 8E reveals
excellent fits for the models of topological sequence 5’-hybrid-2,-1,-2,-2 (Figure 16). Collectively,
these analyses indicate that in physiological buffer conditions the extended telomeres maximize
their formation of G4 subunits, prioritize hybrid-2 at the 5’ end, and are semi-flexible.
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Figure 14. Results of Tel72 SAXS atomistic modeling efforts. (A) scatter plot of calculated radii of
gyration and sedimentation coefficients for the hybrid-212 model from 100 ns of standard MD
simulation. The inset dashed red and blue lines represent the experimentally measured values for
sedimentation coefficient and radius of gyration, respectively. The outer histograms represent the
distributions of values. The cyan dot represents the single best-fit model as determined by
CRYSOL. Magenta dots represent the four conformers in the best fit ensemble. (B) Experimental
SAXS scattering data with fits from single (cyan) or ensemble (magenta) calculated scattering
overlaid with χ2 values inset. (C) Conformations of the three hybrid-212 configurations (not showing
the hybrid-221) from the best fit ensemble as determined by EOM. Models are oriented with their
5’ ends at the top.
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Figure 15. Results of Tel96 atomistic modeling efforts. Depicted are the four hybrid-2122
conformers derived from EOM analysis of the 100 ns MD simulations with their respective weights
(as % of the reconstructed scattering curve). All conformers are arranged with their 5’ ends at the
top of the figure.

78

79

Figure 16. Telomere G4 ensembles from EOM GAJOE analysis docked into ab initio space-filling
reconstructions from DAMMIN/DAMMIF. (A) Tel48 hybrid-21 conformers, (B) 2JSL with single bestfit NMR-derived model, (C) Tel72 hybrid-212 conformers (the same as in Figure 14C), (D) Tel96
hybrid-2122 models (the same as in Figure 15).
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The Tel72 hybrid-212 preferentially samples a stacked conformation, forming unique
electronegative binding pockets useful for drug targeting

The Tel72 ensembles reflect well the SAXS-derived properties, Rg and Dmax. However, they
do not agree as well with their measured sedimentation coefficients. SAXS scattering is exquisitely
sensitive to changes in particle volume (conformation in this case). Systems which exist in an
equilibrium of stacked and unstacked, or coiled and beads-on-a-string, will have a scattering profile
which is composed of a continuous distribution of conformations (as the scattering intensity, I[0], is
directly related to the volume of the scattering particle) (195). Therefore, we next endeavored to
find the most frequently sampled conformation from the MD trajectory of the Tel72 hybrid-212
construct. Figure 17A shows the top three most frequently sampled conformations across the 100
ns simulations with their respective weighting (% of MD frames). This analysis suggests that
approximately 47% of the frames from simulation sampled a configuration which was partially
(middle) or entirely stacked (left and right models). The major stacked conformation sampled by
hybrid-212 has a calculated sedimentation coefficient which is in excellent agreement with the
experimental (S20,w(calc) = 3.45 versus S20,w(exp) = 3.46, Figure 10) although the calculated radius of
gyration is slightly lower (Rg(calc) = 2.45 nm versus Rg(exp) = 2.60). Electrostatic calculations of the
most prominent form reveal highly electronegative grooves, which are appropriately sized for small
molecules (Figure 17B). Overall, these analyses show that the hybrid-212 model of the Tel72 is
consistent with all available spectroscopic, hydrodynamic, X-ray scattering, and MD-based
analyses, and forms unique junctional grooves for selective small molecule targeting.
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Figure 17. Results of MD clustering analysis of the Tel72 hybrid-212. (A) Top three representative
centroids of DBSCAN clusters accounting for ~47% of frames across the entire 100 ns trajectory.
(B) space-fill electrostatic APBS map of the first model from A with dashed lines indicating the
approximate sizes of each groove created at the two stacking interfaces.
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The major topologies of the extended telomere G4 are hybrid-1 and hybrid-2

Simultaneous with our structural investigations above, we investigated the conformations
of G4 units within higher-order structures by using systematic sequence variations of the wild type
(WT) Tel48 sequence and observing changes in circular dichroism spectra. These sequence
”mutants” were created with variation in terminal nucleotides or by changes in internal sequences
that favor the various hybrid topologies (e.g. hybrid-1 and hybrid-3) (Table 1). The Tel48 spectrum
(black line in Figure 18A) has a main peak at ~290 nm, pronounced shoulder from 265-275 nm,
and a trough at 235 nm, indicating that it is primarily composed of hybrid type folds (46). Comparing
sequence variants of the form TnAGGG(TTAGGG)7Tm, where n = 1 or 2, and m = 0, 1, or 2, we
found no major spectral differences (Figure 19A), indicating that changes in these flanking
nucleotides have no effect on the overall topology. Removal of the 5’-end thymine residues led to
a modest reduction in the shoulder at ~270 nm and peak at 290 nm when compared to the WT
sequences of similar length (Figure 19B, red and blue lines). We speculated that this could be due
to the formation of hybrid-3 in the 5’-most G4 unit, which has been reported in shorter sequences
lacking the 5’ thymine residues (47,79). Indeed, when an inosine is introduced to favor the hybrid3 topology in the 5’-most putative G4 the CD changes observed at 270 and 290 nm become more
pronounced (Figure 19C, blue solid line). Importantly, this suggests that the hybrid-3 topology is
not a major topology, as the extended telomere (in the cell) will always include 5’ thymine residues.
The spectral change due to hybrid-3 incorporation is made more evident when stabilized in both 5’
and 3’ G4 units (Figure 19C, purple), which is of the same shape but approximately 2x the
magnitude of hybrid-3. Thus, the hybrid-3 is not likely to exist in the context of the extended
telomere, aside from as a potential folding intermediate (47).
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Figure 18. Normalized circular dichroism spectra of Tel48 mutants and theoretical monomer G4
spectra. (A) CD spectra comparison of the WT Tel48 G-quadruplex (black) with constructs created
to favor the hybrid-1 form in the second (red), first and second (blue), or first position (green). (B)
Comparison of the Tel48 CD spectrum with theoretical monomer CD combinations of hybrid-22
(red dashed), hybrid-12 with a 30/70 weighting (blue dashed), and a hybrid-11 (purple dashed).
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Figure 19. Normalized CD spectra of Tel48 compared to various flanking residue and internal
mutant sequences.
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Comparison of the hybrid-21, -11, and -12 sequences to Tel48 revealed subtle differences
in each case (where hybrid-2 is assumed as the major conformation in unadulterated telomere
sequence flanked by thymine at both ends) (Figure 18A). Overall, each spectrum was consistent
in shape, but varied in magnitude at various wavelengths. We suspected that this may indicate a
preference for the hybrid-22 form. A theoretical hybrid-22 spectrum overlaid nicely with Tel48
(Figure 18B, red dashed line). In contrast, a theoretical hybrid-11 (Figure 18B, purple dashed line)
had a greatly increased 290 nm peak and slight reduction at ~250 nm and looked similar to the
mutant hybrid-11 spectrum from Figure 18A. Based on the reported 25/75 ratio of hybrid-1 and
hybrid-2 for the monomer telomere sequence flanked at both ends by thymine (45), we next tested
a variety of computed weighted combinations of hybrid-1 and -2 spectra and found that a 30/70
ratio best reflects the Tel48 spectrum (compare blue dashed line with black in Figure 18B).
Collectively, these results indicate a preference for both hybrid-1 and -2 topologies in the extended
telomere sequence, consistent with our EOM analysis of Tel48.

CD indicates that the higher-order telomere sequences converge on a 25/75 ratio of hybrid1 and hybrid-2 with maximization of G4 formation

Strand-normalized circular dichroism spectra are the sum of constituent secondary and
tertiary structure (196). Thus, just as above we expect that the spectra of higher-order telomere
G4s could be recreated by addition of their measured “monomer” spectra. However, comparisons
of the various monomer spectra (hybrid-1,-2,-3, and basket forms) to our higher-order telomere
spectra resulted in non-negligible “difference” spectra of roughly the magnitude expected for di- or
tri-nucleotides. As prior studies suggest, and we have shown here, the extended telomere
sequences maximize their G4 potential by leaving no G-tract gaps. The resulting stacking junctions,
or other inter-G4 interactions that constrain the loop regions, could potentially give rise to a
“junctional” CD signal (196). Thus, to generate the theoretical “junctional” spectrum, we utilized the
Tel48 mutant spectra from above and subtracted from them theoretical constituent monomer
spectra as appropriate. The resulting spectrum is shown in Figure 20B. The junction spectrum has
a peak at 240 nm and troughs at ~260 and ~285 nm, which is consistent with the known CD spectra
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of adenine and thymine polynucleotides (197). This spectrum was then used as a correction factor,
and was subtracted from the Tel48, Tel72, and Tel96 spectra (Figure 20A). A plot of Δε290 versus
the putative number of G4s yields a linear regression with a near zero Y-intercept, which is more
physically relevant than the regression without the correction (Figure 20C). The slope of the
corrected regression data indicates that each additional putative G4 increases Δε 290 by ~128 M1cm-1,

in excellent agreement with the average Δε290 obtained from hybrid (3+1) monomers. These

corrected spectra should now be a composite spectrum of monomer G-quadruplex components. A
novel finding here is that the CD spectra of higher-order G4 structures contain discernable
contributions from G4-G4 interactions.
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Figure 20. Circular dichroism analysis of the higher-order telomere G-quadruplexes. (A) Pre- and
Post-corrected (“Corr”) CD spectra of the Tel48, Tel72, and Tel96 sequences by subtraction of the
“junctional” spectrum in B. (B) The average (dark blue line) and range (light blue space fill) of
“junctional” CD spectra derived from deconstruction of the Tel48 sequences in Figures 18 and 19
using constituent monomer spectra. (C) Regression analysis of the uncorrected and corrected
Δε290nm values as a function of the number of G4 motifs. (D-F) Corrected CD spectra of the Tel48,
Tel72, and Tel96 sequences with overlaid theoretical spectra derived from the linear addition of
monomer spectra. The red spectrum in each plot is the best fit as judged by RSS analysis.
Residuals are shown below each figure.
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The hybrid-1, -2, and -3, as well as the antiparallel basket monomer spectra were
systematically compared with the Tel48, Tel72, and Tel96 corrected spectra. Figures 20D-F show
the corrected spectra in black with “_Corr” indicating the corrected spectrum. Shown below are
residuals from the best fit combinations of monomer spectra. In each plot the red spectrum is the
best fit, followed by blue, etc. based on residual sum of squares (RSS) analysis (Figure 21). The
optimal fit to Tel48_Corr is hybrid-22 (in agreement with Figure 18A), followed by various hybrid1/-2 combinations; Tel72_Corr is best fit by a combination of hybrid-1, -2, and -2; Tel96 is best fit
by a hybrid-1, -2, -2, -2 (not necessarily in that order as shown above). See Figure 21 for the
exhaustive residual sum of squares (RSS) ordering, PDB IDs, and distributions of CD residuals for
each fit. These results suggest an overwhelming preference for hybrid-2 in the longer sequences,
although some other hybrid-1/-2 combinations also yield comparable fits. Altogether, the above
analyses confirm that the primary two topologies making up the WT telomere higher-order G4s are
hybrid-1 and hybrid-2, with proportions approaching a 25% hybrid-1, 75% hybrid-2. Further, the
linearity and slope of the regression analysis and excellent agreement with theoretical fits indicates
that no long gaps exist in the higher-order human telomere.
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Figure 21. Violin plots of residuals obtained as the difference between experimental and theoretical
CD reconstruction curves for Tel48, Tel72, and Tel96. The residuals are plotted from best (left) to
worst (right) based on residual sum of squares analysis in Origin 2020.
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Discussion

These results provide the most detailed characterization of extended human telomere Gquadruplex structures in solution to date. We combine circular dichroism, hydrodynamics, and
small-angle X-ray scattering experiments integrated with available high-resolution NMR studies on
monomeric G4 structures (46) to build medium resolution higher-order structures. For dimeric
structures containing two contiguous G4 units (Tel48), the best model is one featuring a 5’ hybrid2, followed by hybrid-1. For longer sequences with three and four G4 units, a mixture of hybrid-2
and hybrid-1 conformations seems to be present in an approximate 3:1 ratio. Our results show
unequivocally that for all sequences up to 96 nt in length, the human telomere sequence maximizes
its G4 formation, leaving no gaps—in direct contrast to prior EM, AFM, and single-molecule force
ramping investigations (159-161). Our results provide the first quantitative estimates of the rigidity
of folded telomeric DNA through determination of its persistence length (Lp = ~34 Å). We find that
the semi-flexibility of the telomere G-quadruplex is best modeled by an ensemble of configurations
which fluctuate between an entirely stacked multimer and unstacked monomeric G4s, as observed
by MD simulations, providing potentially unique sites for small molecule targeting in the junctional
regions. This model suggests that rigid G4 units are connected by a short, dynamic, interfacial
hinge. That interface constitutes a unique structural element to target in drug design efforts.

The WT human telomere monomer sequences exhibit a high degree of polymorphism in
vitro (46). Under physiologically relevant K+ solution conditions the WT telomere G4 adopts a hybrid
type conformation, favoring hybrid-2 over hybrid-1 (77,152). This conformational bias is seemingly
dictated by the presence of 5’ or 3’ flanking nucleotides. Addition of 5’-TTA to the core sequence,
GGG(TTAGGG)3, leads to the favoring of hybrid-1 by a 5’-end capping adenine triplet, whereas
addition of one or two thymine to the 3’-end results in a favoring of the hybrid-2 form via a T:A:T
triplet stack on the 3’-end (46). The extended, end-flanked sequence, (TTAGGG)4T, forms a major
configuration of hybrid-2 (~75%), with minor amounts of hybrid-1 (~25%) (45). This implies that the
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energy barrier between the two forms may be small. Consistent with this, our mutational analysis
by CD and modeling studies agree with a 75/25 ratio of hybrid-2/-1 for the higher-order WT species.
A significant result from our higher-order CD analyses is the unique junctional spectrum (Figure
20B). This spectrum was useful in providing a rationale for why the higher-order species exhibited
CD signatures that were lower than expected for maximized G4 formation. Moreover, both SAXS
and MD modeling studies revealed favorable, but dynamic, stacking interfaces between G4
moieties, in agreement with thermodynamic analyses (162).

Prior NMR investigations of the WT telomere sequence, (TTAGGG)4T, indicate a dynamic
equilibrium of conformations (46). If a similar equilibrium exists in the higher-order telomere, then
an ensemble of both tertiary conformation and secondary structure would be required to explain
both CD and SAXS results. Consistent with this, the Tel48 scattering is modeled well by an
ensemble with a 50/50 ratio of hybrid-12 and hybrid-21 conformers. The single model hybrid-21 fit
is comparable to the ensemble, and so this solution is, overall, somewhat ambiguous; although,
the lack of thymine residues at the 3’-end would, in theory, favor hybrid-1 in the second position,
giving us confidence in a preferential hybrid-21 model. Our previous investigation of the WT Tel50
sequence (141) (which differs in sequence by two additional thymine residues at the 3’ end)
proposed that the major form is hybrid-12. We used steady-state fluorescence measurements of
2-aminopurine-substitutions to assess the solvent accessibility for each adenine site. From this it
was found that residue A15 is the least solvent exposed, which agreed with SASA calculations of
the hybrid-12 model (in this conformation A15 is buried in the stacking junction between the two Gquadruplex units). Coincidentally, by having the EOM algorithm increase the number of conformers
in the Tel48 ensemble, we find that part of the new solution is a hybrid-12 conformer that is almost
identical to the previously proposed Tel50 hybrid-12 model (Figure 13). Thus, the collective
experimental observables support an equilibrium of hybrid-1 and hybrid-2 in either position.

We have also investigated the possibility of a hybrid-3 form, which is a two-tetrad
antiparallel G-quadruplex that has been characterized in vitro in potassium containing solution (47),
and confirmed as existing in a cellular environment by Bao et al. (79). In both instances the telomere

98

sequences used were lacking 5’ thymine residues. The 5’ thymine residue destabilizes the hybrid3 structure and, ultimately, favors the hybrid-1 (47). In the cell the 5’-flanking thymine is always
present. We have confirmed that the extended WT telomere sequences do not favor the hybrid-3
in solution by mutational analysis, showing that it may only occur in the 5’-most position when
thymine is removed (Figure 19). Thus, the hybrid-3 topology may only function as a folding
intermediate (47), rather than as a major constituent topology of the higher-order telomere G4.

The single-stranded telomere overhang is a critical regulator of genomic integrity. Spanning
the junction of the duplex and single-stranded telomere region is a protective protein complex
known as shelterin (64,198). Shelterin is composed of the proteins TRF1, TRF2, RAP1, TIN2,
TPP1, and POT1. POT1 (protection of telomeres 1) is essential in sequestering the free 3’
overhang, shielding it from eliciting aberrant single-stranded DNA damage responses, preventing
homologous recombination, and regulating the activity of telomerase (156). POT1 binds directly to
the 3’ single-stranded overhang with high affinity and in a highly sequence specific manner
(64,155,199). EM micrographs have revealed that POT1-TPP1 complexes coat the entirety of the
extended telomere 3’ overhang, forming compact, ordered complexes of ssDNA-POT1-TPP1
without gaps (200). Importantly, disruption of POT1’s shielding of the single-stranded overhang
elicits an ATR-dependent DNA damage response through the promiscuous ssDNA binding protein
RPA (156,201). A recent AFM investigation of the Tel96 sequence with POT1 by the Opresko lab
(159) found that maximization of G4 formation “rarely” occurs, and that POT1 associates by simply
recognizing the resulting gaps. We, and others (55,85,157,163), find this conclusion at odds with
solution-based results. Accessible ssDNA gaps between G4s would allow RPA to compete
unimpeded with POT1 binding. Indeed, RPA outcompetes POT1-TPP1 binding to single-stranded
telomere DNA in vitro (202). Further, G-quadruplex secondary structure enhances POT1-TPP1’s
protection against RPA in physiologically relevant levels of K+ (150 mM) (203). We recently showed
that POT1 unfolds and binds to telomere G4s using a conformational selection mechanism (85)
and demonstrated that the kinetics of unfolding the Tel48 sequence is essentially the same as the
Tel24 monomeric G4. Importantly, this suggests that a maximization of G4 formation does not
impede POT1 binding. Taken together, the physiological significance of telomeric G4 maximization
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is two-fold: (1) G-quadruplex secondary structure prevents promiscuous RPA binding and, (2) the
G4 secondary structure promotes exclusive interaction with shelterin through specific POT1
unfolding and binding, tilting the scale in favor of POT1 over RPA.

The mechanistic details of how the shelterin complex orchestrates the sequestration of the
single-stranded 3’ end are still not entirely understood, but are of great importance in drug discovery
(198,204). Recently, the Cech laboratory conducted a thorough investigation of co-expressed and
isolated complexes of the shelterin proteins in vitro (198). Based on their results a shelterin “load
& search” model was proposed, whereby TRF2 and POT1 localize the shelterin complex to the
telomere by specifically recognizing and binding to the single-stranded/double-stranded (ss/ds)
telomere junction. The authors propose that POT1 searches for its optimal binding sequence,
TTAG, at the 3’ end by a scanning search mechanism, eventually looping the 3’ end back forming
a loop bridged by shelterin proteins that is “unlike a T-loop”. An earlier report from the Cech
laboratory found that POT1 and POT1-TPP1 completely coat the long ssDNA telomere repeats in
vitro (200). Thus, the “normal” sequestration mechanism of the human telomere 3’ overhang is
seemingly a POT1-coated loop structure anchored to the ss/ds telomere junction.

DNA looping is a common theme in the cell (190). From a physical stand-point, DNA
looping has been extensively studied for its relationship with genetic packaging into nucleosomes
and effects on transcription (190,205). A commonly reported measure of the structural rigidity of a
biological polymer is the persistence length, Lp¸ that defines the length over which a polymer
remains unbent in solution. In this work, we have applied both SAXS and hydrodynamic modeling
methods to derive an estimate of the telomere G4 persistence length. Using our telomere G4 Lp
estimate, along with values reported for single- and double-stranded DNA, we can compare the
relative forces required to bend each 180° around the arc of a semi-circle of a given radius (Figure
22) (190). From this plot we find that, in the case of single-stranded telomere DNA of length >200
angstroms (~63 nt) the force required to bend the polymer 180° (in the shape of a semi-circle) is
negligible—energy requirements on the order of thermal fluctuations. However, if that same stretch
of 63 nucleotides were to form maximal G-quadruplexes (decreasing polymer length to <100
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angstrom), the increase in energy to bend increases by an order of magnitude—now requiring
energy input equivalent to ATP hydrolysis. Although somewhat intuitive, this implies that in the
absence of significant energy input, short telomere G4s must be made single-stranded in order to
bridge the terminal 3’ TTAG repeat (capped by POT1) with the shelterin complex. More importantly,
this figure indicates that small molecules which bind the inter-G4 grooves, thereby increasing its
effective persistence length, could shift the force curve to the right (towards the dsDNA curve, solid
red in Figure 22) and subsequently drive up the energy cost for associating the POT1-bound 3’
end with the shelterin loop. Indeed, during the drafting of this manuscript Gao et al. have
demonstrated that a small molecule targeting the wild-type Tel48 can shift the distribution of
conformations to favor a more compact, likely stacked, conformation (206)—a transition that would
directly affect persistence length. It is well established that telomere G-quadruplex interacting small
molecules are able to displace shelterin components, uncap the telomeres, and ultimately, inhibit
telomerase in vitro and in vivo (83,207). Thus, there is abundant rationale for future work targeting
these unique G4 junctional sites with stabilizing small molecules.
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Figure 22. DNA force of bending plot for single-stranded (green), double-stranded (red), and G4
telomere DNA (black). Force curve calculations were performed similar to reference (190) using
literature values of persistence length for ssDNA (Lp = 22 Å), dsDNA (Lp = 550 Å), and Telomere
G4 (Lp = 34.8 Å) as measured here. The Y-axis is the estimated force (in pN) to bend a length of
DNA (X-axis) 180° about the arc of a semi-circle (i.e. if you have a 330 angstrom long singlestranded DNA it will require a force of ~0.05 pN to bend it into a semi-circle). Dashed horizontal
lines are visual references to common biological forces found in the cell (orange indicates the
approximate range of force from thermal fluctuations). The light blue region highlights the range in
which short telomere G4s would be found, indicating that a large force would be required to bend
short telomeres (≤96 nt). The dashed red arrow illustrates that if a ~200 Å long ssDNA telomere
(approximately 63 nt) were to spontaneously fold into a contiguous G4 structure, the resulting
bending force required for a 180° turn increases by an order of magnitude. The increase in bending
force is comparable to the same length of DNA in duplex form (330 Å long duplex requires external
forces equivalent to ATP hydrolysis to bend 180°). In the case of duplex DNA, the energy
requirement of “tight” bending is usually compensated for by the highly positive charge on histones.
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Utilizing a robust integrative approach, we have presented here the highest-resolution view
of the higher-order telomere G4 to date. SAXS refinement of MD-derived models constructed from
high-resolution techniques is now a mainstay in structural biology. However, SAXS refinement of
MD generated atomistic models, while excellent for discarding unrealistic topologies and
conformations, is not necessarily definitive when conformational and topological polymorphism
presents itself. Thus, we await higher-resolution techniques that can inform on the distributions of
topologies in the higher-order telomere G-quadruplex.
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CHAPTER III

STRUCTURE-BASED TARGETING OF THE HIGHER-ORDER
HUMAN TELOMERE G-QUADRUPLEX

Disrupting telomere maintenance and homeostasis has emerged as a new avenue of anticancer therapy. Telomere shrinkage appears essential as a natural mechanism of cellular aging,
as once a critical limit is reached the cells undergo senescence. In cancer, the primary mechanism
used to avoid this fate is the re-activation of telomerase. In concert with the shelterin complex,
telomerase uses its reverse transcriptase functionality to restore telomere length leading to
unrestricted cell proliferation. Recently, the human telomeres have been shown to fold into non-B
DNA structures known as G-quadruplexes (G4s). Small molecules that bind to monomeric telomere
G4s with high affinity have been identified and show clear inhibition of telomerase in cells by
sequestering of the free 3’ telomere overhang. We have recently revealed that the telomere G4
multimer contains potentially novel inter-G4 junctional regions which could be targeted with
structure-based drug discovery approaches. Herein we present the results of a massive virtual
screening campaign targeting the telomere G4 multimer inter-quadruplex junctions with small
molecules. Using circular dichroism melting studies as a screen we have identified a small molecule
scaffold that interacts with the higher-order telomere G4. Further, using orthogonal biophysical
methods, we determine a binding stoichiometry of 1:1 with the number of G4 junctions in higher
order telomere G4s, and no binding to monomeric G4s, making it a promising lead molecule for
selectively targeting the telomere.
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Materials and Methods

Virtual drug screening
Virtual screening was performed using Surflex-Dock 2.11 on the Kentucky Dataseam Grid
utilizing over 53 million virtual ligands from the ZINC 2014 (24,877,119 molecules), 2016
(17,244,856 molecules), and 2018 (11,154,739 molecules) drug-like libraries. Docking was
performed on 27 unique sites across three different telomeric G-quadruplex models created
previously (163) with Surflex-Dock’s ‘-pgeom’ parameter set. Surflex-Dock protomols were
generated at residues within the G4-G4 junctions, loops, and grooves using standard Surflex-Dock
procedures with ‘bloat’ and ‘thresh’ set to default values. In total, >53 million virtual small molecules
were docked at each site. The top 1% scoring molecules across all sites, models, and small
molecule libraries were pooled and analyzed in Schrödinger’s (Schrödinger, Inc., New York, NY)
Canvas application using a hierarchical clustering algorithm to cluster molecules based on binary
fingerprints and Tanimoto similarity criteria. From this analysis, the top 100 centroid molecules
(most representative scaffolds of each clade) were then chosen for purchasing. This process was
also repeated using the top 5% of small molecules from the 2014 ZINC library alone. Duplicates
were removed from the final list of molecules considered for purchase. In total, 32 visually assessed
molecules were purchased from Molport.com for initial testing and given the designation “C#”. After
initial screening, 5 addition small molecules were also purchased using a structural similarity search
on compound C21.

Buffers and Compounds
All experiments were conducted in a potassium phosphate buffer with varying levels of KCl
(6 mM Na2HPO4, 2 mM NaH2PO4, 0-185 mM KCl, 1 mM Na2EDTA, pH 7.2). Compounds were
purchased from Molport.com and were dissolved to 10 mM in DMSO upon receiving. Compound
stocks were stored at -20°C until use.

Preparative Size Exclusion Chromatography (SEC)
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Oligonucleotides were purified using SEC as detailed previously (168). Briefly,
oligonucleotides were annealed at concentrations of 40-100 μM in their respective buffers, filtered
through 0.2 μm filters, and injected onto an equilibrated Superdex 75 16/600 SEC column (GE
Healthcare 28-9893-33) using a Waters 600 HPLC system. The flow rate was maintained at 0.5
mL/min and sample fractions were collected every 2 minutes from 100 to 180 minutes run time.
The molecular weights of fractionated species were estimated based on a regression analysis of
elution time vs. log(MW) of protein standards (Sigma #69385), with elution profiles monitored at
260 nm and 280 nm. Purifications were carried out at room temperature and fractionated samples
were stored at -20°C or 4°C prior to downstream analysis.

Circular Dichroism Spectroscopy (CD)
CD melting studies and spectra were collected on a Jasco-710 spectropolarimeter (Jasco
Inc. Eason, MD) equipped with a Peltier thermostat regulated cell holder and magnetic stirrer. CD
and melting spectra were collected using the following instrument parameters: 1 cm path length
quartz cuvette, 240 to 340 nm wavelength range, 1.0 nm step size, 200 nm/min scan rate, 1.0 nm
bandwidth, 2 second integration time, and 3 scan accumulation. Spectra were recorded at 20.0°C
and melting spectra were collected over a range of 20°C to 98°C with 2°C step intervals, 4°C/min
ramp speed, and a 2-minute equilibration time at each temperature before acquisition. Spectra
were corrected by subtracting a buffer blank. Spectra were normalized to molar circular dichroism
(Δε) based on DNA strand concentration using the following equation:
∆𝜀 = 𝜃/(32982 × 𝑐 × 𝑙)
where θ is ellipticity in millidegrees, c is molar DNA strand concentration in mol/L, and l is the path
length of the cell in cm. Fitting of melting curves was performed using least-squares fitting of a
Boltzmann function in Origin 2020.

Fluorescence thermal shift assays (FTSA)
Small molecule screening by FTSA was performed on an Applied Biosystems
StepOnePlus Real-Time polymerase chain reaction (PCR) instrument in 96-well plates as an
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adaption of previous work (208). Briefly, 10 mM compound stock solutions in DMSO were used to
create 96-well stock solution plates by diluting each compound to 2x final concentration in
potassium phosphate buffer. The same volume of DMSO was used as a control. The 5’ 6-FAM
(Fluoroscein) and 3’ TAMRA (Carboxytetramethylrhodamine) FRET-labeled DNA, post-annealing,
were quantified by UV-Vis and diluted to 2x final concentration. FTSA reaction mixes were made
up in 96-well Applied Biosystems MicroAmp PCR plates by mixing 10 μL of 2x compound solution
(or buffer/DMSO control) with 2x FRET-labeled DNA to yield 20 μL of 1x reaction mix. Plates were
then spun down at 1250 rpm for 2-3 minutes in a benchtop centrifuge to remove bubbles. Samples
were denatured by ramping the temperature from 20.0°C to 99.8°C in 0.2°C increments at a rate
of approximately 0.7°C/min. Fluorescence quenching of 6-FAM was monitored at each 0.2°C step
using the instrument’s onboard FAM filter over the entire reaction yielding a melt curve. Melting
temperatures (Tm) were determined from the 1st derivative of the normalized melting curves (209),
and differences in melting temperatures (ΔTm) were determined by taking the difference of control
and sample wells:
𝛥𝑇𝑚 = 𝑇𝑚,𝑠𝑎𝑚𝑝𝑙𝑒 − 𝑇𝑚,𝑐𝑜𝑛𝑡𝑟𝑜𝑙
Where Tm,sample and Tm,control are the melting temperatures of the sample and control, respectively.
Measurements are averages of triplicate experiments repeated on 3 separate days unless
otherwise specified.

Analytical ultracentrifugation (AUC)
Sedimentation velocity (SV) experiments were performed in a Beckman Coulter
ProteomeLab XL-A analytical ultracentrifuge (Beckman Coulter Inc., Brea, CA) at 20.0°C and
40,000 rpm in standard 2-sector cells using An50Ti or An60Ti rotors. 100 scans were collected
over an 8-hour period and analyzed in Sedfit (170) using the continuous C(s) model with a partial
specific volume of 0.55 mL/g for DNA. AUC drug binding experiments were carried out as detailed
previously (210), with a final compound concentration of 100 μM and 10 μM DNA (10:1
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[compound]:[DNA]). All compounds with reported stoichiometry from AUC experiments were
monitored at a wavelength well above 300 nm to ensure DNA had no contribution to estimated drug
concentrations.

Results and Discussion

We began in vitro screening of the initial 32 compounds against the Tel72 sequence (Table
4) using circular dichroism melting experiments with ratios of 1:50, 1:100, or 1:200
[Tel72]:[compound]. This screen resulted in only one compound, C20, which increased the Tm
(Figure 23A). C20 contains a known G4 interacting scaffold (17) and so was not pursued further.
Instead, we investigated compound C21, which caused a substantial decrease in the T m and had
a unique molecular scaffold (not shown). We confirmed that C21 could bind and stabilize the
monomeric telomere-derived G-quadruplexes 143D, 2GKU, and 2JSL, as well as the parallel cMYC promoter-derived 1XAV by FTSA assays (Figure 24). Surprisingly, treatment with C21 led to
Tm increases of 5-12°C with monomeric G4s. Thus, C21 stabilizes monomer G4s but destabilizes
the telomere G4 multimers. Binding of C21 was subsequently verified by AUC studies which
showed an approximate 2:1 binding ratio with Tel72 (Figure 23C).
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Table 4. Oligonucleotide sequences used in this study.
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Name

Sequence

Length

MW (kDa) E260 (M-1cm-1)

2JSL

TAGGGTTAGGGTTAGGGTTAGGGTT

25

7.9

253100

2GKU

TTGGGTTAGGGTTAGGGTTAGGGA

24

7.6

244300

143D

AGGGTTAGGGTTAGGGTTAGGG

22

7.0

228500

Tel48

(TTAGGGTTAGGGTTAGGGTTAGGG)2

48

15.2

489100

Tel72

(TTAGGGTTAGGGTTAGGGTTAGGG)3

72

22.8

733400

1XAV

TGAGGGTGGGTAGGGTGGGTAA

22

7.0

190394
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Figure 23. Screening results for compounds C20 and C21. (A) CD melting plots showing the
fractional change in ellipticity at 290 nm of Tel72 versus temperature in the presence or absence
of compounds. Tel72 was at a concentration of 1 μM and the given compounds were at 100 μM.
BRACO-19 served as a positive control. (B) Representative AUC C(s) versus S distributions of
Tel72 alone (black, S20,w = 3.45), C21 alone (red), and Tel72 in the presence of C21 (green).
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Figure 24. FTSA assay results for compounds C20 and C21 with various G4s. (A) derivative curves
of 143D (black) or 1XAV (red) in the absence (solid lines) or presence (dashed lines) of C20 and
C21. (B) derivative curves of 2GKU (blue) or 2JSL (green) in the absence (solid lines) or presence
(dashed lines) of C20 and C21.
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Based on C21’s confirmed interaction with Tel72 and monomer G4s, we next used
Molport.com’s similarity search tool to identify 5 compounds with similar scaffolds to test for
improved selectivity. These compounds were screened by CD melting analysis as above, with no
clear differences in CD spectra or Tm. However, by FTSA assay, we observed interaction of C37
with the Tel48 sequence, but not with monomeric telomere sequences (Figure 25). This finding
was subsequently confirmed by AUC binding studies that showed no binding to the monomeric
telomere sequences 143D, 2JSL, or 2GKU, and ratios of binding to the higher-order telomere Gquadruplexes of 1.3:1 [compound]:[Tel48] and 2.3:1 [compound]:[Tel72] (Figure 26B).

Due to the lack of interaction with the hybrid-1 (2GKU) or hybrid-2 (2JSL) monomeric
telomere sequences, the above binding stoichiometries indicate that C37 prefers binding between
the constituent G4s at the junctions, which are absent from the monomer forms. Thus, C37 exhibits
a unique interaction mechanism that could be beneficial in inhibiting telomere homeostasis. Further,
C37 is a unique molecular scaffold, making it an excellent lead as a selective telomere binding
small molecule. Cell-based and selectivity investigations with C37 are ongoing.
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Figure 25. FTSA melting analysis of various monomer G4s and Tel48 (black) in the presence of
C36 (red) and C37 (blue). (A) Duplicate results of 143D. (B) Duplicate results of 2GKU. (C)
Duplicate results of 2JSL. (D) Duplicate results of 1XAV. (E and F) Results of Tel48 melting with
two different fluorescence emission filters.
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Figure 26. AUC C(s) versus S distributions of Tel48 and Tel72 with compound C37. Compound
C37 alone is shown in black and exhibits a small peak around 2.1 S, potentially due to molecule
aggregation. C37 in the presence of Tel48 (red) or Tel72 (green) are shown with dashed lines
indicating the measured sedimentation coefficient for each species without compounds. C37 was
measured at a wavelength of 350 nm to avoid any overlap with DNA’s intrinsic absorption.

119

120

Altogether, in this study we have demonstrated the validity of using atomistic models
derived from integrated structural biology techniques in structure-based drug discovery campaigns.
We have identified a novel molecular scaffold, C37, which exhibits a stoichiometric ratio of binding
to the higher-order telomere G4s suggestive of inter-G4 junctional binding. Further, we demonstrate
that it does not bind monomeric G4s, making it a unique and compelling lead molecule for future
investigations.
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CHAPTER IV

THE HTERT CORE PROMOTER FORMS THREE PARALLEL GQUADRUPLEXES

The structure of the 68 nt sequence with G-quadruplex forming potential within the hTERT
promoter has been disputed. One model featured a structure with three stacked parallel Gquadruplex units, while another featured an unusual duplex hairpin structure adjoined to two
stacked parallel and antiparallel quadruplexes. We report here the results of an integrated structural
biology study designed to distinguish between these possibilities. As part of our study, we designed
a sequence with an optimized hairpin structure and show that its biophysical and biochemical
properties are inconsistent with the structure formed by the hTERT wild-type sequence. By using
circular dichroism, thermal denaturation, nuclear magnetic resonance spectroscopy, analytical
ultracentrifugation, small-angle X-ray scattering, molecular dynamics simulations and a DNase I
cleavage assay we found that the wild type hTERT core promoter folds into a stacked, three-parallel
G-quadruplex structure. The hairpin structure is inconsistent with all of our experimental data
obtained with the wild-type sequence. All-atom models for both structures were constructed using
molecular dynamics simulations. These models accurately predicted the experimental
hydrodynamic properties measured for each structure. We found with certainty that the wild-type
hTERT promoter sequence does not form a hairpin structure in solution, but rather folds into a
compact stacked three-G-quadruplex conformation.
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Introduction

G-quadruplexes (G4s) are four-stranded non-B DNA structures formed from Hoogsteen
hydrogen bonding of guanines to form stacked quartets. G-quadruplexes are known to form in the
telomeres of a variety of eukaryotic organisms where their role is primarily in telomere homeostasis
(25,211). Bioinformatic analyses have shown that G-quadruplex sequence motifs are concentrated
in oncogene promoters (11,12,15), and these promoter G-quadruplexes have been under
investigation for their ability to modulate gene expression (15). Many promoter G-quadruplexes are
currently being investigated for their potential in modulating their respective gene products: c-MYC
(16), KRAS (101), HRAS (102), HIF (103), and VEGF (104).
Human telomerase reverse transcriptase (hTERT) is the catalytic subunit of telomerase,
the enzyme primarily responsible for the immortality of cancer cells. hTERT is an important
oncogene with G4 motifs within its promoter (105,106,144). The hTERT gene encodes the reversetranscriptase component of the human telomerase ribonucleoprotein complex (67). Telomerase
(TERT) is responsible for maintenance of telomeres, and this activity is thought to be vital in cellular
immortalization (212,213). TERT is normally undetectable in somatic cells (except for stem cells),
and its aberrant expression is associated with 85-90% of cancers investigated (10,68,69). The
nearly exclusive expression of TERT in cancer cells has been acknowledged for more than two
decades as a target for anti-cancer therapies. Many contemporary techniques which target
telomerase, such as small molecule inhibitors, gene therapy, anti-sense oligonucleotides, and
immunotherapies, have demonstrated TERT inhibition as a viable mechanism in cancer treatment
(214). Unfortunately, no direct inhibitors of telomerase have been clinically successful (215). Some
of the more promising direct inhibitors exhibit severe toxicity in hematopoietic stem cells (216). This
provides a strong rationale for investigating alternative mechanisms to prevent telomerase activity
in cancer.
The wild type (WT) hTERT core promoter region (approximately -180 to +1 of transcription
start site) (217) contains twelve tracts of three or more guanines which enable formation of G-
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quadruplexes (105,106,144,145). Functional genetic studies have identified point mutations within
these G-tracts that are directly linked to increased expression of TERT (218). Two mutations,
G124A or G146A, are found in 60-80% of urothelial carcinomas (219), 71% of melanomas (220),
83% of glioblastomas (221), as well as a variety of other cancers. These mutations result in de
novo formation of E-twenty-six (ETS) transcription factor binding sites and confer a selective
advantage to cancer cells by allelic recruitment of the transcription factor GABP (219,222). These
mutations occur within G-tracts 5 and 8, the terminal G-tracts of the second putative quadruplex
sequence (PQS2) (Figure 27) and have been suggested to impact G-quadruplex transcriptional
silencing (106,145). This has been supported by a G-quadruplex-stabilizing small molecule
targeting the hTERT promoter in MCF-7 breast cancer cells (223). Thus, further investigation of the
secondary structure formed by the promoter DNA sequence is warranted.
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Figure 27. Comparison of WT and AH sequences and contemporary models. (A) (Top) The wildtype hTERT core promoter sequence and (bottom) the modified antiparallel hairpin (AH) sequence
with PQS-1, -2, and -3 indicating the “putative quadruplex forming sequences”, and the artificially
strengthened hairpin region shown with a dashed line. The purple and gold colors correspond to
the purple and gold regions in B. Red nucleotides indicate residues that were modified from WT to
force the formation of the parallel-antiparallel stacked hairpin model as in B. (B) The two current
models proposed for the secondary structure formed in the hTERT core promoter, three parallel
stacked (left) and a parallel stacked onto an antiparallel with 8 bp hairpin. The sugar phosphate
backbone is shown in ribbon, guanines in G-tetrads in blue, and nucleotides involved in the hairpin
shown in orange. Extraneous loop bases were removed for clarity. The purple “PQS1” region
reportedly adopts the same parallel conformation in both models, and this sequence has been
solved (105). The gold region highlights the major difference in the two models, herein referred to
as the “PQS23” region.
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The original three studies (105,106,144) of G-quadruplex forming capability of the hTERT
core promoter utilized a sliding frame approach to identify G-quadruplex formation and stability.
From left to right (5’ to 3’) in Figure 27A we have designated these putative quadruplex forming
segments (PQS) as PQS1, PQS2, and PQS3. Isolated PQS1 has been shown to exist as a mixture
of both parallel and anti-parallel (3+1) structures by nuclear magnetic resonance (NMR)
spectroscopy (105). Isolated PQS3 was shown to adopt a parallel conformation (105,144), albeit
with slightly lower stability than PQS1. Further support for the formation of both PQS1 and PQS3
quadruplexes in the context of the full-length sequence was observed by Taq polymerase stop
assays (106,144). The PQS2 segment alone does not appear to readily form a G-quadruplex.
However, using an inverted Taq polymerase stop assay, Micheli et al. (144) observed that the
PQS2-PQS3 (“PQS23”) region could potentially form stacked parallel G-quadruplexes, implying
that the inter-quadruplex stacking interface provided a stabilizing effect. This observation is
substantiated by the large circular dichroism (CD) signal at 260 nm for the WT PQS2-3 sequence
(223). Micheli et al. (144) proposed a model of “self-organization” that featured three contiguous
stacked parallel quadruplexes, which stems from stabilization of the PQS2 through terminal Gquadruplex stacking interactions. That model was supported by subsequent biophysical studies
combined with molecular dynamics simulations (145) (Figure 27B, left model). Alternatively,
Palumbo et al. (106) proposed a model based on dimethylsulphate (DMS) foot-printing techniques
that featured a parallel PQS1 stacked onto an antiparallel/hybrid G-quadruplex with 8-bp hairpin
loop (Figure 27B, right model). A later study on the same sequence proposed a different structure
(again based on DMS foot-printing) with a longer hairpin joining two parallel G-quadruplexes (224).
In both cases (106,224), the CD spectra shown for the folded hTERT sequence lack the signature
features expected for structures containing a significant amount of hairpin duplex component. In
addition, both proposed hairpin structures contain several thermodynamically destabilizing features
including mismatches and bulges.
The structure of the wild-type hTERT promoter sequence thus remains ambiguous. It is
important to characterize its structure since it is now considered a target for potential cancer drugs.
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For any rational structure-based design of drug candidates, it is essential to know the structure
being targeted with certainty. The goal of our study is to clarify the hTERT promoter structure.
A challenge in the determination of the structures of long multimeric quadruplex-forming
sequences is that conventional high-resolution NMR or crystallographic methods have yet to be
successful, necessitating the use of lower-resolution methods. Herein we report the results of an
integrated structural biology (225) investigation of the full-length hTERT promoter sequence using
a battery of biophysical and biochemical approaches. In addition, we implemented what can be
called a falsum figura (“false shape”) strategy in which we designed and optimized a non-biological
sequence that is forced into the unusual hairpin structure proposed by Palumbo et al. (106). We
show that the biophysical and biochemical properties of that structure are unambiguously distinct
from the structure formed by the wild-type hTERT sequence, indicating that such a structure is not
the predominate folded form of the native sequence. We used classical spectroscopic techniques,
hydrodynamic studies, small-angle X-ray scattering, and DNase I digestion as a biochemical probe
for duplex DNA to characterize the structures, and we built all-atom models using molecular
dynamics simulations to predict testable experimental properties to distinguish structural models.
We conclude that the wild-type hTERT promoter sequence forms a compact structure containing
three stacked parallel G-quadruplex units and that such a structure is the most appropriate target
for any rational drug design effort.

Materials and Methods

Oligonucleotides
Oligonucleotides are given in Table 1. Oligos were purchased from either IDT (Integrated
DNA Technologies, Coralville, IA) or Eurofins Genomics (Louisville, KY) with standard desalting
unless otherwise specified. Upon receipt, stock oligos were dissolved in MilliQ ultrapure water (18.2
MΩ x cm at 25°C) at concentrations between 0.1 and 1 mM and stored at -20.0°C until use. Folding
was achieved by diluting stock oligos into their respective buffer and heating to 99.9°C in a water
bath for 20 minutes, followed by slow cooling overnight and subsequent storage at 4°C.
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Table 5. Oligonucleotide sequences used in this study.
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OLIGONUCLEOTIDE SEQUENCE 5' TO 3'

LENGTH

MW

GGGGAGGGGCTGGGAGGGCCCGGAGGGGGCTGGGCC
GGGGACCCGGGAGGGGTCGGGACGGGGCGGGG
AGGGGAGGGGCTGGGAGGGC

68

21633

Ε260 (M1
CM-1)
672671

20

6369

202900

49

15523

478700

45

14278

436500

57

18145

553100

68

21289

628400

44

13721

398100

AH Hairpin

AGGGGAGGGGCTGGGAGGGCCCGGAGGGGGCTGGGC
CGGGGACCCGGGA
AGGGGGCTGGGCCGGGGACCCGGGAGGGGTCGGGAC
GGGGCGGGG
ATGGGTGGGTGGGTGGGCCCTTAGGGTGGGTGGGTCG
GGATGGGTGGGTGGGTGGGT
TGGGAGGGTCTGGGAGGGCCCTTATGGGTCTGGGCCC
GCGACGCGCGAGGCGTCGCGGCTGGGCGGGT
TGGGTCTGGGCCCGCGACGCGCGAGGCGTCGCGGCTG
GGCGGGT
CCCGCGACGCGCGAGGCGTCGCGGCT

26

7975

230296

1XAV

TGAGGGTGGGTAGGGTGGGTAA

22

6992

228700

Hairpin
Duplex

GCATATATAGGACCCGCGAGCGGTCCTATATATGC

35

10756

339998

NAME
WT
WT PQS1
WT PQS12
WT PQS23
OP
AH
AH PQS23
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Buffers
All buffer reagents, unless otherwise specified, were purchased from Sigma-Aldrich. TBAP
folding buffer (10 mM tetrabutylammonium dihydrogen phosphate, 200 mM KCl, 1 mM EDTA, pH
7.0) was prepared by dissolving 3.4 g of tetrabutylammonium phosphate monobasic, 14.9 g KCl,
and 292 mg of acid EDTA in 10 mL of tetrabutylammonium hydroxide 40% solution in 900 mL of
MilliQ ultrapure water and adjusted to pH 7.0 before bringing to 1 L (density = 1.0081 g/cm 3,
viscosity = 0.01038 poise). Phosphate (PO4) buffer (8 mM phosphate, 200 mM KCl, pH 7.2) was
prepared by dissolving 1.0 g K2HPO4, 272 mg KH2PO4, and 13.9 g KCl in 900 mL of MilliQ ultrapure
water and adjusting pH to 7.2 before bringing to 1 L (calculated density = 1.0081 g/cm 3, calculated
viscosity = 0.00996 poise). DNase I reaction buffer (4x) (80 mM Tris, 8 mM MgCl 2, 40 mM KCl, pH
7.2) was prepared by dissolving 967 mg Tris base, 76 mg MgCl2, and 298 mg KCl in 90 mL of MilliQ
ultrapure water and adjusted to pH 7.2 before bringing to 100 mL. All buffers were filtering through
0.2 μm filters before use.

Preparative Size Exclusion Chromatography (SEC)
Oligonucleotide purification was achieved using SEC as detailed previously (168). Briefly,
oligonucleotides were annealed at concentrations of 40-100 μM in their respective buffers, filtered
through 0.2 μm filters, and injected onto an equilibrated Superdex 75 16/600 SEC column (GE
Healthcare 28-9893-33) using a Waters 600 HPLC system. The flow rate was maintained at 0.5
mL/min and sample fractions were collected every 2 minutes from 100 to 180 minutes run time.
The molecular weights of fractionated species were estimated based on a regression analysis of
elution time vs. log(MW) of protein standards (Sigma #69385), with elution profiles monitored at
260 nm and 280 nm. Purifications were carried out at room temperature and fractionated samples
were stored at 4°C prior to concentration and downstream analysis.

DNase I Degradation Assay
Amplification Grade DNase I was purchased from ThermoFisher and used without further
modification (ThermoFisher, #18068015). PAGE purified oligonucleotides for the hTERT WT and
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AH sequences were annealed in TBAP folding buffer (without EDTA) before being concentrated to
~50 μM in Pierce protein concentrators (ThermoFisher, #88515). The oligonucleotides were
subsequently diluted to 160 ng/μL in TBAP buffer and mixed in a 2:1:1 with DNase I reaction buffer
and nuclease free H2O (DNA:RXN-buffer:H2O) to give a final concentration of 80 ng/μL DNA in 10
μL of reaction mix. The reactions were initiated by the addition of 1 μL DNase I (at 1 unit/μL DNase
I), incubated at room temperature, and stopped at the indicated time points by the addition of 1 μL
of 50 mM EDTA solution. The DNase I cleavage products were then resolved on a 5% agarose gel
(~2.5 hours at ~7 V/cm) with visualization by ethidium bromide or SYBR green stain. Gels were
imaged using a PharosFX Plus imaging system (BioRad).

Circular Dichroism Spectroscopy (CD)
CD melting studies and spectra were collected on a Jasco-710 spectropolarimeter (Jasco
Inc. Eason, MD) equipped with a Peltier thermostat regulated cell holder and magnetic stirrer. CD
and melting spectra were collected using the following instrument parameters: 1 cm path length
quartz cuvette, 210 or 240 to 340 nm wavelength range, 1.0 nm step size, 200 nm/min scan rate,
1.0 nm bandwidth, 2 second integration time, and 4 scan accumulation. Spectra were recorded at
20.0°C and melting spectra were collected over a range of 4°C to 98°C with 2°C step intervals,
4°C/min ramp speed, and a 2-minute equilibration time at each temperature before acquisition.
Spectra were corrected by subtracting a buffer blank. In the case of DNase I degradation assays,
the blank included DNase I. Spectra were normalized to molar circular dichroism (Δε) based on
DNA strand concentration using the following equation:
∆𝜀 = 𝜃/(32982 × 𝑐 × 𝑙)
where θ is ellipticity in millidegrees, c is molar DNA concentration in mol/L, and l is the path length
of the cell in cm.
For CD monitored DNase I reactions, oligonucleotides were prepared as in the standard
DNase I reactions and diluted to a final strand concentration of 3 μM in 500 μL by mixing in the
same v/v ratio of DNA, dH2O, and 4x DNase I RXN buffer. Reactions were initiated by adding 50
μL of DNase I (at 1 unit/μL DNase I) and mixing by pipetting 15 times. Reactions were monitored
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over a total of 4 hours in a 0.5 cm path length quartz cuvette. Four hours after DNase I addition, 20
μL of a 100 μM CaCl2 solution was added (for a final concentration of ~3.5 μM Ca 2+), and the
measurements were resumed to ensure that the DNase I was active.

1

H Nuclear Magnetic Resonance (1H-NMR) Spectroscopy
1D 1H-NMR spectroscopy was performed on a Bruker Avance Neo 600-MHz instrument

equipped with a nitrogen-cooled Prodigy TCI cryoprobe. Experiments were performed at 25.0 or
40.0ºC using standard 3- or 5-mm NMR tubes. Minimization of water signal was achieved using a
water flip-back pulse sequence. For each measurement, 1024 complex points were collected with
an acquisition time of 86 ms. Total scans for each spectrum are as follows: WT (4,096), AH (128),
OP (128), WT PQS2-3 (128), AH PQS2-3 (4). Samples were prepared by annealing in PO4 folding
buffer and purified by preparative SEC. Fractions were pooled and concentrated using pre-rinsed
Pall 3K MWCO concentrators, followed by addition of 5% v/v D 2O. Final concentrations at time of
analysis were: WT (150 μM), WT-XL (200 μM), AH (225 μM), optimized parallel (140 μM), WT
PQS2-3 (285 μM), and AH PQS2-3 (285 μM). After concentration an aliquot was removed from
each sample and analyzed by CD and AUC to ensure that there were no conformational changes
due to concentration.

Analytical Ultracentrifugation (AUC)
Sedimentation velocity (SV) experiments were performed in a Beckman Coulter
ProteomeLab XL-A analytical ultracentrifuge (Beckman Coulter Inc., Brea, CA) at 20.0°C and
40,000 rpm in standard 2-sector cells using An50Ti or An60Ti rotors. 100 to 150 scans over an 8hour period were collected and analyzed in Sedfit using the continuous C(s) model. For the hTERT
oligonucleotides (“WT” and “WT PQS23”) a concentration series of purified oligonucleotide was
used to correct for any non-ideal concentration-dependency in sedimentation. This was done using
the following concentrations and respective wavelengths: 2.5 mg/mL (306 nm), 1.25 mg/mL (302
nm), 0.5 mg/mL (298 nm), 0.125 mg/mL (290 nm), 0.05 mg/mL (272 nm), and 0.01 mg/mL (260
nm) at 20.0°C and 40k rpm. Buffer densities and viscosities used in the SV analyses are provided
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in the buffers section, and the partial specific volume was held constant at 0.55 mL/g. All large oligo
sequences (>~45 nt) regardless of purity at time of purchase had a propensity to aggregate under
normal annealing conditions. Thus, all SV experiments were conducted directly after SEC
purification, except when correcting for concentration effects. Estimation of weight averaged
frictional ratios (f/fo) of the monomeric WT sequences were carried using Sedfit’s C(s,ffo) model,
with a frictional ratio resolution set to 10 and sedimentation coefficient resolution of 100.

SEC Resolved Small-angle X-ray Scattering (SEC-SAXS)
SAXS was performed at BioCAT (beamline 18ID at the Advanced Photon Source, Chicago)
with in-line size exclusion chromatography. Samples in a modified PO 4 buffer (8 mM PO4, 185 mM
KCl, 15 mM NaCl, 1 mM EDTA, pH 7.2) were loaded onto a Superdex 75 10/300 GL column, which
was run at 0.7 ml/min using an AKTA Pure FPLC (GE Healthcare Life Sciences) and the eluate
after it passed through the UV monitor was directed through the SAXS flow cell, which consists of
a 1 mm ID quartz capillary with 50 μm walls. A co-flowing buffer sheath was used to separate the
sample from the capillary walls, helping prevent radiation damage (172). Scattering intensity was
recorded using a Pilatus3 1M (Dectris) detector which was placed 3.5 m from the sample giving
access to a q-range of 0.004 Å-1 to 0.4 Å-1. A series of 0.5 second exposures were acquired every
2 seconds during elution and data was reduced using BioXTAS RAW 1.6.3 (173). Buffer blanks
were created by averaging regions flanking the elution peak and subtracted from exposures
selected from the elution peak to create the I(q) vs. q curves used for subsequent analyses. More
information on SAXS data collection, reduction and interpretation can be found in Table 6.
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Table 6. Tabulated collection parameters, data reduction methods, and data analyses for smallangle X-ray scattering data.
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(a) Sample Details.
Sequence name

WT

OP

AH

WT PQS23

AH PQS23

synthetic

synthetic

synthetic

synthetic

synthetic

IDT

IDT

IDT

IDT

IDT

672671

553100

628400

436500

398100

0.55

0.55

0.55

0.55

0.55

M from chemical composition (Da)
SEC-SAXS column, 10 x 300
Superdex 75

21633

18145

21289

14278

13721

Loading concentration (mg/ml)

4.0

3.7

13.3

5.2

6.5

Injection volume (μL)

300

300

240

250

260

0.75
8 mM PO4, 185
mM KCl, 1 mM
EDTA, pH 7.2

0.75
8 mM PO4, 185
mM KCl, 1 mM
EDTA, pH 7.2

0.75
8 mM PO4, 185
mM KCl, 1 mM
EDTA, pH 7.2

0.75
8 mM PO4, 185
mM KCl, 1 mM
EDTA, pH 7.2

0.75
8 mM PO4, 185
mM KCl, 1 mM
EDTA, pH 7.2

Organism
Source
Extinction coefficient (nearest
neighbor approximation) (M-1cm-1)
vbar (cm3/g)

Flow rate (ml/min)
Solvent (solvent blanks taken
from SEC flow-through prior to
elution of protein)

(b) SAXS data-collection
parameters.
Instrument/data processing

BioCAT facility at the Advanced Photon Source beamline 18ID with Pilatus3 1M (Dectris) detector

Wavelength (Å)

1.033

Beam size (μm)

150 (h) x 25 (ν)

Camera length (m)

3.5

q measurement range (Å-1)

0.004-0.4

Absolute scaling method

N/A

Normalization

To transmitted intensity by beam-stop counter

Monitoring for radiation damage
Exposure time, number of
exposures

Automated frame-by-frame comparison of relevant regions

Sample configuration

0.5 s exposure time with a 2 s total exposure period (0.5 s on, 1.5 s off) of entire SEC elution
SEC-SAXS with sheath-flow cell(172), effective path length 0.542 mm. Size based separation by
an AKTA Pure with a superdex 75 10/300 GL column

Sample temperature (°C)

23

(c) Software employed for SAXS data reduction, analysis, and interpretation.
SAXS data reduction
Extinction coefficient estimate

Radial averaging; frame comparison, averaging, and subtraction done using BioXTAS RAW
1.6.3(173)

Basic analyses: Guinier, P(r), Vp

Nearest neighbor approximation
Guinier fit, Kratky analysis, and molecular weight using BioXTAS RAW 1.6.3, P(r) function using
PRIMUSqt(175)

Shape/bead modelling

DAMMIF(226) via ATSAS online (https://www.embl-hamburg.de/biosaxs/atsas-online/)

Atomic structure modelling
Three-dimensional graphic model
representations

CRYSOL from PRIMUSqt in ATSAS v2.8.4(186)
UCSF Chimera v1.11(176)

(d) Structural parameters.
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Guinier analysis
I(0) (cm-1)

0.000359 ±
0.0000011

0.000989 ±
0.0000035

0.00395 ±
0.0000045

0.00131 ±
0.0000032

0.00322 ±
0.0000034

Rg (Å)

21.93 ± 0.12

16.46 ± 0.12

24.78 ± 0.052

17.05 ± 0.08

20.38

0.0092

0.0068

0.0043

0.0111

0.0074

qRg max (qmin = 0.0066 Å-1)

1.33

1.3

1.27

1.3

1.27

Coefficient of correlation, R2

0.981

0.956

0.992

0.983

0.996

M from Vc (ratio to predicted)

23100 (1.07)

15200 (0.84)

23300 (1.09)

16400 (1.15)

16400 (1.20)

0.00036 ±
0.000001

0.00099 ±
0.0000028

0.004 ±
0.0000041

0.0013 ±
0.0000024

0.0032 ±
0.0000032

21.97 ± 0.47

16.51 ± 0.24

24.77 ± 0.09

17.03 ± 0.21

20.36 ± 0.09

79

53

79

47

66

0.79

0.75

0.98

0.85

0.94

27900 (1.29)

17100 (0.94)

28100 (1.32)

17700 (1.24)

16800 (1.22)

0.01-0.35

0.006-0.35

0.007-0.32

0.006-0.35

0.006-0.35

P1, none

P1, none

P1, none

P1, none

P1, none

0.88 (0.07), 4

0.51 (0.02), 5

1.18 (0.12), 3

0.82 (0.8), 2

1.00 (0.08), 3

0.964-0.965
Unable to
determine

1.153-1.157
Unable to
determine

1.089-1.091
Unable to
determine

1.043-1.045
Unable to
determine

1.509-1.520
Unable to
determine

26 ± 2

17 ± 2

30 ± 2

23 ± 2

27 ± 2

18338 (0.85)

11156 (0.61)

18770 (0.88)

11988 (0.84)

12256 (0.89)

SASDHM3

SASDHP3

SASDHN3

SASDHQ3

SASDHR3

qmin (Å-1)

P(r) analysis
I(0) (cm-1)
Rg (Å)
Dmax (Å)
ꭕ2 (total estimate from GNOM)
Porod volume (Å-3) (ratio
Vp/calculated M)

(e) Shape model-fitting results
DAMMIF (default parameters, 15
calculations)
q range for fitting (Å-1)
Symmetry, anisotropy
assumptions
NSD (standard deviation), No.
of clusters
ꭕ2 range
Constant adjustment to
intensities
Resolution (from SASRES) (Å)
M estimate as 0.5 x volume of
models (Da) (ratio to expected)

(f) SASBDB IDs for data and
models.
ID
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Molecular Dynamics simulations
Molecular dynamics simulations were carried out on the hTERT models created previously
(145) with modifications of bases where necessary using the “swapna” command in UCSF Chimera
1.12 (176) and manual alterations in starting atomic configurations using Schrӧdinger’s Maestro
11.8 (https://www.schrodinger.com/). Coordinating counter ions (K+) were manually added between
G-quartet stacks and minimized prior to simulations. The PDB structures were imported into the
xleap module of AMBER16 (https://ambermd.org/), neutralized with K+ ions, and solvated in a
rectangular box of TIP3P water molecules with a 15 Å buffer distance. All simulations were
equilibrated using sander at 300 K and 1 atm using the following steps: (1) minimization of water
and ions with weak restraints of 10.0 kcal/mol/Å on all nucleic acid residues (2000 cycles of
minimization, 500 steepest decent before switching to conjugate gradient) and 10.0 Å cutoff, (2)
heating from 0 K to 100 K over 20 ps with 50 kcal/mol/Å restraints on all nucleic acid residues, (3)
minimization of entire system without restraints (2500 cycles, 1000 steepest decent before
switching to conjugate gradient) with 10 Å cutoff, (4) heating from 100 K to 300 K over 20 ps with
weak restraints of 10.0 kcal/mol/Å on all nucleic acid residues, and (5) equilibration at 1 atm for 100
ps with weak restraints of 10.0 kcal/mol/Å on nucleic acids. The output from equilibration was then
used as the initial.rst input file for 100 ns of unrestrained MD simulations using pmemd with GPU
acceleration in the isothermal isobaric ensemble (P = 1 atm, T = 300 K). Periodic boundary
conditions and PME were used. 2.0 fs time steps were used with bonds involving hydrogen frozen
using SHAKE (ntc = 2). The hairpin structure was manually placed in three different starting
configurations and simulated three separate times until convergence was obtained. Trajectories
were analyzed using the CPPTRAJ module in the AmberTools16 package (https://ambermd.org/).
Hydrodynamic properties were calculated as average and standard deviation over 100 equally
spaced trajectory snapshots, unless otherwise specified, using the program HYDROPRO10 (179)
with the recommended parameters (180). G-quartet associated potassium ions were included (and
added to the molecular weight) in the hydrodynamic calculations. Values are reported as average
and standard deviations across 100 evenly spaced snapshots of the trajectories. Clustering of the
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hTERT

trajectory

was

performed

as

described

(http://www.amber.utah.edu/AMBER-

workshop/London-2015/Cluster/) using the CCPTRAJ module of Amber.

Molecular Visualizations
All molecular visualizations of MD trajectories and models were performed in UCSF Chimera v1.12
(176).

Results

Sequence design and logic
In the 2014 report from Chaires et al. (145) the authors noted that a parallel-antiparallelhairpin structure, such as proposed by Palumbo et al. (106), should have a CD spectrum distinctly
different from that observed for the WT sequence. To validate this assertion, we modified the WT
hTERT sequence to generate an optimal sequence that would fold into the hairpin structure
proposed by Palumbo et al. (106) to contrast its properties with that of the WT sequence (Table 5,
AH). The AH sequence was designed to include base substitutions (G>T) to restrict G-quadruplex
formation to runs of only 3 guanines and modified residues in the putative hairpin region to
maximize hairpin formation and concomitantly disfavor G-quadruplex formation. It is worth noting
that a significant number of modifications (15 out of 68 WT bases) were required to stabilize the
hairpin structure, as fewer mutations resulted in mixtures of two or more species. We also created
an optimized all-parallel structure (Table 5, OP) using three runs of a canonical parallel Gquadruplex motif which retains a 6-nucleotide modified non-guanine-containing loop sequence
similar to the WT (Figure 27A, segment between PQS1 and PQS2). OP was designed to minimize
possible G-register exchange (227) and thereby minimize heterogeneity while retaining the threestack G4 structure. In addition, several truncated sequences were designed to contain isolated
structural elements of the longer wild-type form. These represent the first (PQS1), first and second
(PQS12), and second and third (PQS23) G4 forming regions of hTERT WT. A high-resolution
structure of PQS1 has been reported that can be integrated into our structural models (105). For

139

the AH sequence analogs, a hairpin-G4 structure (AH-PQS2-3) and an isolated duplex hairpin (AHhairpin) were designed. Table 5 contains the complete list of sequences used in this study.

Circular dichroism and DNase I cleavage assays reveal only G-quadruplex moieties
within the wild type hTERT core promoter sequence.
We began our structural investigations using CD spectroscopy in potassium buffer. The
differences in the spectra of folded WT and AH are unambiguous (Figure 28A). Consistent with
earlier reports (106,144,145), the strand-normalized hTERT WT spectrum exhibited strong positive
molar ellipticity at 260 nm, a trough at 240 nm, and a small trailing shoulder at 290 nm. This large
260 nm amplitude is consistent with a high degree of anti-anti guanine base steps (44,196), typical
of parallel quadruplexes, and could only arise from stacking of a large number of G-quartets.
Indeed, the CD amplitude at 260 nm is linearly correlated with the number of stacked, parallel, Gquartets (228), so we can estimate from these data that the folded WT sequence contains 9 stacked
quartets. In contrast, the AH spectrum has only a modest peak at 260 nm, a trough at 245 nm, and
a relatively larger shoulder at 290 nm when compared with the WT. We found that the WT CD
spectrum could be reconstructed by addition of spectra obtained with the truncated sequences,
PQS1 and PQS23 that are known to form only parallel quadruplex structures (Figure 28B, Table
5). In contrast, the AH spectrum can only be reconstructed using a combination of parallel G4 [PDB
ID: 1XAV (229)], antiparallel-hybrid G4 (196), and duplex hairpin CD spectra (Figure 28C). The
low amplitude at 260 nm for AH is consistent with the contribution of three stacked G-quartets in
the parallel conformation, while the pronounced shoulder near 290 nm arises from a three-quartet
antiparallel contribution. The assumed B-form duplex contributes comparatively little to the CD
spectra (230).
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Figure 28. CD spectra for WT, AH, and their putative component spectra. (A) Strand-normalized
CD spectra of the WT and AH sequences annealed in the presence of 200 mM K+, showing distinct
differences in the troughs (~240 nm vs. 245 nm), peak height at 260 nm, and shoulder at 290 nm.
(B) The WT sequence can be faithfully reconstructed (dashed line “sum”) from the addition of the
PQS1 (red) and PQS23 (green) fragment spectra which adopt parallel topologies in 200 mM K +
buffer (as shown below). (C) The AH spectrum can be reconstructed (dashed line “sum”) from the
addition of the parallel 1XAV (red), a hairpin (green), and an antiparallel G-quadruplex spectrum
(blue).
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The Hurley group recently re-investigated using DMS foot-printing the WT hTERT
sequence (224) and suggested formation of a different, larger hairpin which putatively forms within
the internal PQS2 region, sandwiched between two outer parallel G4s (PQS1 and PQS3). Other
DNA conformational forms might contribute to CD spectra. We reasoned that it may be possible
for the hairpin to adopt an A-form duplex (44), and that perhaps this might contribute to the CD
magnitude at 260 nm, compensating for the magnitude expected for a parallel quadruplex forming
within PQS2, complicating interpretation of the CD spectra. As an independent, selective, test for
the presence of duplex regions we used an enzymatic assay to probe the structures. Any proposed
hairpin structure, whether in B- or A-form, should be susceptible to cleavage by deoxyribonuclease
I (DNase I), while parallel G4 structures should remain undigested due to the occluded phosphate
backbone (231,232). Upon treatment with DNase I (Figure 29) we found that the WT sequence is
entirely protected from DNase I cleavage while AH is degraded into discrete components (Figure
29A & B). Further, the AH cleavage bands observed after 10 minutes at ~14 and ~8 base pairs are
approximately the sizes expected for cleavage of the antiparallel hairpin (Figure 30) (233). A
scaled-up DNase I cleavage reaction was also monitored using CD spectroscopy, revealing that
there was no discernable change in the WT CD spectrum but a significant alteration of the AH CD
(Figure 29C & D). The shapes of the difference spectra observed in Figure 29D for the digestion
of AH over the course of the DNase I digestion are consistent with the degradation of a B-form
duplex domain within the structure. Overall, these results clearly demonstrate that a DNase Isusceptible hairpin is not detectable in the WT hTERT core promoter sequence.
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Figure 29. DNase I cleavage susceptibility assay. (A) Representative agarose gel showing DNase
I treatment times (NT = no treatment) in minutes for WT or AH sequences after annealing in TBAP
(without EDTA). The gel shows that the WT sequence is not sensitive to nuclease cleavage,
whereas the AH sequence is cleaved into discrete bands by 10 minutes treatment time. (B)
Densitometry of the AH lanes from A with dashed lines showing the appearance of discrete bands
at ~14 bp (or ~28 nt) and ~8 bp (or ~16 nt). (C & D) CD difference plots showing the change in CD
signal over the DNase I treatment time course. In both windows the left Y-axis corresponds to the
black curves, which is the strand-normalized ellipticity of the WT or AH sequence pre-DNase I
treatment. The right Y-axis corresponds to the colored spectra which (from blue to red) indicate the
change in CD (difference spectra) from the original spectrum due to DNase I treatment. (C - Inset)
Color scale representing time interval from addition of DNaseI (Blue, time = 0) to end of experiment
(Red, time = 4 hours). The right Y-axis is scaled such as to emphasize where changes are
occurring.
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Figure 30. Proposed mechanism of hairpin cleavage by DNase I. (A) Schematic representation of
the optimized hairpin region of the antiparallel hairpin (AH) sequence, with putative cleavage sites
and fragment sizes indicated by red lightning bolts. (B) (Left) Structure of the antiparallel hairpin
derived from MD simulations with GAC/CTG cleavage site colored as in A. (B, right) X-Ray
crystallography-derived structure of DNase I (orchid ribbon) bound to the d(GGTATACC)2 duplex
(PDB ID: 1DNK (234)) with phosphate backbone cleavage site represented as atoms and catalytic
histidine residues displayed in green (some ribbon and residues have been omitted for clarity).
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Treatment of the optimized, G4-stacked, OP structure, or the truncated WT sequence (“WT
PQS23”) with DNase I had no cleavage effect, consistent with the absence of any duplex structure.
A slight degradation over time was observed in the WT PQS12. In contrast, the AH truncated
sequence (“AH PQS23”) and the control AH hairpin sequence alone (“HP”) were completely
degraded by 15 minutes (Figure 31).
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Figure 31. DNase I protection assays of truncated sequences. Agarose gel separation of DNase I
treated nucleotide sequences with oligo name and time (in minutes) of DNase I treatment indicated
above each lane. The ladder is an ultra-low range DNA ladder that spans from 300 to 10 bp.
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1

H-NMR confirms that the WT hTERT sequence forms only parallel quadruplexes.
We next analyzed the WT and modified sequences at the atomic level using 1H-NMR to

gain a better understanding of the secondary structures giving rise to the observed CD spectra
(Figure 28). Figure 32A shows the Hoogsteen and Watson-Crick imino proton region of the 1HNMR spectra (~10-14.6 ppm) for the WT, AH, OP, and truncated PQS23 sequences (Figure 32A
& C), along with their respective CD spectra (Figure 32B & D). In the WT spectrum (Figure 32A,
black) we observed a very broad envelope encompassing the guanine Hoogsteen imino protons
between ~10 and 12 ppm, indicative of G-quadruplex formation, along with a slight, almost
negligible, signal at ~12.9 ppm. In contrast, we find that the spectrum of AH exhibits the expected
Watson Crick-like (W.C.) base-pairing interactions for a hairpin in the region from 12.6-13.6 ppm,
along with a broad envelope in the Hoogsteen G-quadruplex region from 10.8-12 ppm, confirming
the presence of both duplex and G-quadruplex structures. The contrasting behavior of WT and AH
show that there is no appreciable duplex base pairing in the unmodified hTERT sequence.
Additional sequences were also studied by NMR. The OP sequence displays only G-quadruplex
imino proton shifts in the range of 10-12 ppm, with no signals within the W.C. range. The OP
sequence was created as a reference “idealized” three-parallel G-quadruplex system with minimal
loops connecting the stacked G4 units. Figure 32B shows that the WT and OP sequences exhibit
nearly identical magnitude and shape from 220 to 270 nm by CD, the only difference being the
shoulder at ~290 nm in the WT spectrum. Importantly, we find that the strand-normalized integrated
intensity in the Hoogsteen imino proton signals for the OP and WT sequences is 1.1:1 (Figure 33).
The truncated WT PQS2-3 and AH PQS23 sequences also show a clear difference by
NMR and CD (Figure 32C & D). With the removal of PQS1 (and ~6 nt connecting loop region), we
find that the AH PQS23 imino proton spectra resolves ~12 G-quadruplex peaks, the number
expected for a single three-tetrad G-quadruplex, with the same number W.C. imino peaks as the
full-length AH construct. This is in clear contrast to the WT PQS23 segment, which displays almost
twice as many G-quadruplex imino peaks by integration (1.8:1). Taken with their respective CD
spectra, this clearly demonstrates that the full-length and truncated WT sequences preferentially
form only parallel G-quadruplexes.
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Figure 32. 1H-NMR spectra and corresponding CD spectra of WT, AH, OP, and truncated
sequences. (A & C) Proton imino spectra from 10 to 14.6 ppm showing Watson-Crick and
Hoogsteen type imino proton shifts for the OP, AH, WT, and truncated sequences WT PQS23 and
AH PQS23. Intensities in A are only approximate, whereas concentrations and intensities in C are
the same. (B & D) Strand-normalized CD spectra corresponding to spectra in A and C, respectively.
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Figure 33. Full 1H-NMR spectra comparing the WT, AH, and OP and regions for scaling. Scaling
of the Hoogsteen imino region peak intensities are approximate. The blue and black dashed regions
represent the areas used for normalizing W.C. or Hoogsteen imino proton peaks to strand
concentration.
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Hydrodynamic size and shape of the WT sequence indicates a very compact and
globular structure.
Hydrodynamic experimentation and modeling methods (235) have gone hand-in-hand in
structural biology for over 75 years (236). It is now routine in our laboratory to use experimental
hydrodynamic properties of nucleic acids to infer, and iteratively refine, their structural models using
molecular dynamics modeling simulations (78,163,237). These techniques have allowed for the
study of a wide array of DNA conformations in their native state and under biologically-relevant
conditions (238). We used this powerful approach to examine the annealed and SEC-purified WT,
AH and truncated hTERT promoter sequences by hydrodynamic, X-ray scattering, molecular
dynamics and bead modeling methods.
To discern differences in the overall hydrodynamic shapes formed by the sequences listed
in Table 5 we employed analytical ultracentrifugation sedimentation velocity (AUC-SV)
experiments to determine sedimentation coefficients from which molecular weights and frictional
coefficients may be easily calculated. The results are tabulated in Table 7. Figure 34 shows the
significant difference in sedimentation coefficient distributions for the folded WT and AH sequences
by C(s) species analysis (170). There is very little overlap between the WT and AH c(s)
distributions, indicating different hydrodynamic shapes. The corrected S20,w values for WT and AH
sequences were 3.86 ± 0.01 and 3.25 ± 0.09, respectively (Table 7)—the former WT value being
consistent with our earlier report (145). (We note that the C(s) distribution of the WT shows a very
slight heterogeneity with a few percent of the sample sedimenting between 2-3 S.)
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Figure 34. Experimental and calculated sedimentation coefficient distributions. The red and black
curves are representative SEDFIT C(s) distributions of the WT (black) and AH (red) sequences
corrected to density and viscosity of water at 20.0°C (S20,w). The overlaid histograms are of
sedimentation coefficient values (S20,w) obtained from hydrodynamic calculations of PDB frames
extracted from 100 ns of explicit solvent MD trajectories for the stacked parallel model (black) or
the hairpin model (red).
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Table 7. Comparison of hydrodynamic properties measured by AUC-SV experiments with values
calculated from molecular dynamics trajectories of given models. The table is organized such that
the models with the best agreement from calculations are nearest their respective experimental
values.
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WT

WT PQS2-3

AH

AH PQS2-3

Property

Exp.

Parallel
Stacked
(calc.)

Exp.

Parallel
Stacked
(calc.)

Exp.

Hairpin
(calc.)

Exp.

Hairpin
(calc.)

Sedimentation
Coefficient,
S20,W (x10-13 S)

3.86
(±0.01)

3.89
(±0.03)

2.95
(±0.03)

2.96
(±0.05)

3.25
(±0.09)

3.30
(±0.05)

2.70
(±0.01)

2.64
(±0.03)

Molecular
Weight (kDa)

24.0
(±0.13)

22.0

16.5
(±0.15)

14.5

24.4
(±1.44)

21.5

16.8
(±0.68)

14.0

Stokes
Radius, Rs
(nm)

2.46
(±0.01)

2.22
(±0.02)

2.22
(±0.04)

1.96
(±0.03)

2.56
(±0.07)

2.58
(±0.03)

2.49
(±0.07)

2.14
(±0.02)

Frictional
Ratio, f/fo

1.42

1.26

1.45

1.26

1.7

1.54

1.6

1.45
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A similar trend was also observed for the truncated sequences WT PQS2-3 and AH PQS23 (S20,w values of 3.0 and 2.7, respectively) (Figure 35). Since the molecular weights of the pairs
of sequences in question are approximately the same (given the limit in experimental accuracy),
the measured sedimentation coefficients directly report the particle frictional coefficients that reflect
differences in shape. These data indicate that all WT sequences are much more compact than their
AH counterparts.
To rationalize these differences in size and shape, as well as the secondary structure
derived from CD and NMR studies, we used molecular dynamics simulations and hydrodynamic
calculations to refine the most plausible structural models (237). These models were constructed
based on the proposed secondary structures (Figure 27) in conjunction with coordinates from the
protein databank (PDB). The WT all-parallel stacked and hairpin models were used from previous
work (145), with the latter modified to reflect the AH sequence with optimized duplex base pairing
given in Table 5. Truncated models were created simply by removal of the PQS1 and 6 nt loop
region. Each model was subjected to 100 ns of unrestrained, fully solvated molecular dynamics
simulation. The resulting MD trajectories were then used to calculate the hydrodynamic properties
of each system (Table 7) using HYDROPRO10 (179), which calculated the sedimentation and
diffusion coefficients. These experimentally accessible measures were extracted from PDB
coordinates of structures in evenly spaced frames throughout the trajectories to obtain statistically
meaningful ensemble values (visualized as the histogram in Figure 34 and averages in Table 7).
We found that the sedimentation coefficient for the all-parallel stacked molecular dynamicsderived model agreed extremely well with the WT experimental value (calculated S20,w = 3.89 ±
0.01 vs. experimental S20,w = 3.86 ± 0.03). The AH hairpin model also agreed well with the AH
experimental sedimentation coefficient (calculated S20,w = 3.30 ± 0.05 vs. experimental S20,w = 3.25
± 0.09) (Figure 34, Table 7). The agreement between WT PQS23 with a two-parallel stacked model
was even closer (calculated: 2.96 ± 0.05 vs. experimental: 2.95 ± 0.03). The AH-PQS23 model was
also consistent with experimental data (calculated S20,w = 2.64 ± 0.03 vs. experimental S20,w = 2.70
± 0.01) (Table 7, Figure 35). The calculated and experimental S20,w values were effectively within
experimental error in all cases. These hydrodynamic studies show that the folded hTERT WT
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promoter is too compact to contain an extended 8 bp hairpin. In addition, it must contain fully
stacked G4 units, since the more extended models with a displaced terminal G4 unit predict a
sedimentation coefficient distinctly different from the observed experimental value.
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Figure 35. AUC-SV analysis and models of the WT and AH truncated oligonucleotides. (A) SEDFIT
C(s) distributions for the WT (black) and AH (red) PQS23 oligonucleotides in potassium buffer
showing a distinct difference in sedimentation coefficients. (B) Molecular dynamics-derived models
of the hairpin (left) and parallel stacked (right) PQS23 oligonucleotide with extraneous loop bases
removed for clarity. Yellow represents the sugar phosphate backbone, blue represents guanines
involved in G-tetrad formation, and orange indicates nucleotides involved in hairpin formation.
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Small-angle X-ray scattering (SAXS)
Figure 36 shows the results of SEC-SAXS experiments obtained with folded hTERT
constructs. Table 6 provides complete details of SAXS experiments, with all information suggested
by recent publication guidelines (174). Several general qualitative conclusions can be drawn by
inspection of these plots (192,195). Figure 36A-B show the primary SAXS data. The double
logarithmic plots of the scattering intensity for the WT, OP and AH structures (Figure 36B),
revealing distinct differences between the structures. It is clear that scattering of WT is different
from AH. The use of in-line size exclusion chromatography ensured the absence of contaminating
species and sample monodispersity, which was also demonstrated by the Guinier plots shown in
Figure 36C, which are linear for all samples (residuals plot for linear fits for all samples are shown
to the right of panel C). Parameter estimates for the radii of gyration (Rg) obtained by analysis of
Guinier plots are given in Table 6.
The differences between the WT, AH and OP are further illustrated by the pair-distance
distribution (Figure 36D). The hairpin structure is inconsistent with the observed scattering of the
folded wild-type hTERT sequence. For a homogeneous structure, the exact character of the P(r)
plot depends on particle shape (e.g. globular, prolate, oblate) and the domain structure of the
particle (239). The shape of the AH P(r) curve (Figure 36D, red), with a pronounced multimodal
character, suggests the presence of multiple domains within the structure, consistent with the
presence of an extend hairpin coupled to G4 units. In contrast, the WT P(r) curve (Figure 36D,
black) is more symmetrical, indicative of a more compact structure. OP was designed to optimize
the stacked G4 structure. Accordingly, the P(r) curve for OP (Figure 36D, green) is more symmetric
(but still with a trailing edge at larger distances), consistent with a compact three-stacked G4
structure with an elongated shape. All P(r) plots yielded radii of gyration which were within 0.1 of
those derived from Guinier approximation (Table 6).
Kratky plots (Figure 36E) for WT, AH and OP provide a qualitative appraisal of the degree
of unfolding and the flexibility of samples (240). Compact, fully folded particles are expected to
exhibit a Gaussian shaped curve, while unfolded or flexible particles would show nonzero plateau
regions at high q. The major observation from the data in Figure 36E is that WT and OP (Figure
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36E black and green, respectively) are clearly distinguishable from AH (Figure 36E, red line). A
hairpin structure is inconsistent with their scattering data. WT and OP curves reach zero at high q,
with nearly Gaussian shapes, indicating that they are fully folded and globular. In contrast, AH
shows a more complex curve. While it seems to be nearly fully folded as judged by its intercept on
the x-axis, the data for AH show a distinct plateau in the q range spanning 0.05-0.15 that indicates
particle flexibility. We attribute this flexibility to the region linking the hairpin to the G-quadruplex
domain, which was observed in our MD simulations (not shown). These data demonstrate that the
WT sequence folds into a distinctly different compact globular structure. Figure 37 shows the
scattering behavior of the partial hTERT constructs WT-PQS23 and AH-PQS23. The general
behavior and trends are similar to what was seen for the full-length constructs. Importantly, the
more asymmetric hairpin-G4 structures can be clearly distinguished from compact, globular G4
structures.
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Figure 36. SEC-SAXS results for the WT (black), AH (red), and OP (green) oligonucleotides. (A)
I(q) versus q as log-linear and (B) log-log plots. (C) Guinier plots (with fits shown in blue) for qRg <
1.3, along with corresponding residual plots (right). (D) P(r) versus r profiles from the data in (a and
b) normalized to equal areas. (E) Normalized Kratky plots for the data in (a and b). Collection
parameters, I(0), Rg, Dmax, and other values can be found in Table 6.
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Figure 37. SEC-SAXS results for the WT (black) and AH (red) PQS23 truncated oligonucleotides.
(A) I(q) versus q as log-linear and (B) log-log plots. (C) Guinier plots (with fits shown in blue) for
qRg < 1.3 along with corresponding residual plots (right). (D) P(r) versus r profiles from the data in
(a and b) normalized to equal areas. (E) Normalized Kratky plots for the data in A and B.
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Ab initio bead models for WT, OP and AH were obtained using the DAMMIF program (226),
with the results shown in Figure 38. The key point from inspection of these shapes is that both
hairpin structures, AH and AH PQS23 (Figures 38C & 38E), feature clear protuberances that are
absent from all other structures. These protuberances are most likely the hairpin duplex domain.
We are aware of the utility of SAXS data in more detailed atomistic structural modeling of
macromolecules with conformational heterogeneity (164,183,184). Efforts in that direction are
currently underway in our laboratory.
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Figure 38. Ab initio bead model results for the WT, OP, AH, and truncated oligonucleotides.
Averaged and filtered DAMMIF bead models for the OP (A), WT (B), AH (C), WT PQS23 (D), and
AH PQS23 (E) oligonucleotides. All models are displayed at the same scale.
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Thermal denaturation of hTERT structures
Figure 39 shows thermal denaturation studies, monitored by CD, for WT and AH
structures. There are clear differences between the two structures, with hairpin-containing AH
noticeably less stable. In 200 mM KCl (Figure 39A, right most panel), melting of WT is incomplete
even at 98°C, while AH is clearly less thermally stable with a T m near 79°C. By lowering the KCl
concentration to 10 mM, complete thermal denaturation curves for both structures were obtained
(Figure 39B). The right most panel shows that AH is thermodynamically less stable than WT. The
apparent Tm values for WT and AH are 82.5 and 65.2°C, respectively, in 10 mM KCl. The 17.3 °C
difference in Tm shows unambiguously that the hairpin-containing structure is thermodynamically
less stable. A more detailed thermodynamic analysis of the thermal stabilities of WT and AH using
CD and differential scanning calorimetry will be the subject of a manuscript that is in preparation.
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Figure 39. CD thermal denaturation profiles of the hTERT WT and antiparallel hairpin sequences.
(A) Strand-normalized CD spectra from 220 to 320 nm over 4 to 98 °C for the WT and AH
sequences annealed in potassium phosphate buffer with 200 mM KCl (left) with normalized melting
curves (right). (B) Strand-normalized CD spectra (left) and melting curves (right) for WT and AH
sequences annealed in phosphate buffer with 10 mM KCl.
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Discussion

The results of our integrated structural biology approach show conclusively that the 68-nt
wild-type hTERT promoter DNA sequence folds into a compact G-quadruplex structure that lacks
any hairpin duplex domain. A structure with three stacked G4 units in the parallel conformation is
both qualitatively and quantitatively consistent with our biophysical and biochemical data (circular
dichroism, thermal denaturation, analytical ultracentrifugation, SEC-small angle X-ray scattering,
nuclear magnetic resonance, DNase I cleavage assays, and molecular dynamics). An optimized
hairpin-containing structure based on the model proposed by Palumbo et al. (106) shows
unambiguously different biophysical and biochemical properties from the wild-type sequence.
Figure 40 shows a detailed model of the hTERT promoter structure obtained by our
molecular dynamics simulations. This model integrates the high-resolution structure of the PQS1
region that was obtained by NMR by Phan and coworkers (105). The model features nine stacked
G-quartets (arising from three stacked parallel G4 units), consistent with the large experimental CD
amplitude observed in Figure 28. This model accurately predicts the experimentally observed WT
hTERT sedimentation coefficient (Figure 34) and is qualitatively consistent with the SAXS data in
Figure 36. Several features of the structure are of interest. Apart from the G4 stacking interactions,
the structure shows several stabilizing loop-loop interactions, which are consistent with slight
contributions to the WT 1H-NMR of base-base interactions (small peak at ~12.9 ppm) and the lack
of these in the designed OP 1H-NMR (Figure 32). In addition to the K+ ion coordination sites within
G-quartets, the loop topology presents additional specific K+ binding sites. This structure presents
unique groove and interfacial geometries for small molecule binding interactions. Overall, the model
in Figure 40 represents an excellent target structure for rational drug discovery and development.
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Figure 40. MD-derived model of the three-stacked parallel hTERT G-quadruplex. All-atom model
of the stacked hTERT system (5’ top, 3’ bottom) showing phosphate backbone in tan, nucleotides
in blue and potassium atoms in purple. This structure was derived from clustering over 100 ns of
explicit solvent MD. The potassium ions observed in the central tetrad cavity, loops and grooves
were observed in 66% of all frames used in clustering.
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One of the major difficulties encountered in studying G-rich DNA sequences in their
biological context is in dealing with G-tracts with greater than three guanines or with numbers of Gtract greater than four. These sequences are known for forming multiple isoforms through Gregister exchange and changes in loop directionality, and often require base modifications such as
inosine or thymine substitutions to select for only one structure (42). This phenomenon was
observed in the hTERT PQS1 sequence (105,241). The physical consequence of G-register
exchange, as shown by the Mittermaier lab (227), is an entropic stabilization of the folded state
(albeit an ensemble of folded states). In addition to the five runs of three guanines, the full-length
hTERT core promoter sequence has six runs of four guanines (G 4) and one run of five guanines
(G5) (Figure 27). This equates to a theoretical 192 isomers ([6 x G4] x [1 x G5] which is 26 x 31)
when in the all-parallel stacked conformation, whereas this number decreases substantially to only
~48 if in the hairpin conformation proposed by Palumbo et al. (106,227). This implies that the allparallel stacked WT sequence would have an inherent entropic advantage over the hairpin
structure, as well as increased thermodynamic stability, which is reflected in Figure 39.
Such conformational heterogeneity is also evident in structural characterizations. While the
heterogeneity complicates interpretation of biophysical data, it in fact represents the reality of wildtype sequences whose complexities must be considered instead of being expeditiously simplified
by arbitrary sequence modifications. In Figures 32 and 33 we observed a clear broadening of all
peaks in 1H-NMR measurements of the WT sequence, suggesting the presence of parallel Gregister isomers. This broadening was not exhibited by OP, which is by design a single, all-parallel
stacked conformer. Moreover, we observed minor amounts of hTERT species with differing
sedimentation coefficients (Figure 34, shoulder at ~2.4 S). A possible explanation for this
discrepancy is that there is a dynamic equilibrium between parallel stacked and unstacked
structures. Alternatively, this could be attributed to a mixture of slow and fast rearrangements (such
as G-register sliding or folding), which depending on the timescales, could easily complicate
analyses (240,242). Overall, however, the major form appears consistent with the stacked
conformation as in Figure 40.
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G4 stacking and multimerization is now a well-known phenomenon (20). Various Gquadruplex stacking interfaces have been characterized (243-245), and the physical forces
involved investigated (54). All of these studies support a 5’-3’ (head to tail) stacking mode,
consistent with our model. However, our understanding of the biological relevance of G4 stacking
is lacking. In promoters, stacked G4 structures are now speculated to be involved in a variety of
roles, primarily as unique recognition sites for proteins, enhanced sensing of ligands through
cooperativity, or as concentration-dependent G4 biological switches (20). In line with this is the
unique opportunity of selective gene expression modulation via small molecules which stabilize or
disrupt these stacking interfaces.
We have shown that these higher-order structures can be successfully examined using an
integrated structural biology approach, coupled with judicious sequence design to create additional
test structures with contrasting or confirmatory features. There are thousands of sequences in
promoter regions in the human genome that have greater than four runs of multi-guanine tracks,
yet almost all remain uncharacterized. An in-depth examination and understanding of these
potential multimeric quadruplex structures will lead to the identification of unique binding sites and
a potentially more selective way to target these G4 regions in the genome for transcription
regulation.
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CHAPTER V

G-QUADRUPLEX VIRTUAL DRUG SCREENING: A REVIEW

Over the past two decades biologists and bioinformaticians have unearthed substantial
evidence supporting a role for G-quadruplexes as important mediators of biological processes. This
includes telomere damage signaling, transcriptional activity, and splicing. Both their structural
heterogeneity and their abundance in oncogene promoters makes them ideal targets for drug
discovery. Currently, there are hundreds of deposited DNA and RNA quadruplex atomic structures
which have allowed researchers to begin using in silico drug screening approaches to develop
novel stabilizing ligands. Here we provide a review of the past decade of G-quadruplex virtual drug
discovery approaches and campaigns. With this, we introduce relevant virtual screening platforms
followed by a discussion of best practices to assist future G4 VS campaigns.
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Introduction

G-quadruplexes (G4s) are secondary structures which occur in both DNA and RNA under
physiologically relevant conditions (25). G4s contain 2 or more stacks of 4 coplanar guanine
residues stabilized via Hoogsteen hydrogen bonding. The stacking interaction is also facilitated by
monovalent cations, such as sodium and potassium, as well as π-stacking of the purine bases
(Figure 41) (40). Although it is unclear what promotes G4 formation in vivo, they are increasingly
implicated in important biological events such as telomere maintenance, transcription regulation,
mRNA translation, and replication (25,116,246-250). More recently, chromatin immunoprecipitation
and high through-put sequencing analyses have provided in vivo evidence for the presence of
~9,000 non-telomeric G-quadruplexes that reside in nucleosome-depleted promoter regions,
confirming many of the previously proposed regulatory G4s (31,251). Thus, G-quadruplexes
appear to be excellent targets for anti-cancer therapeutics (248).
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Figure 41. G-quadruplex structure. (A) Orientation of guanines in a G-quadruplex quartet. (B)
Monovalent cations often occupy the middle of two quartets, helping to stabilize the partial negative
charge shared among the O6 oxygen of adjacent quartets. Phosphate backbone is shown as
vertical black lines.
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Currently there are greater than 1,000 characterized G-quadruplex stabilizing ligands that
have been discovered through virtual screening (VS), traditional high-throughput screening (HTS),
and plenty of serendipity (see: http://g4ldb.org/ for a listing of many verified G4 ligands). Although
many of these compounds (TMPyP4, pyridostatin, telomestatin, BRACO-19, etc.) bind with high
affinity to G4s, it is often by an end-pasting mechanism and, therefore, non-specific. Furthermore,
these compounds commonly do not possess drug-like properties, e.g. they do not pass Lipinski’s
rule of five (252), nor do they have documented ADMET (absorption, distribution, metabolism,
excretion, and toxicity) profiles (87). Extensive work has gone into modifying general end-pasting
drug scaffolds such as porphyrins (253-256), phenanthrolines (257-260), anthracenes (261,262),
naphthalenes (263), and quinolones (264,265) (Figure 42A-E). Only Quarfloxin (CX-3543) (Figure
43A), an end-paster, has progressed to clinical trials (15). Alternative G4 drug discovery strategies
have focused on developing ligands that target the loops and grooves. An example groove-binding
ligand is distamycin A (Figure 43B) which was shown by Randazzo et al. to interact with the
grooves of the parallel tetramolecular quadruplex [d(TGGGGT)]4 by 1H-NMR (proton nuclear
magnetic resonance spectroscopy) studies (266,267). Unfortunately, most G4 groove-binding
ligands have poor selectivity over double-stranded DNA (dsDNA), which was the case for
distamycin A and netropsin (268) (Figure 43C). To address this selectivity problem, many
researchers have turned to VS drug discovery methods.
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Figure 42. Common G-quadruplex “end-pasting” molecular scaffolds found in the literature. (A)
porphyrin, (B) phenanthroline, (C) anthracene, (D) naphthalene, (E) quinoline.
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Figure 43. Structures of (A) Quarfloxin, (B) Distamycin A, and (C) Netropsin.
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VS strategies have been building momentum in G4 drug discovery both as a low-cost
enrichment step and as a lead development step in the discovery pipeline, which our laboratory
has previously discussed (269). Whereas traditional HTS methods rely on obtaining and screening
hundreds or thousands of compounds from curated libraries, VS simply requires knowledge of
known ligand structures (for similarity and pharmacophore searches) or a receptor structure to
which a library of virtual compounds can be docked. These methods are known as ligand-based or
receptor-based drug discovery, respectively. Ligand-based methods use an identified set of known
active ligands to search a database for compounds that have similar properties. These techniques
operate under the assumption that ligands with a similar 2D or 3D structure will offer similar
interactions with their targets. Conversely, receptor-based methods screen virtual libraries against
a target structure, and so require an X-ray crystallographic, NMR, or homology-derived 3D atomistic
model of the target. These coordinate files can be downloaded from databases such as the Protein
Data Bank (PDB) (>133,000) or the Nucleic Acid Database (NAD) (>900), which are continuously
being updated with new structures.
VS platforms have been extensively used in ligand discovery (270,271), however, until
now, there has not been an assessment of strategies specifically targeting G4s. Here we briefly
discuss some of the common screening strategies, such as docking and pharmacophore screening,
as well as relevant aspects including: library preparation, scoring, and analysis. This is followed
with a commentary on suggested best practices for in silico G4 drug discovery based on the
authors’ own experience and knowledge gleaned from successful campaigns.

Pharmacophore & Similarity Based Screening
Ligand-based methods such as pharmacophore and similarity search platforms are widely
used and often integrated into a VS docking campaign pre- and/or post-docking (see section on
docking below). The term ‘pharmacophore’ as we use it refers to an abstract, 3D physio-chemical
representation of the chemical moieties necessary for ligand-receptor interaction. Pharmacophore
screens use multiple ligands of the same binding site to derive an ensemble of chemical features
necessary for an ideal interaction (i.e. hydrogen bond donor/acceptor, aromatic ring elements,
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cations, anions, etc.). The resulting model is known as a hypothesis. These hypotheses, which are
3D chemical descriptors, are then used to screen a virtual library to find “pharmacophore-similars”
that satisfy the hypothesis (272). The result is a list of compounds that are ranked for their
probability of favorable interactions based on their physical and chemical similarity to the initial
query structure. Various pharmacophore search platforms are available such as Pharmer (ZINC)
(273), Discovery Studio’s 3D-QSAR module (Accelrys: http://accelrys.com/products/discoverystudio), LigandScout (Inteligand) (274), MOE (Chemical Computing Group) (275), Phase
(Schrӧdinger) (276), SYBYL-X2.1.1 (Certera) (http://tripos.com), and Pharao (Silicos) (277).
An example of a successful G4 pharmacophore screening campaign comes from Chen et
al. (278) in which the authors used Discovery Studio’s 3D-QSAR pharmacophore generation
module to construct a model based on acridine derivatives. By weighting hydrophobic interactions
higher than aromatic interactions in the hypothesis the authors enriched for compounds with
scaffolds unlike the acridines. This was achieved by screening their own in-house library. The
resulting compound was a triaryl-substituted imidazole derivative (Figure 44A) that has a KD of 0.5
μM against a human telomere G4 and displayed selectivity over dsDNA based on circular dichroism
(CD) and fluorescence melting experiments. Interestingly, this compound is very similar to the
triaryl-pyridines discovered previously (279) (Figure 44B).

192

Figure 44. Structures of (A) a triaryl imidazole and (B) a triaryl pyridine.
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The second and most rapid ligand-based strategy is known as a structural similarity search.
These platforms require only knowledge of active ligand’s chemical composition (i.e. a chemical
structure). In the past, this method utilized a rigid-body alignment approach using 2D (2dimensional) and 3D chemical fingerprints to align and rank each molecule. This method was
enhanced with the advent of semi-flexible and flexible superposition algorithms that allow for a
more comprehensive search in 3D space by ranking each molecule based on the volume overlap
within the query structure. See (280) for a more in-depth discussion.
The structural similarity software vROCS (OpenEye) (https://docs.eyesopen.com/rocs/)
has been utilized by Musumeci et al. (281) to screen the Maybridge (http://www.maybrdige.com)
HitFinder database (~14,400 compounds) using Distamycin A (Figure 43B) as a query. Using the
Tanimoto coefficient (Section 6.4) and vROCS’s colour scoring (atom/feature similarity) criteria the
authors discovered a set of novel G-quadruplex groove-binding ligands (Figure 45A-C). These
ligands bound with higher affinity to the grooves of human telomeric quadruplexes over dsDNA
[detected by UV-Vis, fluorescence, and oligo affinity support analysis (281)] but had no observable
melting temperature (Tm) shift. It was also shown that 3 of the 7 compounds induced a DNA
damage response at the telomeres, further confirming their G4 binding activity. While this isn’t the
first reported campaign using vROCS in G4 drug discovery (282) it is a proof-of-concept that this
relatively straight forward lead-discovery approach can enrich for novel scaffolds which interact in
a favorable manner.
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Figure 45. Structures of the human telomere groove-binding ligands discovered by Musumeci et
al.
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Libraries
Arguably the most important consideration in virtual screening methodologies is the
selection of compound library. VS libraries contain hundreds to millions of virtual compounds that
will inevitably dictate the scaffold diversity of resultant hits. The benefit of using large, diverse
libraries is the expanded chemical search space. Fortunately, there are many large libraries
available:

MayBridge

(http://www.maybrdige.com),

discovery.com/screening-libraries/),

ZINC

AnalytiCon

(https://ac-

(http://zinc.docking.org/),

ChemDiv

(http://www.chemdiv.com/services-menu/screening-libraries/),
Mcule (https://mcule.com/database/), eMolecules

SPECS

(http://www.specs.net),

(https://www.emolecules.com), PubChem

(https://pubchem.ncbi.nlm.nih.gov/), Life Chemicals (http://www.lifechemicals.com), ChemBridge
(http://www.chembridge.com/screening_libraries/). Some databases, such as the ZINC database,
offer sub-libraries for a more tailored search (e.g. lead-like, fragment-like, drug-like, and natural
products), which often contain readily purchasable or synthesized compounds. Conversely, some
researchers choose to develop their own curated libraries (278,283) that can be beneficial when
the user has limited computing resources available.
The biggest challenge is finding the optimal balance among speed, accuracy, and library
composition. A library of ~1 million compounds docked to a single receptor will take as little as
weeks to as much as a year of computing time with a single workstation using a rigorous algorithm.
Many researchers have circumvented this by reducing libraries to smaller, more manageable
subsets that only contain, compounds that conform to a predefined criterion. Specifically, using a
shape-based or pharmacophore search on a library, one can significantly reduce the size and
enrich for chemical moieties that are well suited to the system of interest [see (278,281,282,284286)]. However, limiting searches to a pre-defined chemical search space introduces significant
bias and is bound to limit compound diversity.
Alternatively, increased computing power by use of a research cluster or computing grid
can greatly reduce the computational time required for a screening campaign of >1 million
compounds (287). The authors have had success using grid computing which can dock as many
as ~25 million compounds in just a few days to a single receptor site (269). While grid computing
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is becoming more commonplace in research institutes, not everyone has access to large-scale
grids. Therefore, care must be taken if curating a library to be docked at a smaller scale. Hand
picking small subsets of compounds can lead to significant bias (see discussion section below), or
worse, no enrichment of meaningful hits (288).

Docking
Docking has been in use since the early 80’s and has gained traction commensurate to the
number of published protein and nucleic acid structures since (289). In general, docking seeks to
use the physical and chemical information provided by an atomistic receptor to dock whole or
fragmented molecules from a library and rank them using a scoring function. Each docking platform
has its own algorithm as well as flavor of scoring function, which has made cross-platform
comparisons difficult (290-292). The lack of convergence onto any one platform is likely due to the
unique features inherent to each, such as: cost, speed, scoring terms, ease-of-use, scalability,
receptor flexibility, ligand flexibility, and the option of implementing molecular dynamics (MD) force
fields.
There are multiple docking platforms suitable for use with nucleic acid receptors. These
include: DOCK v4-6 (UCSF) (293), AutoDock (Scripps) (294), AutoDock Vina (Scripps) (295),
GOLD (Cambridge Crystallographic Data Centre) (296), Surflex-DOCK (BioPharmics) (297), Glide
(Schrӧdinger) (298), and ICM (Molsoft) (299). Many of these programs have been compared
elsewhere in the context of protein docking (300). The authors have also compared two of these
platforms, Surflex-DOCK and AutoDock, in the context of nucleic acids (301). Both platforms
performed equally well with Surflex being slightly faster and more easily scalable. DOCK,
AutoDock, AutoDock Vina, and GOLD are all freely available to academic institutions. Each docking
platform varies with respect to sampling algorithms and scoring functions.
A sampling algorithm is a systematic way to sample from a population of possible molecular
conformations and binding modes without exhausting all possibilities. The primary hurdle in docking
is the vast number of potential docked positions for a given set of molecules. Minimizing the
computational time necessary for each docking run is of prime importance for high-throughput

199

screening. Strategies to minimize computational time include: library optimization (reduced size,
generation of tautomers, protonation, filtering), robust computational infrastructure (computing
grids), and selection of the appropriate sampling algorithm(s). Such sampling algorithms include:
geometric matching algorithms (GM), incremental construction methods (IC), Monte Carlo (MC)
searches, genetic algorithms (GA), and molecular dynamics (MD) [see ref. (302) for an overview].
Table 8 lists the various algorithms employed by the docking platforms discussed here.
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Table 8. Docking platforms and algorithms presented and discussed in this review.
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Docking Platform

Algorithm

Glide
ICM

OPLS-AA force field optimization with Monte-Carlo refinement
(FFMC/MD)
Flexible Monte-Carlo (MC)

AutoDock Vina

Flexible Monte-Carlo (MC)

DOCK V4-V6

Geometric matching and Incremental (GM/IC/MD)

AutoDock

Flexible Genetic Algorithm (GA)

GOLD

Flexible Genetic Algorithm (GA)

Surflex-DOCK

Hammerhead fragment-based algorithm and Genetic algorithm
(IC/GA)
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Docking: Geometric Matching (GM)
The first sampling algorithm, which is used in versions 4-6 of DOCK (303), shares
characteristics with similarity or pharmacophore search algorithms. DOCK (v4-6) uses a geometric
matching (GM) algorithm to place fragments into the receptor. In this algorithm the receptor is
treated as a rigid object in which flexible ligands are docked. The receptor is defined by a set of
overlapping spheres, while each ligand is defined by rigid segments whose conformation can be
optimized within the user-defined binding site. The ligand ‘flexibility’ comes from an anchor-andgrow algorithm that uses the molecule’s rotatable bonds to partition it into rigid segments. Initial
docked segments are deemed ‘anchors’, and from these anchors the remainder of the molecule is
appended, followed by optimization and scoring (293). By mapping each molecule into the active
site of a receptor, GMs have the advantage of being very rapid techniques and well suited for large
database screening (293,300). The recent release of DOCK v6 has added features that allow much
more versatility to both the docking and scoring functions. Most importantly it has incorporated MD
simulation capabilities (304), validated using a set of RNA-ligand complexes.
Park and Kang used DOCK (v5.4) in conjunction with the UNITY-3D pharmacophore
platform to identify three compounds (Figure 46A-C) that stabilize the c-MYC G-quadruplex (284).
The authors filtered 560,000 compounds from publicly accessible databases, ChemDiv and
SPECS, based on a query generated in UNITY-3D. The resulting set of compounds were energy
minimized and then docked into an NMR-derived c-myc quadruplex (PDB ID: 2A5R). The authors
optimized this receptor by changing inosine bases back to their original wild type bases followed
by short energy minimization. After docking and scoring, each compound was re-scored using a
Generalized Born solvent accessible surface area (GBSA) scoring function to account for solvation.
Interestingly, the top three compounds showed little or no thermal stabilization based on Fӧrster
resonance energy transfer (FRET) screening, but were diverse in structure, and had polymerase
stalling ability as well as in vivo activity in Ramos, CA46, and HeLa cell lines.
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Figure 46. Structures of the reported c-myc quadruplex stabilizing compounds from Kang et al.
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Docking: Incremental Construction (IC)
The incremental construction (IC) docking approach fragments the ligand where it has
rotatable bonds and systematically docks each fragment. This allows for very rapid flexible ligand
docking and is employed by DOCK (v4+) and Surflex-Dock. The Surflex-Dock approach, which is
an adaptation of the Hammerhead docking procedure (305), places head fragments from each
ligand into the receptor site and aligns them to ‘probe’ atoms. These probes are predefined
idealized representations of favorable interactions. After placement, each head fragment is scored,
and the top scoring fragments are retained. The algorithm next aligns the tail fragments to the head
fragments and adjacent probes and scores them. In this way there is a drastic reduction in
computation time by only following up with a small portion of possible conformations (301).
As an example of successful IC docking, Hou et al. identified a novel c-myc stabilizing
ligand with the Surflex-Dock platform (306). Using the NMR derived quadruplex (PDB ID: 1XAV)
the authors docked 28,530 compounds from the ChemBridge database, which was filtered for
compounds containing ≥3 aromatic rings. These compounds were subsequently re-docked to a
duplex DNA structure (PDB ID: 1Z3F) and scored based on intercalation. A third round of docking
and scoring was performed on each compound, this time in the groove(s) of a duplex DNA (PDB
ID: 1K2Z). Compounds with a score ratio of >1.0 (G4 score/ dsDNA score) and >1.1 (G4 score/
Groove score) were chosen. Although the resultant top hit, a pyrollopyrazine derivative (Figure
47A) was less effective than the control compound SYUIQ-5 (Figure 47B) in luciferase assays, it
was much more selective for the G-quadruplex over dsDNA as determined by surface plasmon
resonance assays. Furthermore, there are no similar reported scaffolds in the G4 ligand database,
indicating that this is a novel quadruplex stabilizing ligand.
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Figure 47. Structures of (A) a pyrollopyrazine compound which stabilizes the c-myc quadruplex
discovered by Hou et al. and (B) SYUIQ-5.
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Docking: Stochastic Sampling
ICM, AutoDock Vina, AutoDock, Glide, Surflex-Dock, and GOLD are platforms that
incorporate the stochastic algorithms: Monte Carlo (MC) and genetic algorithms (GA). Stochastic
sampling algorithms iteratively generate new molecular conformations to be placed and scored
using random movements (MC) or ‘mutations’ and ‘selection’ (GA). Although stochastic algorithms
can be computationally more expensive than GM or IC methods alone (301), they have traditionally
out-performed in reproducing poses of ligands co-crystallized with their receptors (300).

Docking: Stochastic Sampling (MC)
In MC algorithms, each ligand’s initial conformation is altered through random steps of
bond rotation, rigid-body translation, or rotation, and subsequently scored until a pre-defined
number of steps have been reached. At each step, the score is assessed based on steric conflict
that is followed by an empirical potential calculation (see Scoring section below). If this new step
has improved the score sufficiently, then the molecule’s configuration will be saved and used in
another iteration of random conformational sampling (307). MC sampling is used in ICM, Glide,
AutoDock Vina, and earlier versions of AutoDock.
ICM has previously been shown to perform exceedingly well at reproducing the correctly
docked conformation of ligands to protein receptors over DOCK, AutoDock 3.0, and GOLD (308).
In 2010, Lee et al. (309) used ICM-Pro to screen a natural products database (AnalytiCon) of
20,000 compounds against the c-myc nuclear hypersensitivity element III1 (NHE III1) G4, which
was modified from a human telomeric quadruplex structure (PDB ID: 1KF1). Testing the top 5
scoring compounds in polymerase stop assays resulted in the discovery of fonsecin B (Figure
48A), a naphthopyrone pigment, which at the time of discovery was a novel scaffold. Later, Chan
et al. (310), using the same modified receptor (PDB ID: 1KF1) and docking platform (ICM-Pro),
screened 3,000 compounds from a library of FDA approved drugs. This screening campaign led to
the identification of methylene blue (Figure 48B), a phenothiazinium derivative. Methylene blue is
already known to be a dsDNA intercalator and is likely a G4 end-paster. Thus, the authors modified
this scaffold with side chains to improve selectivity. Interestingly, one derivative (Figure 48C) had
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higher affinity for the c-myc quadruplex both in vivo (luciferase assays, MTT proliferation assays),
as well as in vitro (fluorescent intercalator displacement assay, PCR stop assay, mass spec, UVvis). The Ma group later applied the same approach (ICM-Pro targeting c-myc PDB ID: 1KF1) (311)
to screen a natural product-like database of 20,000 compounds to identify potential groove-binding
scaffolds by limiting their search space to the grooves. This screen resulted in a compound
containing carbamide, diphenyl ether, and tetracyclic moieties (Figure 48D), which is a unique G4
scaffold. NMR titration and re-docking were then used to show that the ligand is a de facto groovebinder. Whether this ligand is specific for G-quadruplexes over dsDNA has yet to be determined.
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Figure 48. Structures of (A) fonsecin B, (B) methylene blue, and the c-myc quadruplex stabilizing
compounds (C) a methylene blue derivative discovered by Chan et al., and (D) a carbamide
containing compound discovered by Ma et al.
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Another MC software which offers speed, a user-friendly interface, and great reproducibility
of co-crystallized conformations (312) is AutoDock Vina. Vina was used by Alcaro et al. (285) in
2013 as a final step in their screening pipeline where they discovered a psoralen derivative (Figure
49). Psoralens have long been known as DNA intercalators; however, this is the first reported
instance of psoralens as G-quadruplex stabilizers. Their initial screening began with the ZINC
library of >2.7 million compounds, which were filtered down to ~4,000 compounds using 7 query
structures in shape-based ROCS [Rapid Overlay of Chemical Structures (313)] and 2D fingerprint
filter MACCS (Molecular ACCess System – MDL Information Systems inc.). This screen was
followed by the removal of inorganic components, adjusting pH to 7.4, energy minimizing the
structures, and finally, removing compounds that have a similarity of less than 0.7 Tanimoto
coefficient (see Screening Analysis section below). Altogether, ~7,000 compounds were docked in
AutoDock Vina using ensemble docking against the human telomere quadruplexes (PDB ID: 143D,
1KF1, 2HY9, and 2JPZ). This integrated VS approach resulted in 904 compounds that were
clustering to obtain 28 compounds for testing, resulting in the psoralen.
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Figure 49. The psoralen derivative discovered by Alcaro et al., which stabilized the human telomere
quadruplexes.
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Docking: Stochastic Sampling (GA)
GA sampling uses a molecule’s location, orientation, and conformation to specify the state
of a random population of individuals. These individuals have a genotype (the ligand’s states) and
a phenotype (atomic coordinates) and the ligand’s overall fitness is equivalent to its interaction
energy with the receptor. Individuals from the initial top scoring population are iteratively “mated”
and have offspring that gain random mutations (state changes) as well as inherit genes (states)
from both parents, known as “crossover”. Selection of each offspring for subsequent mating occurs
based on the individual’s fitness score (314). Algorithms such as these can be computationally
expensive, but have traditionally performed well at reproducing known ligand orientations in active
sites (300). GOLD and AutoDock (v3.0+) use this type of sampling method.
Kaserer and colleagues used GOLD (282) in parallel with the structural similarity search
ROCS(313) and the pharmacophore search LigandScout (274) to find consensus hits between the
three techniques. The pharmacophore models were generated based on the human telomere
quadruplexes in complex with naphthalene diimide derivative BMSG-SH-3 (PDB ID: 3SC8),
naphthalene diimide derivative MM41 (PDB ID: 3UYH), and berberine (PDB ID: 3R6R). Overall,
they found 252 unique hits from the Specs.net database. Next, using vROCS, they selected the 9
best-performing shape-based models, which were based on queries derived from co-crystallized
ligands (PDB IDs: 3UYH, 3SC8, 3R6R) or from the energy-minimized ligand. Using an Implicit MillsDean force field, with additional weighting for aromatic interactions, they found 2620 hits. Last, the
authors selected the human telomere quadruplex (PDB ID: 3CE5) to directly dock the Specs library.
From this screen, the top 10 ranked molecules were selected. In total from the three techniques, 5
consensus compounds and 30 other top scoring compounds were tested, plus some derivatives.
Overall, they found 14 ligands (Figure 50) that were active and had affinities that compared well
with other contemporary VS screening approaches (278,285,315,316). This tour de force campaign
demonstrated that a combined approach with cross validation can significantly enrich for real hits,
although it did not produce much scaffold diversity.
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Figure 50. Structures of the 14 compounds discovered by Kaserer et al. using a multi-platform
consensus approach to target the human telomere quadruplexes.
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Autodock (v4.2) remains a powerful tool in identifying G4 groove-binding ligands. In 2009,
Cosconati et al. (317) used Autodock to screen the Life Chemicals database of ~6,000 compounds
against the tetramolecular, parallel G4 sequence [d(TGGGGT)] 4 (PDB ID: 1S45) using a grid
enveloping just one of the identical grooves. The compounds were scored and selected based on
visual inspection. Specifically, compounds unable to form H-bonds with guanine bases or establish
electrostatic interactions with the backbone phosphates were removed. Thirty top-scoring
compounds were selected and used in NMR titrations, which resulted in an impressive 6 out of 30
interacting as groove-binders. This study was followed up with a more in-depth investigation by
Trotta et al. (318) showing that 3 of these compounds (Figure 51A-C) bind with higher affinity to
the grooves of [d(TGGGGT)]4 than distamycin A using isothermal titration calorimetry (ITC) and
NMR. Similarly, Di Leva (319) used Autodock to screen ~19,000 compounds from the ChemDiv
database against the 24 nt human telomere quadruplex (PDB ID: 2GKU). Out of the 18 compounds
tested, one (Figure 51D) showed significant thermal stabilization and appeared to interact as a
groove-binder based on NMR and re-docking experiments. The identified benzylpiperidinecontaining compound was also shown to cause telomere damage in three cancer lines (HeLa,
U2OS, HT29), but not a normal fibroblast line (BJ-hTERT). Subsequently, Amato et al. (320) used
Autodock to screen ~59,000 compounds from the Mcule database against a G-triplex structure
(PDB ID: 2MKM), an apparent intermediate state in the G-quadruplex folding pathway (321). 15
compounds were selected for purchase, but only one (Figure 51E) had significant stabilizing ability.
Although this compound did not distinguish G-quadruplex from G-triplex, it did have selectivity for
the higher order structures over dsDNA. Thus, these studies are undeniably a testament to
Autodock’s ability to successfully enrich for compounds which target the grooves of Gquadruplexes.
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Figure 51. Structures of (A-C) the parallel groove-binders discovered by Trotta et al. and (D) the
human telomere interacting groove-binder discovered by Di Leva. (E) The dual G-quadruplex/Gtriplex stabilizing compound discovered by Amato et al.
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Docking: Stochastic Sampling and MD
MD is primarily associated with simulations of molecular and macromolecular systems but
is also applied to other modeling techniques such as docking. MD has long been used as a method
to simulate structural changes and molecular interactions at the resolution of atoms using force
fields (322). Force fields are the equations that are solved to determine the potential of a given
system and are necessary to determine the force acting on each atom. Once a force is determined,
Newton’s laws of motion can dictate the new atomic position (323). The forces, therefore, must
consider each atom’s charge, bond length, and angle relative to all other atoms in each system.
Thus, docking that utilizes MD allows for the ultimate amount of flexibility of ligand and receptor,
resulting in efficient local optimization of docked ligands (300,302). Unfortunately, this level of
flexible sampling comes with a high computational cost (324), and so is typically only used as a
post-docking refinement step or in estimations of binding free energy (325).
Glide incorporates both MC and MD in its algorithm and performs well relative to other
flexible algorithms (GOLD, ICM) in protein docking (300). Glide (grid-based ligand docking with
energetics) docks in essentially two stages: (1) each ligand is passed through hierarchical filters
that evaluate spatial fit and complementarity of ligand-receptor interactions and, (2) poses that pass
the initial screen are subjected to MD minimization based on the OPLS-AA force field (optimized
potentials for liquid simulations – all atom force field) (324). Kar and colleagues (286) applied Glide
(v5.7) SP (standard precision) mode to dock 14,400 molecules from the Maybridge database,
followed by re-docking with the more extensive XP (extra precision) mode to the human telomere
quadruplex (PDB ID: 2ld8). A docking site was not selected, rather, the authors constructed a grid
encompassing the entire quadruplex. Two G4 ligands (Figure 52A, B) were selected from this
screen and were shown to have moderately low affinities (KD of 31 and 137 μM), as measured by
fluorescence titrations, but had selectivity over GC-rich dsDNA.
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Figure 52. Structures of the two telomere interacting compounds discovered by Kar et al. with
moderate selectivity for G4s over dsDNA.
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In a mixed pharmacophore/docking approach, Rocca et al. (326) used the pharmacophore
screen LigandScout (274) to generate hypotheses based on 9 ligands known to bind DNA and RNA
G4s. The ligand conformations for hypothesis derivation were extracted from top-ranked docked
positions in the human telomere or TERRA (TElomeric Repeat-containing RNA) quadruplexes
(PDB IDs: 3CE5, 2KBP). 257,000 natural product compounds from the ZINC database were
minimized and ionized to pH 7.4 in Maestro’s Ligprep module (Schrӧdinger) before being subjected
to pharmacophore screening. The compounds were subsequently filtered based on Lipinski’s rule
of five. The resulting compounds (~12,000) were clustered and then subjected to Glide’s ensemble
docking and scoring. Testing of the top 20 scored compounds resulted in one ligand (Figure 53)
that showed interaction in vitro as determined by CD, FRET melting, and mass spectrometry.
However, the compound reported is a naphthyridine derivative, a class which has previously been
reported to interact with telomeric G4s and inhibit telomerase (327).
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Figure 53. Structure of the naphthyridine compound discovered by Rocca et al. and shown to
stabilize both RNA and DNA G-quadruplexes.
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Bhat and colleagues (328) have put forward a robust VS workflow to derive novel ligands
targeting the c-myc NHEIII1 quadruplex (PDB ID: 2A5P). The steps are as follows: (1) the
Maybridge database (~55,000 compounds) was imported into Maestro’s Ligprep program, which
generates all protonation states, conformations, and tautomeric structures for a given pH (~1.5
million compounds); (2) multiple stages of refinement for conformational restraints, conformational
groups, and Lipinski’s rule of five (~88,000 compounds); (3) Glide docking and re-docking to the 5’
end of the quadruplex using all three modes: HTVS (high-throughput virtual screening), SP, and
XP. This campaign resulted in three compounds which were chosen for testing, and one, a
carbamoylpiperidinium-containing compound (Figure 54), stabilized the c-myc G4 by an endpasting mechanism. A biological response was also observed in cells by luciferase expression
assays as well as the induction of apoptosis selectively in T47D cancer cells, but not normal NKE
cells.
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Figure 54. Structure of the carbamoylpiperidinium containing compound discovered by Bhat et al.
and shown to stabilize the c-myc G4 by an end-pasting mechanism.
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Stand-alone MD simulations have also been used to study the interactions of known
ligands with their receptors. These simulations have inherent advantage over traditional docking in
that they can explicitly model solvent contributions. Not only does MD allow for calculation of
relative binding free energies, but it can also estimate the kon and koff rate constants. The latter has
been difficult to assess due to the long timescale simulations needed for the ligand to come back
‘on’ to the receptor. This has been addressed with biased force fields in what is known as funnelmetadynamics (329). This technique has been applied by Moraca et al. (325) to accurately
calculate the free energy of binding of the ligand berberine to the human telomere sequence (PDB
ID: 3R6R). Steady state fluorescence measurements were made to determine the actual free
energy of ΔG = -9.8 kcal/mol, which compares well with the calculated ΔG = -10.3 kcal/mol.
Techniques such as this will likely play a major role in virtual lead development in the future.

Scoring Functions
Docking algorithms attempt to find solutions to the orientation and ranking of ligandreceptor interactions. In doing so, the algorithms must have a way to order the thousands or millions
of complexes. Ranking is achieved by scoring, which approximates the binding affinity (ΔGbind).
Relative binding free energies can be approximated by free energy perturbation methods using
molecular dynamics simulations (324); however, these methods are far too computationally
expensive for routine docking, and so more approximate solutions have been devised.
The first type of free energy approximation is the “empirical” (330) scoring function, which
is an additive equation derived from each of the different modes of interaction of the system
(324,331). As implied by the name, empirical score values are derived from a set of known ligandreceptor complexes. As an example (as adapted from (324)):

ΔG𝑏𝑖𝑛𝑑 = ΔGℎ𝑏 + ΔG𝑖𝑜𝑛𝑖𝑐 + ΔG𝑟𝑜𝑡 + ΔG𝑣𝑑𝑤

(1)

where ΔGbind would be the total docking score based on the additive scores from H-bonds (hb),
ionic interactions (ionic), rotational constraints of constituent groups (rot), and Van der Waals (vdw)
interactions. These terms can also be modified by the user with weighting to favor or disfavor
interactions depending on the system in question. Similarly, there are modifier (or “penalty”) terms
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which can be applied to disfavor improper H-bond angles, distance restraints, hydrophobic
interactions, and torsions. Autodock 4, DOCK v4-6, GOLD, Surflex-Dock, and Autodock Vina use
empirical scoring terms.
Another scoring method relies on force-field (FF) based scoring functions. These functions
implement current molecular mechanics (MM) force fields (e.g. AMBER, CHARMM) to estimate
enthalpy of binding from VDW and electrostatic interactions, strain energies, and solvation effects.
The latter is typically estimated by calculating the desolvation energy using MM/PBSA (PoissonBoltzmann surface area) or MM/GBSA (generalized Born surface area) methods. However,
MM/PBSA and MM/GBSA are too computationally expensive to be used in high throughput
screening (332). FF scoring is achieved by pair-wise evaluation of each non-bonded interaction,
with the following general format (example taken from Autodock v4 manual(294)):
𝐿−𝐿
𝐿−𝐿
𝑃−𝑃
𝑃−𝑃
𝑃−𝐿
𝑃−𝐿
) + (𝑉𝑏𝑜𝑢𝑛𝑑
) + (𝑉𝑏𝑜𝑢𝑛𝑑
ΔG = (𝑉𝑏𝑜𝑢𝑛𝑑
− 𝑉𝑢𝑛𝑏𝑜𝑢𝑛𝑑
− 𝑉𝑢𝑛𝑏𝑜𝑢𝑛𝑑
− 𝑉𝑢𝑛𝑏𝑜𝑢𝑛𝑑
+ 𝛥𝑆𝑐𝑜𝑛𝑓 ) (2)

where L is the ligand, P is the receptor, and V is the calculated potential term from MD force fields.
Eq. (2) shows the 6 pair-wise evaluations and entropy term to account for any changes in
conformational entropy. The force field potentials used here are comparable to that used in the
Amber, CHARMM, or GROMACS force fields but can be modified by the user if desired. Glide,
ICM, and early versions of DOCK and Autodock use FF based scoring functions with empirical
weighting.

Discussion

Virtual screening approaches in the discovery of new G-quadruplex ligands have clearly
shown promise. Higher throughput computational screens are allowing for more comprehensive
searches of chemical space. As workstation computing power increases and more researchers
gain access to resources such as computing clusters, we expect to see the number of successful
VS screening campaigns increase. While some campaigns described here have proven the utility
of virtual drug discovery methods, the methodologies and pitfalls are worth discussing.
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Receptors
G-quadruplex receptors can be downloaded from one of the various databases (Protein
Data Bank, Nucleic Acid Data Bank, etc.) or modeled. NMR solution structures should be used if
available or the quadruplex modeled based on similar NMR coordinates. X-ray crystallography
derived structures are prone to conformational bias and may be artificial due to the packing
environment (78). Thus, X-ray structures require pre-treatment with modeling techniques, such as
short MD simulations with energy-minimizations (78). Often, modified bases such as inosine are
used to select for a single conformation in NMR or X-ray crystallographic techniques. These should
be modified, as described above (284), by swapping the inosine with their natural residue and
carefully energy-minimizing the structure prior to docking. A second major concern is loop flexibility.
Loops have inherently high mobility, and this is rarely accounted for in traditional rigid receptor
docking. This can be addressed with short MD simulations to allow the loops to search
conformational space. Multiple conformations from MD or NMR PDB files can then be used in
ensemble docking (285,326), which is an excellent tactic for highly flexible receptors. These
approaches are sufficient for most single G4 systems, such as the c-myc or 22-24 nucleotide long
telomere G-quadruplexes. However, targeting non-canonical G4s (245), or large, multi-G4
complexes (145,162) with unknown structure can be challenging.
Multi-G4 systems have the interesting characteristic of large loop domains that span G4G4 junctions. In theory, these loop-G4 pockets (Figure 55) can potentially serve as highly specific
binding sites, much like that of enzyme substrate pockets. Unfortunately, determination of large
nucleic acid secondary structures with traditional techniques is difficult. Nucleic acids rarely exist
as a homogenous population in solution, making them difficult to characterize. Base substitution of
non-tetrad guanine with inosine has often been used in NMR experiments to elucidate small G4
structures, but larger systems are not amenable due to spectral overlap and low proton density.
Large DNA and RNA complexes are also difficult to crystallize. Even when crystallization is
achieved, the packing environment can promote the formation of unrepresentative structures or
features that are absent or only present in a small minority of the molecules in solution (78). Thus,
low resolution techniques (small angle X-ray/neutron scattering, analytical ultracentrifugation,
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dynamic light scattering, and CD spectroscopy) paired with MD simulations are now commonly
used to develop structures currently unobtainable with traditional techniques (145,171,245,333).
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Figure 55. (Left) hTERT core promoter G-quadruplex model created by Chaires and Trent et
al.(145). Phosphate backbone is shown in tan, nucleotides in blue, and potassium in purple. (Right)
Surface representation showing a large binding pocket (dark area inside of yellow dashed oval) at
the junction between the first and second G4s of the hTERT G-quadruplex. Images were rendered
in Chimera v1.12 (176).
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Libraries
When docking any library, no matter the size, there will always be top scoring compounds.
Thus, many campaigns often use theoretical validation, such as re-docking, complementary
screening, or receiver operating characteristic (334) analyses for assessing the ability of their
screen to detect real hits (282,284,286,310,335). This is particularly important when working with
small databases and can help to minimize false positives. Conversely, docking known ligands as
positive controls or simply increasing the library size can help to identify real high scoring
compounds. Keep in mind that the use of in-house curated libraries, small drug libraries, or filtered
libraries can impose serious limitations on the potential for identifying unique scaffolds. In fact, this
appears to be the case for some of the campaigns mentioned here (278,285,306,310,317,326).
Three of these reports limited their chemical search space by filtering larger databases and one
searched a database with only 3,000 compounds. In every instance, the resulting hits were already
known to bind nucleic acids. Conversely, focused libraries can be useful when searching for lead
compounds based on validated hits, which was the case for Musumeci et al. (281) who used a
similarity search to enrich for groove-binders based on a well characterized groove-binding ligand.
Before using a library, the compounds typically require optimization. Fortunately, many of
the virtual screening databases have pre-optimized ligands for screening. Optimization ensures
that each ligand has been desalted, neutralized, energy-minimized, and correctly protonated before
docking (252,270,336). This can be achieved using programs such as Maestro’s Ligprep module
(177). Similarly, when ligands are optimized for a screen this should be reported, along with other
relevant information such as the version of the database, the type of database, total number of
compounds docked, purchased, tested, and validated as hits. Optimizations such as these will
allow for a more comprehensive comparison of G4 docking techniques.

Screening
The choice of screening approach(s) used is highly dependent on the user’s intentions.
Lead optimization strategies should include pharmacophore or similarity screens of large
databases (281,282), potentially followed with docking and/or MD minimizations and GBSA
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scoring. This approach will minimize time by selecting for ligands that closely resemble the
validated scaffolds while also allowing for solvated and flexible receptor-ligand interactions to
determine improvement of binding scores (325). However, this approach may not be so useful in
de novo drug discovery campaigns, where it is more advantageous to screen a large diverse library.
As mentioned above, filtering and reducing your library places an inherent bias on the size of the
chemical space that will be evaluated, leading to redundancy in scaffolds (see Figures 44 & 50).
Ideally one should select as large a database as possible and screen with a rapid, flexible ligand
screening platform, such as Surflex-dock or Autodock (which has now been surpassed in speed
and user friendliness with the release of Autodock Vina), followed with extensive re-docking,
consensus docking, or MD simulations with MM/PBSA or MM/GBSA calculations.
A second consideration is the definition of the site to be docked. Most docking platforms
have features to allow for ligand-based docking site generation. Conversely, in de novo discovery
(which is often the case of groove-binders), there is usually no defined site, and therefore a site
must be chosen by the user. This is done by defining a 3D grid about the putative ligand binding
site (Glide, Autodock, Autodock Vina, DOCK, and ICM), by generation of a space filling protomol
[which is a pre-computed representation of an ideal ligand (337)] (Surflex-Dock), or simply by
defining a bound ligand or set of residues (Surflex-dock, GOLD). Drawing on the authors’ own
experience, the docking site should be as small and focused as possible. Unfortunately, most
ligands bound to G4s in crystal structures are cationic, polycyclic, and highly conjugated endpasters bound to the 5’ or 3’ tetrad faces. Using complexes such as these as the basis for docking
will undoubtedly result in top ranked compounds with similar features (282,284,309,310) and, thus,
not useful in the discovery of groove-binders or loop-interacting ligands.

Screening Analysis
Regardless of screening strategy, the user will likely generate more compounds than can
feasibly be tested. If only the highest-ranking molecules are to be purchased, then visual inspection
is recommended. Although tedious, this process appears to increase enrichment in real groovebinders (317,320) by removing erroneous ‘false-positives’, high steric clashing compounds, and
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molecules with poor hydrogen bonding interactions. This can also help rule out compounds docked
into unintentional sites because of poorly defined docking sites or grids. Additionally, post-docking
clustering based on molecular similarity criterion can reduce the redundancy in large screens and
help inform purchasing decisions for diverse scaffolds (285,317,320,326). This is commonly done
using similarity coefficients. Tanimoto, Dice, and Cosine similarity coefficients are numerical values
computed from molecular attributes that are commonly used in clustering analyses (324).
Selectivity can also be enriched for by re-docking the top-ranking compounds to potential offtargets, such as dsDNA (306), and others have reported enrichment from cross-platform consensus
scoring (282).

Conclusion

We present here a comprehensive overview of G4 virtual screening methodologies, along
with suggestions to help guide future campaigns. These reports have shown that proper receptor
optimization, large screening libraries, and appropriate downstream analyses of hits can result in
great enrichment for novel G4 ligands. Conversely, we find that filtered libraries impose a major
limitation on ligand diversity. Furthermore, there is a fundamental deficiency in reporting relevant
information regarding VS campaigns, such as: library sizes, library preparation (optimizing, filtering,
tautomer generation), and contents (fragment-like, drug-like, natural products), total purchased vs.
tested compounds, receptor preparation (protonation, modified bases, energy minimizations, MD),
and downstream analysis (clustering, visual inspections, re-docking). This information is critical for
evaluating G4 virtual drug discovery strategies.
There are potentially hundreds or thousands of G-quadruplexes that form within promoters,
telomeres, RNA transcripts, and even LINEs and SINES (250,251,338,339). As articulated
previously (15), G-quadruplexes are easily targetable with heterocyclic aromatic compounds
because of the common tetrad face. Selectivity, then, must come from groove-interacting ligands
or by end-pasting molecules with “built-in” selectivity for loops around the 5’ or 3’ interface. This
selectivity is best achieved using massive, un-filtered libraries targeted at small pockets in and
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around the loops and grooves (Figure 55). The authors have recently used Surflex-Dock version
2.1 to screen the ZINC drug-like libraries (versions 2014 and 2016) for a total of ~45 million
compounds docked to multiple residue-defined loop/groove pockets of a modeled hTERT Gquadruplex (modeled using guanine stacks from the parallel c-myc G4, PDB ID: 1XAV) (145). The
quadruplex was subjected to MD simulations and stripped of waters and ions before docking.
Docking

was

carried

out

using

a

computing

grid

known

as

the

DataseamGrid

(www.kydataseam.com), which utilizes computers across schools in Kentucky. Ligands were used
as-is from the ZINC drug-like database. Purchased compounds were chosen by hierarchical
clustering of the top 6,000 molecules using Tanimoto similarity coefficients. From this analysis, 69
compounds were selected and screened using FRET, CD, ITC, fluorescent intercalator
displacement assays, and analytical ultracentrifugation. The initial FRET screen resulted in ~33/69
G4 interacting compounds. The top 3 were further characterized, resulting in 2 potent groove or
loop interacting ligands (unpublished, see Chapter VI), which are currently undergoing optimization
and lead development.
Virtual screening of G-quadruplexes and other higher order nucleic acid structures is still
in its infancy. As noted here, few VS platforms have been used in G4 drug discovery and even
fewer have been used extensively enough with nucleic acids as to permit cross-platform
comparisons. Furthermore, like protein systems, nucleic acids remain sensitive (if not more so) to
the limitations of VS technologies. As mentioned previously (271,340), receptor flexibility remains
difficult to address in a high-throughput manner, and so G4 loops remain a challenge to target.
Similarly, while docking algorithms can be very reproducible and rapid, there remains a dire need
for accurate, robust scoring approximations (340). Fortunately, the predictions (341) of hit
enrichment from high performance computing and big libraries were correct. So while the world
awaits breakthroughs in scoring, receptor flexibility, and machine learning (271,342), it might be
wise to seek out your nearest computing cluster to carry out your G4 screening.
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CHAPTER VI

TARGETING THE HIGHER-ORDER HTERT G-QUADRUPLEX:
VIRTUAL DRUG DISCOVERY OF SELECTIVE HTERT
REPRESSING SMALL MOLECULES

Non-canonical DNA structures known as G-quadruplexes are now widely accepted as
viable targets in the pursuit of anticancer therapeutics. Unfortunately, few virtual or actual drug
screening campaigns against monomolecular G-quadruplexes have resulted in selective and druglike small molecules. This dearth of selectivity is likely due to an inadequacy of chemical space
searched, as well as shortcomings in defining receptors. Herein, we show that by increasing the
chemical search space to tens of millions of virtual compounds that it is possible to discover novel,
small molecule scaffolds that are selective for G-quadruplexes over duplex DNA. Using in vitro
screening techniques (fluorescent thermal shift assays and competition dialysis) and fundamental
biophysical interaction techniques (isothermal titration calorimetry, analytical ultracentrifugation,
CD melting), we demonstrate that we can enrich for selective small molecules which are specific
for the loops and grooves of a multimer G-quadruplex formed in the core promoter of the human
telomerase reverse transcriptase (hTERT) gene. Further, using exhaustive virtual docking and
molecular dynamics simulations, we show that the lead molecule, a disubstituted 2-aminoethylquinazoline, binds in loop pockets and grooves, stabilizing G-quadruplex stacking junctions. Lastly,
we provide evidence that this molecule downregulates hTERT transcription in breast cancer cells,
making it a promising lead molecule for treatment of hTERT-reliant cancers.
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Introduction

Nucleic acids have the capacity to form multiple types of secondary structure, such as
duplex (B-, A-, and Z-DNA), triplex, and quadruplex. Genetic regions with high guanine content,
specifically with multiple runs of consecutive guanines, can form highly stable structures known as
G-quadruplexes (G4s) (40). G4s are composed of a stack of planar layers of guanine nucleotide
tetrads held together through Hoogsteen hydrogen bonding. Analyses of the human genome have
revealed between 376,000 and 716,310 potential G4 forming regions (11,31), and as much as 40%
of these PQSs reside in gene promoters (12). With the advent of fluorescent G4-specific small
molecules and antibodies there is now direct evidence of non-telomeric G4 formation in cells
(27,28,343). Importantly, these promoter G4s are abundant in oncogenes (31) and impose proximal
regulatory effects on transcription of adjacent genes (15,344). While this has energized research
targeting promoter G4s of proteins that have previously been thought of as “undruggable” (345), or
in general difficult to inhibit, there remains an outstanding issue of quadruplex drug specificity
(15,346,347).
To date, most of the drug discovery and biological investigations of G4s have been limited
to the small (<12 kDa) monomeric forms—likely owing to the ease at which they can be studied by
NMR or X-ray crystallography. A variety of monomeric promoter G4s have been reported: c-MYC
(16), KRAS (101), HRAS (102), HIF (103), and VEGF (104), which have been utilized in structurebased drug discovery (347). Numerous small molecules have now been unearthed that target
monomeric G4s over duplex and triplex DNA, but few have demonstrated selectivity for a single
G4 target (346). In some cases, small molecules can even convert certain monomeric Gquadruplex topologies to their “preferred” topology (348). A commonality shared among all Gquadruplexes are their planar 5’- and 3’- G-tetrad faces. These faces allow small molecules to endpaste, which is thought to maximize π-π stacking interactions between the ligand and the guanine
bases. It follows that this type of interaction results in mostly indiscriminate binding (346). This nonspecificity can be improved upon by adding or altering constitutive groups or sidechains of the core
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scaffold to increase favorable interactions with distinctive loop or groove regions (349-351);
although, this often comes at a price, as the molecules tend to deviate from “drug-likeness” the
more they are modified (137).
An emerging alternative method of selective G-quadruplex drug discovery is through
targeting higher-order G4 assemblies. G-quadruplexes can stack on top of one another through
sandwiching of flanking nucleotides or direct stacking of terminal G-tetrads (54,243). While this
phenomenon is well known and has important biological implications (20,352), few multimeric G4s
have been structurally characterized. The allure of targeting multimer G4s is that they offer larger,
potentially unique binding pockets for small molecules at G4 stacking junctions and loops, which
could allow for the circumvention of non-specificity due to end-pasting that is commonly observed
in monomeric G4 drug discovery (20,141,347).
One such G4 multimer has been identified in the core promoter region the human
telomerase reverse transcriptase (hTERT) gene (105,106,144). hTERT, and its cognate RNA
(human telomerase RNA component, hTR), form the ribonucleoprotein complex that is responsible
for maintenance of the telomeres. In normal somatic cells, hTERT activity is tightly regulated or
entirely absent (353). Under these “normal” circumstances, dividing hTERT-negative cells will
eventually experience telomere shortening, which elicits a DNA damage response that ultimately
results in senescence or cell death (354). Interestingly, the forced re-expression of hTERT in
hTERT-negative cell lines is all that’s necessary to extend cellular replication (355,356).
Knockdown of hTERT in a variety of cancer cell lines and tumor models results in reduced telomere
maintenance, sensitization of cancer cells to chemotherapeutics, and in some cases, the direct
induction of apoptosis or senescence (357-359). It follows that hTERT’s nearly exclusive
overexpression in malignant cell types has made it an ideal target for anti-cancer therapeutics. The
majority of contemporary techniques targeted at telomerase inhibition, such as small molecules
inhibitors, gene therapy, anti-sense oligonucleotides, and immunotherapies, have all shown that
hTERT inhibition is a viable mechanism to treat cancer (214). Clinically, however, none have been
successful (215). Of note, Imetelstat, a 13-nt antisense oligonucleotide, which appears to directly
inhibit telomerase through base-pairing with hTR, has shown preclinical promise in a variety of
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cancer models for its ability to block telomere extension (360,361). Unfortunately, like many other
telomerase inhibitors, clinical trials have halted due to hematopoietic toxicity, potentially because
of non-specific telomerase inhibition in stem cells (216,362). Currently, there are no FDA approved
small molecule telomerase inhibitors. Hence, alternative hTERT inhibition strategies are warranted.
Overexpression of hTERT largely occurs through alterations in transcription and/or through
increases in gene copy number (222,363-366). The hTERT core promoter region (-180 to +1 of
TSS) has a low nucleosome occupancy, sensitivity to bovine pancreatic deoxyribonuclease (DNase
I) treatment, and a high GC content (12,367,368). The open chromatin and multiple PQSs within
the 12 G-tracts support the formation of DNA G-quadruplexes in the context of the nucleus. Further,
functional genetic studies have found links between elevated hTERT promoter activity in cancers
which contain G>A point mutations within these G-tracts, supporting a G4 regulatory mechanism
(218,219). In fact, a recent investigation of urothelial carcinomas of the bladder found that 60-80%
contain the hTERT mutations “G124A” or “G146A” (located within the core promoter region -124
and -146 from the TSS, respectively), and these mutations confer a selective advantage over nonmutated cells (369). These mutations lead to allele specific deposition of H3K4me3 marks, which
promote transcriptional activity through a mechanism involving the swapping of specificity protein
1 (SP1) to E-twenty-six (ETS) transcription factors (222). However, this switch to transcription
activating transcription factor binding only partly explains the changes in hTERT expression (223).
The secondary structure of the G-rich region spanning -168 to -100 has been extensively
investigated by our lab and others (105,106,143-145,223,224,370). While all investigations are in
agreement that non-B DNA secondary structure is formed by this sequence, there was some
previous contention as to the exact nature of the major form (106,144,145). We have recently
established that the best model for this region of DNA is a stack of three parallel G-quadruplexes
(143,145), which is endowed with multiple unique loop and groove pockets that can be targeted in
a rational drug discovery approach (Figure 56).
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Figure 56. Overview of Surflex-dock virtual screening. (A) Structure of the all-parallel stacked
hTERT G-quadruplex used here for in silico screening. (B) Twelve Surflex-dock protomols (colored
space-filling blobs) superimposed on the hTERT G-quadruplex structure as in A. The hTERT
structure has been made slightly transparent to emphasize the protomols within loop pockets. (C)
Graphical representation of the overall docking procedure, where a pool of more than 40 million
virtual small molecules are docked into each of the twelve protomol sites indicated in B, and
subsequently scored based on interactions made, such as hydrogen bonding, physical clashes,
and van der Waals interactions.
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The initial investigations of the hTERT core promoter G4 have also involved efforts towards
the development of hTERT G4-targeting small molecules. In the first report, Palumbo and
colleagues demonstrated that both TMPyP4 and Telomestatin, two rather promiscuous G4 binding
small molecules, could stabilize the hTERT quadruplex (106). In a second report, Micheli et al.
used modified perylene diimide compounds to investigate Taq polymerase inhibition and
stabilization of both monomeric and multimeric forms. While perylene diimide based small
molecules are well known for their ability to bind G-quadruplexes of various topologies, this study
provides evidence that targeting the multimeric selectively over the monomeric units is viable.
Subsequently, Kang et al. identified an hTERT G4-stabilizing small molecule with an acridine
scaffold that significantly reduced hTERT mRNA and protein levels in breast cancer cells (223).
Although this study is rigorous in demonstrating the ability of this small molecule to reduce hTERT
levels in cells, the authors do not provide significant evidence of selectivity for the hTERT G4 over
other quadruplex topologies or duplex DNA. Moreover, this molecule [designated as GTC365 (223)]
is an acridine derivative, and as such would be expected to show moderate to high affinity for
duplex DNA via intercalation (371), and non-specific interactions with various G-quadruplex
topologies through end-pasting (138,139), making it unlikely to be a truly selective small molecule.
Altogether, the above investigations reveal a cancer specific epigenetic mechanism that exists for
repressing hTERT through targeting its G-quadruplex secondary structure.
There are a variety of obstacles when attempting structure-based drug discovery of novel
small molecules for a particular G-quadruplex target, which we have discussed previously (347).
The biggest shortcoming is the dearth of small molecules in libraries and limited search of chemical
space. Often for time’s sake, one of these two elements will be neglected, resulting in the
rediscovery of molecular scaffolds that are not unique or a general lack of “hits”. Further, the lack
of high-resolution information on G4 groove- and loop-interacting small molecules exacerbates this
problem. Herein, we show that with large enough chemical diversity, search space, and
rigorousness of sampling, we can successfully discover unique small molecules that selectively
target the loop and groove pockets of a higher order G-quadruplex. Using an unparalleled Gquadruplex virtual drug discovery approach, we present here the discovery of novel, drug-like, and
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selective small molecules targeting the hTERT core promoter G-quadruplex multimer. Further, we
demonstrate that modifications of our lead molecule, a disubstituted 2-aminoethyl-quinazoline,
result in differential stabilizing effects in vitro and in cells, demonstrating the potential for rational
improvements as a lead candidate molecule in human telomerase repression.

Materials and Methods

Oligonucleotides
Oligos were purchased from IDT (Integrated DNA Technologies, Coralville, IA) and SigmaAldrich (St. Louis, MO) with standard desalting. FRET-labeled oligos used in FTSA experiments
had

6-FAM

(6-carboxyfluorescein)

attached

to

their

3’

end

and

TAMRA

(5-

carboxytetramethylrhodamine) attached to their 5’ end. Upon receipt, stock oligos were dissolved
in MilliQ ultrapure water (18.2 MΩ x cm at 25°C) at concentrations between 0.1 and 1 mM and
stored at -20.0°C until use. Folding was achieved by diluting stock oligos into their respective buffer
and heating to 99.9°C in a water bath for 20 minutes, followed by slow cooling overnight and
subsequent storage at 4°C. Unlabeled oligonucleotide concentrations were determined from their
extinction coefficients (ε260) using the nearest-neighbor method. FRET-labeled oligo concentrations
were determined using the extinction coefficient of 6-FAM (ε495 = 75,000 cm-1 M-1).

Small Molecules
In the first round of screening, 69 small molecules were purchased as 1 or 5 mg quantities
from the distributer Molport.com, diluted to 10 mM in DMSO, and stored at -80°C until use. Three
of the compounds which were studied more extensively, 2R, 3B, 3B1, and 3B5 were either repurchased (3B from ChemBridge.com and 3B1 from Molport.com) or synthesized (2R, 3B5) inhouse. Compound concentrations were determined using molar extinction coefficients derived from
UV-Visible spectroscopy measurements of stock compounds diluted into potassium phosphate
buffer at pH 7.2.

248

Buffers
All buffer reagents, unless otherwise specified, were purchased from Sigma-Aldrich.
Phosphate buffer (8 mM phosphate, 1 mM sodium EDTA, pH 7.2) was used throughout with
supplementation of KCl as indicated. Buffers were filtering through 0.2 μm filter paper prior to use.

Preparative size-exclusion chromatography (SEC)
Oligonucleotide purification of the unlabeled TERT-FL, Tel48, and Tel72 sequences was
achieved using SEC as detailed previously (168). Briefly, oligonucleotides were annealed at
concentrations of 40-100 μM in their respective buffers, filtered through 0.2 μm filters, and injected
onto an equilibrated Superdex 75 16/600 SEC column (GE Healthcare 28-9893-33) using a Waters
600 HPLC system. The flow rate was maintained at 0.5 mL/min. and sample fractions were
collected every 2 minutes from 100 to 180 minutes run time. The molecular weights of fractionated
species were estimated based on a regression analysis of elution time vs. log(MW) of protein
standards (Sigma #69385), with elution profiles monitored at 260 nm and 280 nm. Purifications
were carried out at room temperature and fractionated samples were stored at 4°C prior to
concentration and downstream analysis.

In silico drug screening
Virtual screening was performed using Surflex-Dock 2.11 (372) on the KY Dataseam
computing grid (http://www.kydataseam.com/) using over 40 million virtual ligands from the ZINC
2014 and 2016 drug-like libraries (373). The all-parallel G-quadruplex hTERT model created
previously (143,145) was used as the receptor. Twelve docking sites were chosen by targeting the
G4-G4 junctions, loops, and grooves, but not the terminal G-tetrad faces (Figure 56). Docking in
Surflex-dock was carried out as previously described(301). Briefly, the command used in SurflexDock for each run was “surflexdock -pgeom +self_score +pflex dock_list <library> <protomol>
<receptor> <output>”. Protomols were generated using residue selection, which allows for the
manual selection of residues in or around putative binding pockets. The options “proto_thresh” and
“proto_bloat” were left at their default settings. Protomols were visualized in UCSF Chimera v1.11
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(176) to ensure adequate coverage of docking area (Figure 56). Scoring was based on the
empirical -Log(KD) term reported for each docked molecule (clash, polar, and strain values were
not considered in scoring). From each docking site (24 in total, 12 for 2014 library and repeated for
the 2016 library), the top scoring 500 poses were analyzed in Schrodinger’s Canvas (374)
application using a hierarchical clustering algorithm to cluster molecules based on binary
fingerprints and Tanimoto similarity criteria. The highest ranked 100 centroid molecules (most
representative scaffolds of the clade) were then chosen for purchasing. From this selection only 69
were available from Molport.com.

Fluorescence thermal shift assay (FTSA)
Small molecule screening by FTSA was performed on an Applied Biosystems
StepOnePlus Real-Time PCR instrument in 96-well plates, adapted from previous work (208).
Briefly, 10 mM compound stock solutions in DMSO were used to create 96-well stock solution
plates by diluting each compound to 2x final concentration in potassium phosphate buffer. The
same volume of DMSO was used as a control. FRET-labeled DNA, post-annealing, were quantified
by UV-Vis and diluted to 2x final concentration. FTSA reaction mixes were made up in 96-well
Applied Biosystems MicroAmp PCR plates by mixing 10 μL of 2x compound solution (or
buffer/DMSO control) with 2x FRET-labeled DNA to yield 20 μL of 1x reaction mix. Final
concentration of DNA was 0.25 μM in all experiments unless otherwise specified. Compound
concentrations are as specified in each figure legend. After mixing, plates were then spun down at
1250 rpm for 2-3 minutes in a benchtop centrifuge to remove bubbles. Samples were denatured by
ramping the temperature from 20.0°C to 99.8°C in 0.2°C increments at a rate of approximately
0.7°C/min. Fluorescence quenching of 6-FAM was monitored at each 0.2°C step using the
instrument’s onboard FAM filter over the entire reaction, providing a melting curve. Melting
temperatures (Tm) were determined from the 1st derivative of the normalized melting curves (209),
and differences in melting temperatures (ΔTm) were determined by taking the difference of control
and sample wells:
𝛥𝑇𝑚 = 𝑇𝑚,𝑠𝑎𝑚𝑝𝑙𝑒 − 𝑇𝑚,𝑐𝑜𝑛𝑡𝑟𝑜𝑙
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Where Tm,sample and Tm,control are the melting temperatures of the sample and control, respectively.
Measurements are averages of triplicate experiments repeated on 3 separate days unless
otherwise specified.

Competition Dialysis
Competition dialysis assays were conducted as described (375) in either 96-well plate
format or scaled up to beakers. Nucleic acids were annealed in a 185 mM K+ phosphate buffer,
SEC purified, and concentrated to create stock solutions of 20-100 μM (strand concentration). From
these stocks, nucleic acids were diluted to 75 μM working concentration based on monomeric unit,
where each nucleotide, base pair, triplex, or tetrad is considered a single monomeric unit (e.g. the
full-length hTERT is three G-quadruplexes and has 9 G-tetrads, whereas c-MYC only has 3 Gtetrads, so c-MYC is 3x the strand concentration as hTERT). Each dialysis membrane had 200 μL
(96 well) or 500 μL (scale up) of nucleic acid sample or buffer only (control). The dialysis
membranes were then submerged in at least 2 mL (96 well) or 200 mL (scale up) of a 4 or 5 μM
solution of compound and allowed to incubate on a rocker (96 well) or with stir bar (scale up)
overnight at room temperature. Approximately 24 hours later, the sample was removed and mixed
with Triton X-100 to a final concentration of 1% v/v to disrupt ligand interactions with receptors.
Ligand concentrations were determined from their extinction coefficients by measuring absorbance
using a Tecan Safire II plate reader (Tecan, Männedorf, Switzerland). Total concentration of bound
compound (Cb) was determined as follows:
𝐶𝑏 = 𝐶𝑡 − 𝐶𝑓
Where Ct is the total concentration of ligand in sample membrane and Cf is the concentration of
compound in the buffer membrane (which did not deviate from the 4 or 5 μM compound in dialysis
buffer). Calculation of apparent binding affinities (Kapp) was achieved using the following equation:
𝐾𝑎𝑝𝑝 = 𝐶𝑏 /{𝐶𝑓 × ([𝑁𝐴]𝑡𝑜𝑡𝑎𝑙 − 𝐶𝑏 )}
Where [NA]total is the total DNA concentration in the well (75 μM).

Thiazole orange (TO) displacement assay
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The TO displacement assay, which is functionally similar to standard fluorescence
intercalator displacement assays, was performed exactly as described previously (196). Briefly,
annealed nucleic acids, in their respective annealing buffers, were mixed with Thiazole Orange
(TO) and test compound at final concentrations of 2 μM DNA, 1 μM TO, and 5 μM compound in a
total volume of 150 μL in a 96 well black flat-bottom polystyrene plate. Control wells with DNA and
TO, and TO alone were also prepared in the respective buffers. After a brief incubation, TO
fluorescence emission was measured at 1 nm intervals from 510 to 750 nm with an excitation
wavelength of 500 nm. The percentage of TO displacement (%FID) was calculated from the
intensity at 527 nm using the following equations:
%FID = 100 − (100 ×

F
)
Fo

F = F(ligand+DNA+TO) − F(buffer+TO) − F(DNA+ligand)
Fo = F(DNA+TO) − F(buffer+TO)
where F is the fluorescence intensity reading from each well at 527 nm (λex = 500 nm).

Circular dichroism spectroscopy (CD)
CD melting studies and spectra were collected on a Jasco-710 spectropolarimeter (Jasco
Inc. Eason, MD) equipped with a Peltier thermostat regulated cell holder and magnetic stirrer. CD
and melting spectra were collected using the following instrument parameters: 0.5 or 1cm path
length quartz cuvette, 210 or 240 to 340 nm wavelength range, 1.0 nm step size, 200 nm/min scan
rate, 1.0 nm bandwidth, 2 s integration time, and 4 scan accumulation. Spectra were recorded at
20.0°C and melting spectra were collected over a range of 4°C to 98°C with 4°C steps, 4°C/min
ramp speed, and a 1-minute equilibration time at each temperature before acquisition. Spectra
were corrected by subtracting a buffer blank. Spectra were normalized to molar circular dichroism
(Δε) based on DNA strand concentration using the following equation:
∆𝜀 = 𝜃/(32982𝑐𝑙)
where θ is ellipticity in millidegrees, c is molar DNA concentration in mol/L, and l is the path length
of the cell in cm. In Tm shift experiments, the concentration of DNA was 1.1 μM, and compounds
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25 μM (except for the control, BRACO-19, which was 2.5 μM). The same v/v DMSO was used as
the control.

Analytical ultracentrifugation (AUC)
Sedimentation velocity (SV) experiments were performed in a Beckman Coulter
ProteomeLab XL-A analytical ultracentrifuge (Beckman Coulter Inc., Brea, CA) at 20.0°C and
40,000 rpm in standard 2-sector cells using An50Ti or An60Ti rotors. 100 to 150 scans over an 8hour period were collected and analyzed in Sedfit (170) using the continuous C(s) model with a
partial specific volume of 0.55 mL/g for DNA. AUC drug binding experiments were carried out as
detailed previously (210), with a final compound concentration of 100 μM and 10 μM DNA (10:1
[compound]:[DNA]). All compounds with reported stoichiometry from AUC experiments were
monitored at a wavelength of 318 nm.

Molecular dynamics simulations
Starting coordinates for small molecule-G4 complexes were based on the output of flexible
docking performed using Glide XP (376) with the Maestro (177) suite using the hTERT G4 model
created previously as the receptor (143,145). Briefly, Sitemap (377) was used to generate multiple
docking sites among the loops, grooves, and G-tetrad faces of the hTERT receptor (see Figure 56
Surflex-Dock protomols), followed by flexible docking and scoring at each site. Molecular dynamics
simulations were subsequently carried out on the highest scoring ligand-hTERT complexes for a
total of 5 ns. The PDB structures were imported into the xleap module of AMBER18 (178),
neutralized with K+ ions, and solvated in a rectangular box of TIP3P water molecules with a 12 Å
buffer distance. All simulations were equilibrated using sander at 300 K and 1 atm using the
following steps: (1) minimization of water and ions with weak restraints of 10.0 kcal/mol/Å on all
nucleic acid and ligand residues (2000 cycles of minimization, 500 steepest decent before switching
to conjugate gradient) and 10.0 Å cutoff, (2) heating from 0 K to 100 K over 20 ps with 50 kcal/mol/Å
restraints on all nucleic acid and ligand residues, (3) minimization of entire system without restraints
(2500 cycles, 1000 steepest decent before switching to conjugate gradient) with 10 Å cutoff, (4)
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heating from 100 K to 300 K over 20 ps with weak restraints of 10.0 kcal/mol/Å on all nucleic acid
and ligand residues, and (5) equilibration at 1 atm for 100 ps with weak restraints of 10.0 kcal/mol/Å
on nucleic acid and ligand residues. The output from equilibration was then used as the input (.rst)
file for 100 ns of unrestrained MD simulations using pmemd with GPU acceleration in the isothermal
isobaric ensemble (P = 1 atm, T = 300 K). Periodic boundary conditions and PME were used. 2.0
fs time steps were used with bonds involving hydrogen frozen using SHAKE (ntc = 2). Trajectories
were analyzed using the CPPTRAJ module in the AmberTools18 package. Small molecules were
parameterized using the Antechamber (378) package with general AMBER force field (GAFF) (379)
and AM1-BCC atomic charges (380). Calculations of theoretical relative Gibb’s free energy (ΔG) of
ligand-receptor complexes was achieved using the single-trajectory MMPBSA method (381).
Trajectory residue interaction network analysis was performed on each trajectory using the
structureViz (382) and RINalyzer (383) modules of the program Cytoscape (384) and UCSF
Chimera v1.11 (176).

Molecular visualizations
All molecular visualizations of MD trajectories and models were performed in UCSF
Chimera v1.11 (176).

Cell culturing
All cell lines were maintained in 5% CO2 at 37°C and 95% humidity in media supplemented
with 10% heat inactivated FBS, penicillin (100 U final concentration), and streptomycin (100 ug final
concentration). HEK293 (ATCC CRL-1573) cells were grown in DMEM media while MCF7 (ATCC
HTB-22) and MDA-MB-231 (ATCC HTB-26) cells were grown in EMEM supplemented with 0.01
mg/mL human recombinant insulin. AlamarBlue assays were conducted as outlined in the manual
(Thermofisher #DAL1100) in 96-well clear bottom plates. Cells were treated with compounds for
the indicated time and concentration and results are presented relative to the control (DMSO)
treated.
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Quantitative real-time polymerase chain reaction (qRT-PCR)
MCF7 cells were seeded at 2 x 105 cells/well in 6-well plates. After overnight attachment,
media was replaced and treated with compounds in DMSO (as indicated in text), or DMSO alone
(control), followed with 2 minutes of gentle mixing before placing back in the incubator. Media
replacement and compound treatment were repeated twice more in 24-hour intervals such that the
end time point was 72 hours of total treatment time. After 72 hours, cells were aspirated and washed
before harvesting of total RNA with PureLink RNA mini kit (Invitrogen, #12183018A), followed by
reverse transcription into cDNA using a high-capacity reverse transcription kit (Applied Biosystems
#4368813). Quantitative PCR was performed using a standard SYBR Green Master Mix (Applied
Biosystems #4309155) in 96-well plates on an Applied Biosystems StepOnePlus RT-PCR system
using

the

standard

ΔΔCt

method.

Primers

were

from

PrimerBank

(https://pga.mgh.harvard.edu/primerbank/) and verified as specific based on monophasic
transitions

during

thermal

denaturation.

TCCACTCCCCACATAGGAATAGTC,
CGTCTCCACACATCAGCACAA,

R-

Primers

(5’

to

3’):

TCCTTCTCAGGGTCTCCACCT,

R-CACTGTCCAACTTGACCCTCTTG,

hTERT

F-

c-MYC

F-

GAPDH

F-

TGCACCACCAACTGCTTAGC, R- GGCATGGACTGTGGTCATGAG.

Western blotting
Total protein extracts prepared from MDA-MB-231 cells treated with either DMSO or
compound treatment were subjected to SDS-PAGE followed by wet transfer to nitrocellulose
membranes. Blots were rinsed 3x with TBST supplemented with milk and subsequently incubated
with primary anti-telomerase reverse transcriptase antibody (Abcam, ab230527) or GAPDH
(Abcam, ab9485) at 4°C overnight. Visualization was achieved by incubation and visualization of
an anti-rabbit Alexa Fluor 488 conjugated secondary antibody using a PharosFX imaging system.

Data analysis
All data fitting, statistical analysis, and graphing were performed using Origin (version
2020) (OriginLab Corporation, Northampton, MA, USA).
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Results

Virtual screening of the ZINC 2014 and 2016 drug-like small molecule databases
To begin our drug discovery campaign, we docked over 40 million virtual small molecules
into sites located in the loops and grooves of the all-parallel stacked hTERT G-quadruplex model
(Figure 56) using Surflex-Dock 2.11. Due to the size of the Kentucky DataseamGrid
(http://www.kydataseam.com/), the entire docking and scoring procedure was accomplished in just
under a month. From this screen, the top 500 scoring small molecules from each protomol site and
library (2 libraries * 12 docking sites * 500 molecules = 12,000 top scoring molecules) were pooled
and clustered by a similarity criterion to group core scaffolds. The centroid molecules, which are
the most representative of each clade, were visually inspected within their docked sites to ensure
reasonable contacts were made. A final list of centroid molecules was then compiled and used as
input for a search at Molport.com. In total, 69 out of 100 searched compounds were available and
purchased for testing.

Experimental screening of first-generation compounds
Screening of the 69 first generation small molecules was achieved using a high-throughput
fluorescent thermal shift assay (FTSA) which was described previously (269). Unfortunately, due
to the thigh GC content of the full-length hTERT sequence (TERT-FL), we were not able to obtain
a FRET labeled full-length oligonucleotides for screening purposes. Instead, we used truncated
versions of the TERT-FL which have previously been characterized (143).
The first (and 5’ most) putative quadruplex sequence, PQS1, which was solved previously
(105), and two other sequences that lack either the 3’ PQS (PQS12) or the 5’ PQS (PQS23) G4
motif were used in place of the hTERT-FL for screening (Table 9). We also included an array of
promoter and telomere PQSs with the intention of quickly vetting for hTERT selective molecules
(Table 10). Initial screening of the first-generation compounds was carried out in a phosphate buffer
with physiological (185 mM) K+ concentration. Subtle shifts in melting temperature (ΔT m) were
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observed for the hTERT sequences with only 3/69 compounds, ranging from ~0.5-2.5 °C (Figure
57). The hTERT G-quadruplex is extremely stable in physiological K + concentrations [likely owing
to the added stability through stacking (54,143,144)] and so we decided to re-screen at slightly
lower (100 mM) K+ concentrations. Reducing the potassium confirmed that compounds 1-3 bound
to at least one of the larger hTERT constructs (PQS12 or PQS23), but not a control hairpin
sequence (HP) (Figure 57A, compounds 1, 2, and 3). This assay allowed for both high-throughput
assessment of binding as well as an indication of selectivity over an array of hairpin and G4
topologies.
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Table 9. hTERT oligonucleotides used throughout this study.
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NAME

OLIGONUCLEOTIDE SEQUENCE 5' TO 3'

LENGTH
(NT)

MW

Ε260 (M1CM-1)

TERT-FL

GGGGAGGGGCTGGGAGGGCCCGGAGGGGGCTGG
GCCGGGGACCCGGGAGGGGTCGGGACGGGGCGG
GG
AGGGGAGGGGCTGGGAGGGC

68

21633

672671

20

6369

202900

PQS12

AGGGGAGGGGCTGGGAGGGCCCGGAGGGGGCTG
GGCCGGGGACCCGGGA

49

15523

478700

PQS23

AGGGGGCTGGGCCGGGGACCCGGGAGGGGTCGG
GACGGGGCGGGG

45

14278

436500

PQS1

259

Table 10. Additional DNA oligonucleotides used in this study.
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Name
143D
2GKU
2HY9
2JSM
2JPZ
2JSL
2KF8
2KKA
Tel48
2O3M
Rb
Her2
Bcl-2
VEGF
KRAS
Zeb1
Hif1a
c-myc
1XAV
I-motif
telo
I-motif
c-myc
AT
Hairpin
GC
Hairpin

Sequence (5' to 3')
AGGGTTAGGGTTAGGGTTAGGG
TTGGGTTAGGGTTAGGGTTAGGGA
AAAGGGTTAGGGTTAGGGTTAGGGAA
TAGGGTTAGGGTTAGGGTTAGGG
TTAGGGTTAGGGTTAGGGTTAGGGTT
TAGGGTTAGGGTTAGGGTTAGGGTT
GGGTTAGGGTTAGGGTTAGGGT
AGGGTTAGGGTTAGGGTTAGGGT
TTAGGGTAAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTA
GGGTT
AGGGAGGGCGCTGGGAGGAGGG
CGGGGGGTTTTGGGCGGC
AGGAGAAGGAGGAGGTGGAGGAGGAGGGC
AGGGGCGGGCGCGGGAGGAAGGGGGCGGGAGCGGGGC
GGGCGGGCCGGGGGCGGGGTCCCGGCGGGGCGGGAG
GGGAAGAGGGAAGAGGGGGAGG
GGGGTGGGGGGGAAGGGGGAGGGAGGGGG
GCGCGGGGAGGGGAGAGGGGGCGGGAGCGCG
TGGGGAGGGTGGGGAGGGTGGGGAAGG
TGAGGGTGGGTAGGGTGGGTAA
CCCTAACCCTAACCCTAACCCT
TTCCCCACCCTCCCCACCCTCCCCTAA
ATATATATATCCCCATATATATAT
GCGCGCGCGCTTTTGCGCGCGCGC
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Length
(nt)
22
24
26
23
26
25
22
23

MW
(g/mol)
6967
7575
8219
7271
8183
7879
6958
7271

50
22
18
29
37
36
22
29
31
27
22

15829
7012
5644
9276
11799
11388
7069
9396
9879
8688
6992

22

6504

27

7917

24

7269

24

7339

Figure 57. Generation 1 FTSA screen. (A) Heatmap of Tm shifts for the first generation compounds
in 185 mM K+ potassium buffer vs. a DNA panel. HP is a FRET labeled hairpin control. (B)
Structures of compounds 1-3.
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Figure 58. First and second generation FTSA screening. (A) FTSA results for screening
compounds 1, 2, and 3, along with their derivatives (buffer consisted of 20 mM K +). HP is a FRET
labeled hairpin control. (B) Representative CD melting profiles and ΔT m measurements for each of
the indicated small molecules. (C) Results of FTSA DNA panel screening with indicated
compounds. A few small (~3°C or less) negative shifts in melting temperature was observed in
some cases but have been omitted here for the sake of clarity.
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We next sought to confirm the interaction of compounds 1-3 with both the truncated and
full-length hTERT constructs by orthogonal methods. As a “medium-throughput” method for
assessment of binding, as well as estimation of stoichiometry, we turned to analytical
ultracentrifugation (AUC) (210). This technique allowed us to confirm binding of both compounds 2
and 3 to the truncated and full-length hTERT G4s (Figure 59), but not compound 1 as it had an
inconvenient absorption spectrum. Instead, using isothermal titration calorimetry (ITC), compound
1 was confirmed as binding to PQS23, but not PQS12 (Figure 59C), consistent with FTSA results
(Figure 58), and showed comparable binding affinity to that of compounds 2 and 3 (dissociation
constants, KD, ranged from 10-80 μM).
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Figure 59. Isothermal titration calorimetry and AUC binding of compounds 1-3. (A) Representative
AUC C(s) curves showing enrichment of compounds 2 and 3 at ~3.8 S, approximately where TERTFL sediments (3.9-4.0 S dashed line). (B) Table of binding stoichiometries for various compounds
determined from area under the curve in A. (C) ITC binding energetics profiles of compounds 1-3
when titrated into PSQ12 or PQS23 sequences.
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Selectivity assessment of second-generation compounds
The initial hits, compounds 1-3, had only moderate affinity, and so we proceeded to a
structure activity relationship (SAR) type of approach. To this end we searched Molport.com for
readily purchasable molecules with similar core scaffolds. In total, 25 molecules (arbitrarily
designated with a letter, A-Y, preceded by the number of the compound they were derived from)
were selected for purchasing and testing. Figure 58A shows the results of FTSA screening of
compounds 1-3, along with their derivatives. Immediately it is evident that there is differential
binding due to R-group modifications (which are shown in Figure 60). Compound 1 resulted in a
single molecule with a comparable Tm shift (1N), whereas there were multiple derivatives of
compounds 2 and 3 that exhibited enhanced stabilizing ability (2G, 2R, 2S, 2T and 3A, 3B, 3Y).
These derivatives also exhibited differential binding to the hTERT truncated sequences PQS12 and
PQS23. Only one molecule, 3A, had noticeable binding to the control hairpin duplex in FTSA
screening experiments (Figure 58A). The compounds 2S, 3A, and 3B were subsequently
confirmed to bind the full-length hTERT G4 (TERT-FL) by AUC binding experiments (Figure 59B)
and compounds 1N, 2R, 2S, 3A, and 3B by CD melting studies (Figure 58B).
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Figure 60. Structural variations of first-generation compounds (1-3) with their “SAR by catalogue”
derivatives. Red is used to help visualize structural changes between parent molecules and
derivatives.
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As selectivity is of primary interest, we next wanted to investigate the DNA interaction
profiles of the most stabilizing derivatives (3A, 3B, 2R, 1N, 2S, and 2T) against as many types of
DNA topologies as possible (Figure 58C). Based on Tm shifts, we found that there was less
discrimination among various G-quadruplex topologies than expected [it should be emphasized
that Tm shifts are a function of affinity, stoichiometry, enthalpies of binding, and enthalpies of
denaturation so direct comparisons are not necessarily reflective of differences in affinity (385)].
We did, however, observe differential interactions among the molecules, suggestive of distinct
binding modes. For instance, although 2R, 2S, and 2T were all derived from compound 2, their
binding profiles vary markedly. 2R has a profound thermal stabilizing effect (ΔT m = +30 °C in some
cases) and is indiscriminate among G-quadruplex DNA, whereas 2S and 2T exhibit some
selectivity. Another differential interaction was observed with 3A and 3B. Although they have very
similar profiles, only 3B stabilizes both the c-MYC derived G-quadruplexes (c-MYC, 1XAV) as well
as the c-MYC I-motif. Further, 3A, 3B, 2R, and 1N all bind to the HER2 G-quadruplex, while 2S and
2T show no interaction. Last, we find that none of the derivatives tested bind the two duplexes (AT
and GC duplex), which indicates their selectivity over duplex DNA.
Many of the small molecules discovered through our FTSA screen had poor spectroscopic
properties, with absorption spectra overlapping with DNA’s intrinsic absorption. The poor
spectroscopic properties being a limitation, we proceeded to a fluorescent indicator displacement
assay (FID) (196,386), which can provide information on binding affinity as well as topological DNA
preferences without relying on intrinsic spectroscopic properties of the test molecules. The results
were somewhat ambiguous (Figure 61). First, compounds 2S and 2T appeared to be either too
low in affinity to out compete the fluorescent indicator (TO) or were not cognate ligands for the DNA
topologies tested. 3A, 3B, and 2R all showed only week preference for the parallel c-MYC Gquadruplex over other topologies, demonstrating that they have moderate affinities (KD in the range
of ~10-100 μM) for the parallel c-Myc structure. We also observed a large negative FIDs for all five
compounds with respect to the GC duplex, A/T duplex, and H-Tel duplex. This phenomenon has
been observed elsewhere (196) and is not readily explainable. Overall, this assay points to modest
selection for the parallel type G4 structure with 3A, 3B, and 2R.
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Figure 61. Results of FID and luciferase assays using second generation molecules. (A) FID assay
showing % TO displaced based on measured fluorescence relative to controls for each indicated
molecule against each given topology. (B) Relative reduction in luciferase expression based on a
dual-reporter assay. In each case, samples are displayed as relative to DMSO control. Two
different DMSO controls are used, as we found that DMSO had a small but significant dosedependent effect in the ranges used in these assays.
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Compounds 3A, 3B, and 2S have absorption spectra above 300 nm allowing for their use
in absorption-based selectivity assays. One of the most powerful selectivity assays is the
competition dialysis assay. In this assay, direct comparisons can be made between affinities of
small molecules for any DNA structure based on the local enrichment of molecules inside the
membrane due to strength of interaction (375). Figure 62 displays the results of a competition
dialysis experiment using 3A, 3B, and 2S. Compound 3A displays promiscuity with duplex, triplex,
and G-quadruplex DNA (Figure 58). Conversely, compounds 3B and 2S exhibited a high selectivity
for the larger, multimeric G-quadruplexes (TERT-FL, Tel48, and Tel72) over monomeric G4s,
duplex or triplex DNAs. It is important to point out that the concentration of DNA used in the
competition assays is the same in terms of monomeric unit (i.e. base pairs for duplex forms, triplets
for triplex, and tetrads for quadruplexes). This allows for the direct comparisons in affinity across
all receptor sizes and helps to account for multiple binding sites (375). Using the bound
concentrations (Cbound), we are also able to calculate apparent dissociation constants (387), which
are 24 μM for 3B and 22 μM for 2S with respect to TERT-FL, 45 μM or greater for Tel48 and Tel72,
and ≥140 μM for all others. These affinity values are consistent with the prediction from the FID
assay (Figure 61) and ITC data for their respective first-generation scaffolds (Figure 59). Overall,
these data show that 3B and 2S have a strong preference for G-quadruplex DNA over duplex and
triplex conformations and show preference for TERT-FL over the telomere G-quadruplex multimers
(Tel48 and Tel72).
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Figure 62. Results of competition dialysis. Cbound is the amount of compound in micromolar that
was locally increased inside the dialysis membrane after background subtractions, directly
reflecting the differential affinity of ligands with receptors. All DNA structures are at the same
monomeric concentration, and so the higher local concentration of compound is interpreted directly
as higher affinity.
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During the above in vitro discovery and screening processes we also worked toward
generating an in-cell reporter method for screening. Others have previously demonstrated that
luciferase-based G-quadruplex promoter assays allow for direct detection of transcriptional
changes based on G4 formation and stabilization (223,388,389). Here, we used a previously
validated (222) luciferase vector containing the full-length hTERT core promoter to screen for
transcriptional down-regulation (Figure 61B). To our surprise, all derivatives of compound 2 (2R,
2S, and 2T) that were tested exhibited dose-dependent increases in luciferase expression. No
changes were observed in cells treated with 3A. Only 3B and the positive control BRACO-19 (223)
exhibited the anticipated dose-dependent reduction in luciferase expression. Thus, only compound
3B, a di-substituted quinazoline (Figure 60), was further pursued. Importantly, as of the time of
writing, the core scaffold of 3B is unique and has not been reported as a DNA binding molecule.

SAR of compound 3B derivatives
One of the drawbacks of virtual drug discovery approaches is the potential for unavailability
of small molecules, whether that be by purchasing or synthesis. The most selective compound, 3B,
was not able to be synthesized. Therefore, we proceeded to another round of “SAR by catalogue”,
with the intention of discovering a more selective and readily synthesizable small molecule. We
purchased 5 derivatives of molecule 3B based on a structural similarity search (>80% similarity via
Molport.com) and designated them as 3B1 through 3B5 (Figure 63A). Figure 63B shows the
results of the FTSA thermal shift analysis, comparing compound 3B to each of its derivatives. We
find that modifications made to the 2-phenylethyl moiety (such as in 3B1 and 3B2) resulted in
minimal perturbations to Tm shifts with respect to PQS12, but large increases in Tm with respect to
PQS23. 3B3, with the addition of the N-(propan-2-yl)acetamide side chain to the tertiary amine and
removal of the terminal 2-aminoethyl group, had a major reduction in thermal stabilizing effect on
PQS12 compared to the former. 3B3 also exhibited destabilization of the control hairpin (HP), which
is undesirable as this indicates interaction with duplex DNA. The most substantial change in thermal
stabilizing effect was observed with the swapping of the 2-aminoethyl group for a fluorophenyl
moiety, which prevented binding entirely (3B4). The last compound, 3B5, showed a reduction in
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thermal stabilization of PQS12 with a concomitant increase in stabilization of PQS23, likely
indicating that the methyl group on the tertiary amine reduces interaction with PQS23.
Apparent binding affinities for 3B1, 3B2, and 3B5 were able to be estimated from FTSA
titration experiments (Figure 64) (assuming similar binding stoichiometries). Their apparent KD
values are given in Figure 63A (3B3 and 3B4 Tm could not be fit to any binding models). These
affinity estimations, while much higher than expected (which is reasonable when considering the
dependency of KD on temperature), indicate that compounds 3B1 and 3B5 bind most tightly to the
truncated hTERT G-quadruplex sequences. These analyses also highlight the fact that Tm shift
data from a single drug concentration may not necessarily approximate affinities (e.g. at saturation,
3B1 increases PQS23 melting temperature by 18.5 °C, with KD = 69.7 μM, while 3B5 only increases
the melting temperature by 6.8°C, yet yields a similar KD = 69.9 μM). Subsequent ITC titration
analysis of 3B1 to hTERT-FL showed a KD1 = ~3-4 uM, and that the binding is best fit by a threesite model (Figure 63C). Altogether, this data indicates that the 2-aminoethyl group plays a role in
the interaction with PQS12, and that by removing the methyl group from the tertiary amine the
affinity for PQS23 increases.
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Figure 63. “Catalogue SAR” analysis of compound 3B derivatives. (A) Structures of 3B and
derivatives 3B1-5. Red is intended to help visually emphasize the areas where molecular additions
were made. The inset descriptions are (in order): compound ID, ZINC ID, FTSA Tm shifts in degrees
Celsius, and dissociation constants, KD as measured in FTSA titration experiments. (B) Plot of
FTSA Tm shifts of 3B and its derivatives. (C) Representative ITC data of 3B1 titrated into hTERTFL fit to a three-site model with fit and KD values inset and residuals on bottom.
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Figure 64. FTSA dose-response curves for indicated compounds against both truncated TERT
constructs: PQS12 and PQS23. Data were fit to a standard, single-site binding model. All fits had
R2 ≥ 0.97.
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To gain some understanding of the differential binding of compound 3B and its derivatives,
we conducted extensive virtual docking with post-docking MD simulations (Figure 65). Docking
sites around loops, grooves, and terminal tetrad faces (3’ and 5’ ends) of the hTERT model from
Figure 56 were generated, followed by Glide XP (376) flexible docking of 3B and its derivatives,
3B1-5. Overall, seven sites had deep enough grooves identified for docking. Due to the high binding
stoichiometry observed for compound 3B via AUC measurements (Figure 58A-B) and the ITC
analysis indicating three sites bound by 3B1 (Figure 61C), multiple binding sites were investigated
for each derivative. Using the top scoring docked positions for each molecule (as well as
conformers and tautomers) we conducted 5 ns explicit solvent MD simulations (totaling 615
nanoseconds of simulation time). Figure 65A depicts the sites targeted in Glide docking. Figure
65B shows the post-MD theoretical Gibbs free energy values for the highest energy interaction
poses calculated from evenly spaced frames of the trajectory. Surprisingly, the free energy values
trend with the FTSA data in Figure 64 (i.e. 3B, 3B1, and 3B2 trend toward higher affinity than 3B3,
3B4, and 3B5). Further, neither 3B1 or 3B2 were able to dock at the 5’ end, and only 3B2 could
bind to the site “DG4”, indicating that the major stabilizing binding site for 3B1 and 3B2 resides in
the loop pocket designated as “DG22”. This pocket is formed by the connecting loop between the
5’-most and middle G4 units (Figure 65D), indicating that these molecules prefer loop/G4-junctions.
Similarly, 3B1 and 3B2 interact strongly at site “DG38” and stabilize the phosphate backbone
across the junction of the middle and 3’-most G4 units. 3B1 is predicted to have the highest affinity
in a groove nearest the 3’ tetrad face, with partial stacking on the terminal tetrad. Overall, this
suggests that 3B1 has only three preferred sites, all of which involve groove and loop interactions,
which is consistent with ITC results.
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Figure 65. Glide XP docking and MD trajectory analysis of compound 3B and derivatives. (A)
Schrodinger Sitemap docking sites (only the main 4 sites) shown as colored surfaces mapped onto
the hTERT G-quadruplex structure. (B) Calculated theoretical Gibb’s free energy of interaction for
each compound-receptor combination from 5 nanoseconds of fully solvated MD. Scores are
representative of only the largest free energy values for each ligand at each site. Missing values
indicate that no docking solution was found. (C-E) Representative interactions of 3B1 docked in
each of its three predicted binding sites (C – DG38, D – DG22, and E – 3’ end). Ligand colors
correspond to sites in A. Labeled residues in C-E indicate the residues essential to interaction.
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Biological assessment of compound 3B1
The above investigations demonstrate that a variety of these small molecules bind and
stabilize the hTERT core promoter G-quadruplex multimer in vitro and have plausible binding
modes in loop regions. We next wanted to see if a biological response would occur in cells known
to have elevated hTERT expression with a wild-type core promoter (366). We began with
quantitative PCR studies in MCF7 breast cancer cells (Figure 66). At 10 μM and 72 hours of
treatment with compounds 3B1 and 3B5, we observed a statistically significant reduction in hTERT
mRNA. Since c-MYC is the most thoroughly studied of all oncogene promoter G4s and its protein
product can act directly on the hTERT promoter to modulate expression, we included it as a test
for selectivity. We find that compound 3B5, but not 3B1 or GTC365, increases c-MYC levels
significantly, indicating that 3B5 is not selective. The ability of 3B1 to reduce hTERT protein was
subsequently confirmed by western blotting using the triple negative breast cancer cell line MDAMB-231, which has a naturally higher level of hTERT protein expression (Figure 66B). Note, this
seemingly subtle reduction in hTERT protein by western blotting is consistent with GTC365 (223),
and studies using siRNA to directly knockdown hTERT (390,391).
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Figure 66. Biological assessment of compounds 3B1 and 3B5. (A) Changes in hTERT and c-MYC
mRNA levels as determined by RT-qPCR analysis with 10 μM treatment of compounds 3B1 and
3B5 for 72 hr. in MCF7 breast cancer cells. Measurements are normalized to GAPDH and displayed
as relative to DMSO control. Statistical analysis was by two-way ANOVA and Tukey post-hoc test
(alpha level of 0.05, n=4, each data point is from an independent experiment conducted on different
days). (B) Immunoblot analysis and densitometry for hTERT protein after 10 and 30 μM treatment
with compound 3B1 of MDA-MB-231 breast cancer cells for 72 hours. (C) IC50 measurements
verses time for compounds 3B, 3B1, and GTC365 in MCF7 cells.
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We next investigated cell proliferation in the presence of 3B and 3B1 compared to GTC365
in breast cancer cells. Overall, IC50 values were approximately the same in both MCF7 and MDAMB-231 cells (Figure 67). The values of IC50 measured between the two cells lines are consistent
with an earlier report for GTC365, but differ slightly in magnitude (223). Because telomerase
reduction can lead cells to a state of metabolically active senescence, rather than apoptosis (392),
the IC50 values measured might not necessarily correlate with the effects of hTERT repression.
Interestingly, by plotting the measured IC50 values in MCF7 cells versus time, we find that
compound 3B1’s IC50 has a much stronger dependency on time than GTC365. The dependency of
IC50 on time is expected for agents that selectively repress hTERT expression (390,391).
Altogether, these biological data support that 3B1 can repress human telomerase in breast cancer
cells.
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Figure 67. IC50 curves for compounds 3B, 3B1, and GTC365 in MCF7 and MDA-MB-231 breast
cancer cells. Cells were treated for 72 hr. with compounds as indicated and analyzed by
AlamarBlue assay. Data are reported relative to DMSO treated control cells. Data were fit to a
standard dose-response model in Origin, from which IC20, IC50, and IC80 were obtained.
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Discussion

G-quadruplexes are now widely accepted as important drug targets for anticancer
therapeutics. To date, most attempts at targeting promoter G4s with small molecules have been
limited to their monomeric forms, and in some cases this has proven successful (16,103). However,
this approach is limited in the following ways: (1) monomeric G-quadruplex units are small and
often have shared characteristics, such as open G-tetrad faces, which encourage promiscuity of
small molecules(18); (2) adding to, or expanding upon, core scaffolds to increase selection for
monomeric G4s, leading to a decrease in drug-likeness (18) and potential bioavailability problems;
(3) targeting a monomeric G4 fails to take into consideration its physiological context, as it may
function in a larger, multimeric structure (20,144,352). Therefore, efforts towards revealing binding
pockets among larger G4 multimers, by use of integrative structural biology approaches (143,165),
are now needed to address this issue. Here, we have provided substantial evidence that this
approach works by successfully discovering novel small molecules targeting the hTERT core
promoter G-quadruplex multimer.
Discovery of novel small molecules for an intended target requires an adequate search of
chemical space (271,347), which is achieved only through use of cheminformatics approaches [the
only method that can approach the ~1033 possible drug-like small molecules (393)]. Here, we have
utilized a G4 virtual screening approach of unprecedented in size (347) to targeting the loops and
grooves of the all-parallel stacked model of the hTERT core promoter. From this, we have
unearthed multiple new molecular scaffolds that show specificity towards G-quadruplex structures
over duplex and other forms (Figures 58, 62, and 63). Although the focus of this work is selective
targeting of the hTERT G4, we note that one such molecule, 2R (and to a lesser extent 2S and 2T),
exhibited a substantial thermal stabilizing effect across nearly all G-quadruplexes tested in our
FTSA panel, and no indications of interactions with other DNA topologies (Figure 61). 2R appeared
to interact most favorably with the c-MYC G4s based on FTSA and FID (Figures 58C and 61A).
Surprisingly, 2R caused a significant increase in c-MYC mRNA in MCF7 cells (10 μM treatment for
72 hr.) (Figure 68A). Molecular docking studies using the modified c-MYC NHEIII G-quadruplex
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(PDB ID: 1XAV) reveal that 2R has a preferred interaction across the phosphate backbone of the
first propeller loop (Figure 68B). This interaction seems to be facilitated by an ideal geometry of
hydrogen bonding that spans three consecutive backbone residues. Thus, 2R’s apparent exclusive
interaction with G4s can be rationalized by its preference for the bent phosphate network found in
parallel, single-nucleotide G4 loops. To the best of our knowledge, 2R has never been reported in
any type of biological or biochemical investigation. The same holds true for compounds 2, 2S, and
2T. Thus, this somewhat serendipitous discovery is a testament to using massive virtual drug
screening for enriching for new G4-interacting molecular scaffolds.
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Figure 68. RT-qPCR and docking results of compound 2R. (A) RT-qPCR results of 2R 10 μM
treatment of MCF7 breast cancer cells after 72 hours showing a significant increase in c-MYC
mRNA relative to DMSO control. (B) Glide XP docking results of 2R with the modified all-parallel cMYC G-quadruplex (PDB ID: 1XAV) showing an ideal hydrogen bonding network between H-bond
donating amine groups of 2R with the first propeller loop’s phosphate backbone. All four images
are of the same docked position from different orientations.
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As for the primary goal of this work, we have discovered a unique disubstituted quinazolinebased small molecule, 3B1, that selectively targets the hTERT core promoter G-quadruplex. This
discovery was accomplished using a SAR-by-catalogue approach combined with our G-quadruplex
drug discovery funnel approach (269). In this process, we have taken top hits from over 40 million
virtual docked small molecules and refined them using a robust high-throughput FTSA assay
(Figures 58, 59, 64). At each generation, orthogonal assays have been employed that allowed us
to define the regions of the scaffolds that contribute to potential selectivity (Figures 58-60, 62, 63).
Scaffold 3B shows selectivity for the hTERT G4 over both duplex DNA and monomeric G4s, with
a moderate selectivity over the higher-order telomere G4s. Further, we provide biological evidence
that the modified scaffold 3B1 is able to reduce hTERT levels in breast cancer cells, similar to
GTC365 (Figures 65 and 67) (223). However, in contrast to GTC365, 3B1 is a more drug-like small
molecule [based on Lipinski’s Rule of Five: MW = 336.4 g/mol, LogP = 3.184, < 5 H-bond donors,
< 10 H-bond acceptors(137)]. Most importantly, 3B1 is more selective for G-quadruplex DNA over
duplex DNA, whereas GTC365 shows a high degree of non-specificity based on competition
dialysis (Figure 69). 3B1 is also unique, with no previous reports of disubstituted quinazolines with
an aminoethyl group at the 2 position of the quinazoline ring system.

297

Figure 69. Competition dialysis results of 3B1 and GTC365 showing high selectivity of 3B1 for G4s
over duplex DNA and the low selectivity of GTC365 for G4s over AT rich duplex DNA.
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Based on extensive molecular docking and modeling studies, we find that 3B1 has three
putative primary binding sites, the first of which is a pocket within an inter-G4 loop between PQS1
and PQS2, whereas the second is a shallow loop pocket spanning the PQS2 and PQS3 junction.
A third site is found inside of a strand reversal loop pocket of the third (PQS3) G4 with partial
stacking on the 3’ tetrad face. Because there are 3 identified binding sites for 3B and 3B1, we can
attempt to rationalize the unexpectedly large stoichiometry of ~8:1 observed for 3B (Figure 59). In
each MD simulation of the molecules 3B, 3B1, and 3B2, there is a preferential stabilization of the
phosphate backbone groups via the aminoethyl group. This interaction is slightly more favorable
for 3B1, since there is also the secondary amine group at position 4 of the quinazoline ring. Since
the AUC experiments are done in conditions of saturation (10:1 [Drug]:[DNA]), we reason that there
are additional sites in which 3B is weakly associated through ionic interactions, leading to
overestimations in stoichiometry from transport during sedimentation. However, we do not expect
that this would impact competition dialysis experiments, as the ratio in these experiments is inverted
(1:15 [Drug]:[DNA]). Consistently, three sites appear preferential based on ITC, MD, and AUC
studies. This information will be beneficial moving forward as 3B1 is used in lead development, as
we have shown that modifications to either the aminoethyl group or the 2-phenylethyl moiety reduce
or improve its interactions with various hTERT sequence fragments (Figure 63).
Collectively, this study demonstrates that the discovery of novel, selective drug-like small
molecules targeting multimeric G-quadruplexes can be achieved with an adequate search of
chemical space. We show that a SAR approach, coupled with a robust, rapid FTSA assay, can
yield novel small molecule scaffolds with moderate to high affinity. Further, we provide detailed
insight into the binding mode of 3B1 in the binding pockets of the hTERT core promoter Gquadruplex that will benefit future campaigns and lead development strategies aimed at inhibiting
the expression of human telomerase.
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CHAPTER VII

CONCLUSION

In this dissertation, I provide an overview of an integrative structural biology approach for
the medium- to high-resolution characterization of multimeric DNA G-quadruplexes. Importantly,
this approach circumvents the need for perturbing the native sequences and allows for their study
under biologically relevant conditions. Current approaches used to investigate the higher-order
structure of DNA G-quadruplex multimers are limited. NMR techniques are hampered by the fact
that proton resonances overlap significantly, making interpretation of higher-order G-quadruplexes
difficult, if not impossible. X-ray crystallography, AFM, and EM-based methods require unnatural
environments that can select out irrelevant structures or deform native structures through
interactions with grids. Thus, my approach using a combination of robust solution-based
biophysical techniques provides an excellent solution to this problem, as I have demonstrated with
the higher-order telomere G4s and hTERT core promoter G-quadruplex. Further, this dissertation
provides evidence that G-quadruplex multimers offer unique binding sites, allowing for
development of selective ligands using in silico approaches.
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The structure formed in the higher-order human telomere sequence has been debated for
almost a decade. Both in vitro and in-cell experimentation have shown that the two major
topological forms of the monomeric telomere sequences are hybrid-1 and hybrid-2. However, in
the context of longer sequences, information about the structure and assembly has yet to be firmly
established. Low-resolution structural studies of long telomere repeats ([TTAGGG]n, where n >>
16) by EM, AFM, and molecular tweezer studies conducted under harsh, non-physiological
conditions have suggested that gaps exist between G-quadruplex monomers (i.e. that Gquadruplex formation is not maximized) (159,160). Studying the smaller sequences ([TTAGGG]n,
where n is ≤ 16) others have proposed that the maximum number of G-quadruplexes form, and
that the most likely configuration is a compact, stacked combination of hybrid-1 and hybrid-2
topologies (141,162,394). Consistent with the latter, I’ve shown by SEC-SAXS and circular
dichroism studies that the annealed telomere sequence, in a physiologically relevant buffer,
maximizes its formation of G-quadruplex units, yet remains semi-flexible. The hybrid-1 and hybrid2 topologies are most consistent with my analyses and prior intra-cellular studies (79). Further, MD
simulations, SAXS modeling, and hydrodynamic studies suggest that the flexibility of the telomeres
is due to stacking and unstacking transitions, with a significant proportion existing in the stacked
state. G4 maximization and inter-G4 stacking offers an explanation to biological function, that is,
the lack of gaps between G4s prevents access of proteins that recognize exposed single-stranded
DNA, such as replication protein A (RPA), preventing aberrant DNA damage repair pathway
activation. Altogether, this study adds significantly to our understanding of telomere biology insofar
that it provides a detailed look at the structure and dynamics of the higher-order telomere at the
highest resolution to date.
The atomistic models obtained from MD simulations of the higher-order telomer G4s reveal
unique G4-junctions and loop sites which I have targeting using a high-throughput virtual screen.
Using these models as receptors, I have identified a unique small molecule which binds with a
stoichiometric ratio to the inter-G4 junctional regions. This molecule is an exciting lead for future
development, as it shows selectivity for the higher-order G4 multimers over monomeric telomere
G4s.
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I next sought to determine the primary structure formed in the G-rich strand of the 68-nt
long hTERT core promoter. This region of the hTERT core promoter is important as it is frequently
mutated in a variety of cancers, leading to allele-specific increases in hTERT expression (222).
These mutations appear to impinge upon secondary structure formation, such as G-quadruplexes
(223). There has been an ongoing debate over the major structure formed within this sequence for
over a decade, beginning with near simultaneous reports of a single parallel G-quadruplex in the
first ~25 nucleotides (105), a novel parallel-antiparallel-hairpin structure (106), and an all-parallel
stacked multimer (144,145). Determining the major structure formed is important from the
perspective of both rational drug discovery and biological points of view (20), since targeting this
structure with G-quadruplex ligands has been shown as a novel method of reducing hTERT
expression in cancer cells (223). To this end, I have created two representative artificial DNA
constructs that favor either an optimized all-parallel (“OP”) or parallel-antiparallel-hairpin (“AH”) for
biophysical characterization and comparison to the wild-type (“WT”). Like my human telomere
study, I have combined a suite of biophysical tools in an integrative fashion to compare the three
oligonucleotide sequences. Spectroscopic studies with circular dichroism and DNase I cleavage
assays indicated an absence of a hairpin moiety in both OP and WT and confirmed that both OP
and WT had consistent CD spectra shape and magnitude—consistent with stacked parallel
structures. Maximal parallel G-quadruplex formation in OP and WT (i.e. three parallel Gquadruplexes) was confirmed via 1H-NMR studies. Lastly, I combined hydrodynamic techniques
with SEC-SAXS and MD simulations to show, unequivocally, that the WT sequence is much more
compact than the AH. Importantly, SEC-SAXS revealed that the AH structures contained multiple
domains, whereas the WT sequence was very globular and is qualitatively akin to the all-parallel
OP. From these results, we conclude that the major form of the hTERT promoter G-quadruplex is
an all-parallel stacked G4 multimer. The immediate biological implications of this structure are
uncertain. However, going forward there is now a model in which to test hypotheses, which is often
accomplished in part by targeting with small molecules. Altogether, my combined results highlight
the broad applicability of this integrative structural biology platform.
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Nucleic acids have long remained in the shadow of proteins as biological targets in virtual
screening approaches (269). As more in vivo evidence for the existence of novel non-B DNA
structures is unearthed, more in vitro DNA structures will become in silico molecular targets.
Indeed, G-quadruplexes, which are now widely accepted as important biological targets, are rapidly
being used in virtual drug discovery approaches (Figure 70). Thus, it is prudent now to evaluate
these initial virtual discovery campaigns and attempt to identify the aspects that make them
successful. Therefore, I have created a compendium of the past decade of G-quadruplex virtual
screening. In this comprehensive review, I have introduced the relevant screening methodologies,
libraries, and scoring functions used in G4 virtual drug discovery, which provides a useful starting
point for future investigators. Further, in comparing the contemporary methods, I have identified
the two major limiting factors in successfully enriching for novel hits: library size and chemical
search space. Overcoming these issues largely hinges on both advances in search and scoring
algorithms, as well as increased accessibility to higher throughput computing infrastructure. I also
show that most monomer G-quadruplexes that are targeted at their terminal tetrad faces enrich for
heterocyclic molecules, known as “end-pasters”. End-pasters commonly lack selectivity due to their
similar interactions with the common tetrad faces (like the specificity problem of tyrosine kinase
inhibitors). Docking campaigns that focus on loops and grooves increase the likelihood of
identifying selective hits. Thus, based on prior studies, we propose that virtual drug discovery
should focus on the loop and groove regions of the higher-order G-quadruplex multimers. Lastly,
we provide an overview of best practices that were gleaned from previous studies, which will
undoubtably benefit G-quadruplex virtual campaigns moving forward.
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Figure 70. Plot of publications per year in the Scifinder database based on the search term “Gquadruplex virtual screening” (left Y-axis, black), and the cumulative number of deposited atomic
coordinate files for DNA G-quadruplexes in the Protein Databank (right Y-axis, red).
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I next utilized a massive virtual and actual screening campaign targeting the hTERT core
promoter G-quadruplex multimer. hTERT, and its cognate RNA hTR, form the ribonucleoprotein
complex telomerase that is responsible for maintenance of the telomeres. hTERT’s expression
levels often correlate with its activity in cancer (395). Knockdown of hTERT is sufficient to cause
telomere atrophy and, in some instances, direct induction of senescence (357-359). Due to its
absence in most “normal” cells, hTERT has been a target of anti-cancer drug discovery for
decades. To date, no small molecules inhibitors have been clinically successful (215), which has
led many investigators to seek alternative strategies of inhibition. Recently, a new mechanism of
hTERT repression was reported that involves targeting its core promoter with G-quadruplex
interacting small molecules (223). Thus, I have used the all parallel hTERT G-quadruplex multimer
receptor for in silico drug discovery. I docked over 40 million virtual small molecules to 12 different
loop and groove locations across the hTERT G-quadruplex using Surflex-Dock v2.11. Based on
docking scores, the top 500 molecules from each site were combined and clustered for scaffold
similarity and to reduce the total top molecules. From the final group of unique scaffolds, 69 were
purchased for screening. Using an iterative process of screening with thermal shift assays coupled
with a catalogue-SAR approach, multiple small molecule scaffolds were identified that selectively
stabilized G-quadruplexes over duplex and triplex DNA. Using competition dialysis and cell assays,
I discovered that a single, di-substituted quinazoline molecule showed selectivity for hTERT over
other G-quadruplex topologies. Additional catalogue-SAR investigations resulted in a disubstituted
2-aminoethyl-quinazoline molecule that significantly reduced hTERT mRNA levels in breast cancer
cells and had no effect on c-MYC mRNA. Rigorous docking and molecular dynamics coupled with
free energy calculations confirmed that this molecule preferentially stabilized loops and grooves.
Importantly, the identified compounds are unique, and have not been reported in the literature to
date. Thus, the resulting molecule represents an ideal candidate for future optimization as a novel,
selective hTERT-repressing small molecule.
In conclusion, the integrative structural biology platform outlined in this work represents a
robust means to answering questions about higher-order DNA G-quadruplex structures that
previously could not be answered. It also emphasizes that selectivity can be achieved by targeting
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the unique pockets created when G-quadruplex multimers form. However, I note that there is room
for improvement. Refinement of G-quadruplex multimers against small-angle X-ray scattering is
complex. While the interpretation of SAXS scattering is somewhat straight forward from a
qualitative standpoint, the same cannot be said for the structural refinement, especially when
heterogeneity, dynamics, and flexibility are taken into account (396). Therefore, while this approach
allows us to integrate complexes of monomer subunits that have been solved by NMR or X-ray
crystallography techniques previously, it does not allow us to identify G-quadruplex structures ab
initio. To this end, future work will need to focus on the creation and implementation of Gquadruplex conformational search algorithms by which all plausible G-tetrad stacking and loop
conformations can be generated for selection against SAXS scattering and prior experimental
information. Similar algorithms are currently in use to some extent in the RNA community, although
they are not applicable to G-quadruplex folds (397). Limitations aside, this dissertation is the first
application of this robust integrative approach to characterizing DNA G-quadruplex multimers. This
work represents the first steps towards characterizing, targeting, and understanding multimeric Gquadruplex structures as targets in human disease.
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